US20200071291A1 - A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof - Google Patents
A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof Download PDFInfo
- Publication number
- US20200071291A1 US20200071291A1 US16/614,493 US201816614493A US2020071291A1 US 20200071291 A1 US20200071291 A1 US 20200071291A1 US 201816614493 A US201816614493 A US 201816614493A US 2020071291 A1 US2020071291 A1 US 2020071291A1
- Authority
- US
- United States
- Prior art keywords
- unsubstituted
- substituted
- alkyl
- aryl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 119
- ZPEPWSSGBIABSZ-UHFFFAOYSA-N isoindol-1-imine Chemical group C1=CC=C2C(=N)N=CC2=C1 ZPEPWSSGBIABSZ-UHFFFAOYSA-N 0.000 title claims abstract 3
- 239000000203 mixture Substances 0.000 title description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 125000005647 linker group Chemical group 0.000 claims abstract description 9
- -1 substituted Chemical class 0.000 claims description 75
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 46
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 35
- 150000002431 hydrogen Chemical group 0.000 claims description 34
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 22
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 20
- 229910052805 deuterium Inorganic materials 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 125000006413 ring segment Chemical group 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 8
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 8
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 8
- 125000006718 (C3-C7) heterocycloalkenyl group Chemical group 0.000 claims description 8
- 125000000732 arylene group Chemical group 0.000 claims description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
- 125000006587 (C5-C10) heteroarylene group Chemical group 0.000 claims description 6
- 125000004450 alkenylene group Chemical group 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 4
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims description 4
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims description 4
- 125000004419 alkynylene group Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 4
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 claims description 2
- 108010069898 fibrinogen fragment X Proteins 0.000 claims description 2
- 125000001151 peptidyl group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 19
- 125000006721 (C5-C10) heteroaryl (C1-C6) alkyl group Chemical group 0.000 claims 1
- 230000004900 autophagic degradation Effects 0.000 abstract description 14
- 102000007353 Autophagy-Related Protein 8 Family Human genes 0.000 abstract description 8
- 108010032769 Autophagy-Related Protein 8 Family Proteins 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 8
- MTKKGHVQPVOXIL-UHFFFAOYSA-N 3h-isoindol-1-amine Chemical group C1=CC=C2C(N)=NCC2=C1 MTKKGHVQPVOXIL-UHFFFAOYSA-N 0.000 abstract description 2
- 238000004949 mass spectrometry Methods 0.000 description 160
- 0 *c1ccc(C(CC(C2=CC3NC3c3cccc4c3CN(C(CCC(N3)=O)C3=O)C4=[U])=[U])CC2=[U])cc1 Chemical compound *c1ccc(C(CC(C2=CC3NC3c3cccc4c3CN(C(CCC(N3)=O)C3=O)C4=[U])=[U])CC2=[U])cc1 0.000 description 48
- 238000006243 chemical reaction Methods 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 238000005160 1H NMR spectroscopy Methods 0.000 description 34
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 33
- 206010028980 Neoplasm Diseases 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
- 239000000543 intermediate Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 26
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 26
- 229960004942 lenalidomide Drugs 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 238000001308 synthesis method Methods 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 24
- 125000005843 halogen group Chemical group 0.000 description 21
- 229940125904 compound 1 Drugs 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 19
- 239000012043 crude product Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 16
- 239000012267 brine Substances 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- 238000004809 thin layer chromatography Methods 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- CRSOQBOWXPBRES-UHFFFAOYSA-N CC(C)(C)C Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 12
- 125000002950 monocyclic group Chemical group 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 125000003710 aryl alkyl group Chemical group 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 125000000392 cycloalkenyl group Chemical group 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 208000034578 Multiple myelomas Diseases 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 239000007821 HATU Substances 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 125000002877 alkyl aryl group Chemical group 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 230000003285 pharmacodynamic effect Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 125000004434 sulfur atom Chemical group 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- CPKHDSAEGWVGOW-QGOAFFKASA-N CC1(C#N)C(=O)/C(=C/NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)CC1C1=CC=CC=C1 Chemical compound CC1(C#N)C(=O)/C(=C/NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)CC1C1=CC=CC=C1 CPKHDSAEGWVGOW-QGOAFFKASA-N 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 150000001204 N-oxides Chemical class 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- ROYWMOIYCNIMIB-PDGQHHTCSA-N O=C1CCC(N2CC3=C(N/C=C4\C(=O)NC5=C(C=CC6=C5C=CC=C6)C4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(N/C=C4\C(=O)NC5=C(C=CC6=C5C=CC=C6)C4=O)C=CC=C3C2=O)C(=O)N1 ROYWMOIYCNIMIB-PDGQHHTCSA-N 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 4
- PVHODPDKIVYOQM-QLYXXIJNSA-N O=C1CCC(N2CC3=C(NCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 PVHODPDKIVYOQM-QLYXXIJNSA-N 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229940084954 dexamethasone 1 mg Drugs 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 3
- JSOLZWXMGMAORE-UHFFFAOYSA-N 1-(2-azidoethyl)piperazine Chemical compound [N-]=[N+]=NCCN1CCNCC1 JSOLZWXMGMAORE-UHFFFAOYSA-N 0.000 description 3
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 3
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N Benzylformate Chemical compound O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- XMDPELIGWKQBHI-LBQOLGSKSA-N CC(C)[C@H](NC=C1C(=O)CC(C2=CC=CC=C2)CC1=O)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 Chemical compound CC(C)[C@H](NC=C1C(=O)CC(C2=CC=CC=C2)CC1=O)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 XMDPELIGWKQBHI-LBQOLGSKSA-N 0.000 description 3
- KMQZFZYLSWAEJM-MYYYXRDXSA-N CC(NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1)=C1C(=O)CC(C2=CC=CC=C2)CC1=O Chemical compound CC(NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1)=C1C(=O)CC(C2=CC=CC=C2)CC1=O KMQZFZYLSWAEJM-MYYYXRDXSA-N 0.000 description 3
- NQFKLEGTXGYTTG-PDGQHHTCSA-N CC1=CC(Br)=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C=C1 Chemical compound CC1=CC(Br)=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C=C1 NQFKLEGTXGYTTG-PDGQHHTCSA-N 0.000 description 3
- GXGHWKKPIXKOMK-ULJHMMPZSA-N CC1=CC(C(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)=CC=C1NC=C1C(=O)CC(C2=CC=CC=C2)CC1=O Chemical compound CC1=CC(C(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)=CC=C1NC=C1C(=O)CC(C2=CC=CC=C2)CC1=O GXGHWKKPIXKOMK-ULJHMMPZSA-N 0.000 description 3
- VGPBDBMSWXCRGW-UYRXBGFRSA-N CC1=CC=CC=C1C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 Chemical compound CC1=CC=CC=C1C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 VGPBDBMSWXCRGW-UYRXBGFRSA-N 0.000 description 3
- YGARXKFWAILDBS-CPNJWEJPSA-N CC1C(=O)/C(=C/NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)CC1C1=CC=CC=C1 Chemical compound CC1C(=O)/C(=C/NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)CC1C1=CC=CC=C1 YGARXKFWAILDBS-CPNJWEJPSA-N 0.000 description 3
- BZGGIIOHGKVCKF-UHFFFAOYSA-N CCOC(=O)C1C(=O)C(=CNC2=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)CC1C1=CC=CC2=C1C=CN2 Chemical compound CCOC(=O)C1C(=O)C(=CNC2=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)CC1C1=CC=CC2=C1C=CN2 BZGGIIOHGKVCKF-UHFFFAOYSA-N 0.000 description 3
- BYCZNBKPHCQSBC-UHFFFAOYSA-N CCOC(=O)C1C(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)CC1C1=CC=CC2=C1C=CN2 Chemical compound CCOC(=O)C1C(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)CC1C1=CC=CC2=C1C=CN2 BYCZNBKPHCQSBC-UHFFFAOYSA-N 0.000 description 3
- LCUURJOZDJVKHA-UVTDQMKNSA-N CCOC(=O)C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 Chemical compound CCOC(=O)C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 LCUURJOZDJVKHA-UVTDQMKNSA-N 0.000 description 3
- AYFYZTGHNOZCTP-UYRXBGFRSA-N CN(C)C1=CC=C(Br)C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)=C1 Chemical compound CN(C)C1=CC=C(Br)C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)=C1 AYFYZTGHNOZCTP-UYRXBGFRSA-N 0.000 description 3
- ZNTSVCOHIRFREE-GDNBJRDFSA-N CN1C(=O)/C(=C\NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C2=C1C=C(C(F)(F)F)C=C2 Chemical compound CN1C(=O)/C(=C\NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C2=C1C=C(C(F)(F)F)C=C2 ZNTSVCOHIRFREE-GDNBJRDFSA-N 0.000 description 3
- KCTVOBXSXFQXHK-UYRXBGFRSA-N COC(=O)C1=CC=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C=C1 Chemical compound COC(=O)C1=CC=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C=C1 KCTVOBXSXFQXHK-UYRXBGFRSA-N 0.000 description 3
- SSSARTDQWZSOLR-WJDWOHSUSA-N COC1=C(F)C(F)=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C=C1 Chemical compound COC1=C(F)C(F)=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C=C1 SSSARTDQWZSOLR-WJDWOHSUSA-N 0.000 description 3
- MAWKZONJCKAJPM-UYRXBGFRSA-N COC1=CC=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C(OC)=C1 Chemical compound COC1=CC=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C(OC)=C1 MAWKZONJCKAJPM-UYRXBGFRSA-N 0.000 description 3
- HAJJECVHWIQUFH-UYRXBGFRSA-N COC1=CC=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C=C1 Chemical compound COC1=CC=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C=C1 HAJJECVHWIQUFH-UYRXBGFRSA-N 0.000 description 3
- ZDRMNZSYUWWUCV-XLNRJJMWSA-N COCCOCCOC1=CC=CC=C1C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 Chemical compound COCCOCCOC1=CC=CC=C1C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 ZDRMNZSYUWWUCV-XLNRJJMWSA-N 0.000 description 3
- JZFQFBVLTSPNRS-YJGYASCHSA-N C[C@@H](CC(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1)NC=C1C(=O)CC(C2=CC=CC=C2)CC1=O Chemical compound C[C@@H](CC(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1)NC=C1C(=O)CC(C2=CC=CC=C2)CC1=O JZFQFBVLTSPNRS-YJGYASCHSA-N 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 3
- GDPPBWBLRHDVRJ-CLCOLTQESA-N NC1=C2CN(C3CCC(=O)N(C(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C3=O)C(=O)C2=CC=C1 Chemical compound NC1=C2CN(C3CCC(=O)N(C(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C3=O)C(=O)C2=CC=C1 GDPPBWBLRHDVRJ-CLCOLTQESA-N 0.000 description 3
- LPCMTZRKBQHEOE-BORXOZNFSA-N O=C(/C=C\CN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 Chemical compound O=C(/C=C\CN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 LPCMTZRKBQHEOE-BORXOZNFSA-N 0.000 description 3
- GAMOWWZNLAFPGR-QYQHSDTDSA-N O=C1CC(C2=CC=CC=C2)CC(=O)C1=CNCCN1CCN(CCOC(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1 Chemical compound O=C1CC(C2=CC=CC=C2)CC(=O)C1=CNCCN1CCN(CCOC(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1 GAMOWWZNLAFPGR-QYQHSDTDSA-N 0.000 description 3
- AGIDKZGOXRWMDJ-WMMMYUQOSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)C4=CC=C(CN5CCN(CCNC=C6C(=O)CC(C7=CC=CC=C7)CC6=O)CC5)C=C4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)C4=CC=C(CN5CCN(CCNC=C6C(=O)CC(C7=CC=CC=C7)CC6=O)CC5)C=C4)=C3C2=O)C(=O)N1 AGIDKZGOXRWMDJ-WMMMYUQOSA-N 0.000 description 3
- JQODLBGXYCZAIA-AQTBWJFISA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)C4=CN=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)S4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)C4=CN=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)S4)=C3C2=O)C(=O)N1 JQODLBGXYCZAIA-AQTBWJFISA-N 0.000 description 3
- JBDXDYVLZJKDBY-VYIQYICTSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)CCC(=O)OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)CCC(=O)OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 JBDXDYVLZJKDBY-VYIQYICTSA-N 0.000 description 3
- VAQXGPMCSVQGAE-DAFNUICNSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 VAQXGPMCSVQGAE-DAFNUICNSA-N 0.000 description 3
- WOKFTUBIKLZENN-NULLBWFHSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)OCOC(=O)/C=C/C(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)OCOC(=O)/C=C/C(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 WOKFTUBIKLZENN-NULLBWFHSA-N 0.000 description 3
- ZABKIJHLOARMRH-UVTDQMKNSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=C(Br)C=CC6=C5C(Cl)=CN6)CC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=C(Br)C=CC6=C5C(Cl)=CN6)CC4=O)=C3C2=O)C(=O)N1 ZABKIJHLOARMRH-UVTDQMKNSA-N 0.000 description 3
- GVUQTJVHAJDILM-PTNGSMBKSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=CC=CC(Cl)=C5Cl)CC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=CC=CC(Cl)=C5Cl)CC4=O)=C3C2=O)C(=O)N1 GVUQTJVHAJDILM-PTNGSMBKSA-N 0.000 description 3
- KYTNIZLWCDMNFC-WJDWOHSUSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=CC=CC6=C5C(Cl)=CN6)CC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=CC=CC6=C5C(Cl)=CN6)CC4=O)=C3C2=O)C(=O)N1 KYTNIZLWCDMNFC-WJDWOHSUSA-N 0.000 description 3
- TUCSYLYMBDZFNN-AQTBWJFISA-N O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=CC=CC6=C5C=CN6)CC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=CC=CC6=C5C=CN6)CC4=O)=C3C2=O)C(=O)N1 TUCSYLYMBDZFNN-AQTBWJFISA-N 0.000 description 3
- PORYTJJOBCQCEL-LGMDPLHJSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 PORYTJJOBCQCEL-LGMDPLHJSA-N 0.000 description 3
- DTCBVKXBKQHHQP-NMWGTECJSA-N O=C1CCC(N2C(=O)C3=CC=CC(NS(=O)(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NS(=O)(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 DTCBVKXBKQHHQP-NMWGTECJSA-N 0.000 description 3
- MQCHYOPYZKFHSO-VYIQYICTSA-N O=C1CCC(N2C(=O)C3=CC=CC(OC(=O)OCCOCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(OC(=O)OCCOCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 MQCHYOPYZKFHSO-VYIQYICTSA-N 0.000 description 3
- CFOWUIOELRAJSH-QVTSOHHYSA-N O=C1CCC(N2C(=O)C3=CC=CC(OCCOCCOCCOCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(OCCOCCOCCOCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 CFOWUIOELRAJSH-QVTSOHHYSA-N 0.000 description 3
- BRLNMNFAZDVGMX-DAFNUICNSA-N O=C1CCC(N2C(=O)C3=C\C=C/C(OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C\3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=C\C=C/C(OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C\3C2=O)C(=O)N1 BRLNMNFAZDVGMX-DAFNUICNSA-N 0.000 description 3
- XFZWRFGRKBKDKG-FOWTUZBSSA-N O=C1CCC(N2CC3=C(N/C=C4\C(=O)CC(C5=CC=CC=C5)NC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(N/C=C4\C(=O)CC(C5=CC=CC=C5)NC4=O)C=CC=C3C2=O)C(=O)N1 XFZWRFGRKBKDKG-FOWTUZBSSA-N 0.000 description 3
- AMRJNGBLGNCIHQ-FOWTUZBSSA-N O=C1CCC(N2CC3=C(N/C=C4\C(=O)CC(C5=CC=CC=C5)OC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(N/C=C4\C(=O)CC(C5=CC=CC=C5)OC4=O)C=CC=C3C2=O)C(=O)N1 AMRJNGBLGNCIHQ-FOWTUZBSSA-N 0.000 description 3
- SCQBSHBAQHEIQK-ZROIWOOFSA-N O=C1CCC(N2CC3=C(N/C=C4\C(=O)NC5=C(C=CC(C(F)(F)F)=C5)C4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(N/C=C4\C(=O)NC5=C(C=CC(C(F)(F)F)=C5)C4=O)C=CC=C3C2=O)C(=O)N1 SCQBSHBAQHEIQK-ZROIWOOFSA-N 0.000 description 3
- NCWVMPJOLCEUEX-JWGURIENSA-N O=C1CCC(N2CC3=C(NC(=O)C4=CC=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=C4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)C4=CC=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=C4)C=CC=C3C2=O)C(=O)N1 NCWVMPJOLCEUEX-JWGURIENSA-N 0.000 description 3
- KRUSPAMFHPFUTH-ULJHMMPZSA-N O=C1CCC(N2CC3=C(NC(=O)C4=CC=CC(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)=C4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)C4=CC=CC(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)=C4)C=CC=C3C2=O)C(=O)N1 KRUSPAMFHPFUTH-ULJHMMPZSA-N 0.000 description 3
- FKJLZSPHASNVCS-UYRXBGFRSA-N O=C1CCC(N2CC3=C(NC(=O)C4=CN=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)S4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)C4=CN=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)S4)C=CC=C3C2=O)C(=O)N1 FKJLZSPHASNVCS-UYRXBGFRSA-N 0.000 description 3
- VLDYWCITAPMMJC-PGMHBOJBSA-N O=C1CCC(N2CC3=C(NC(=O)CCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)CCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 VLDYWCITAPMMJC-PGMHBOJBSA-N 0.000 description 3
- PSQFZFIGEYQUJL-HKWRFOASSA-N O=C1CCC(N2CC3=C(NC(=O)CCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)CCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 PSQFZFIGEYQUJL-HKWRFOASSA-N 0.000 description 3
- URFPPXATLFPNBA-PLRJNAJWSA-N O=C1CCC(N2CC3=C(NC(=O)CN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)CN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 URFPPXATLFPNBA-PLRJNAJWSA-N 0.000 description 3
- BQFGPQQBBUBQRU-UYRXBGFRSA-N O=C1CCC(N2CC3=C(NC(=O)CNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)CNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 BQFGPQQBBUBQRU-UYRXBGFRSA-N 0.000 description 3
- YZGXROPEUJUSLL-MXNGAVTRSA-N O=C1CCC(N2CC3=C(NC(=O)NC4=CC=CC=C4OC(=O)CCC(=O)OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)NC4=CC=CC=C4OC(=O)CCC(=O)OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 YZGXROPEUJUSLL-MXNGAVTRSA-N 0.000 description 3
- WXUKLUVXEJNCDQ-STZFKDTASA-N O=C1CCC(N2CC3=C(NC(=O)OCC4=CN=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)S4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)OCC4=CN=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)S4)C=CC=C3C2=O)C(=O)N1 WXUKLUVXEJNCDQ-STZFKDTASA-N 0.000 description 3
- XXVRRUVBQYFYHT-QLYXXIJNSA-N O=C1CCC(N2CC3=C(NC(=O)OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 XXVRRUVBQYFYHT-QLYXXIJNSA-N 0.000 description 3
- UOMUKQYUPFAUPS-HKWRFOASSA-N O=C1CCC(N2CC3=C(NC(=O)OCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)OCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 UOMUKQYUPFAUPS-HKWRFOASSA-N 0.000 description 3
- KYWYVQRQCMEPCP-NFFVHWSESA-N O=C1CCC(N2CC3=C(NC(=O)OCCOCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)OCCOCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 KYWYVQRQCMEPCP-NFFVHWSESA-N 0.000 description 3
- WPMKPTMSXZWIKH-XFSIEYDFSA-N O=C1CCC(N2CC3=C(NC(=O)OCOC(=O)/C=C/C(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)OCOC(=O)/C=C/C(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 WPMKPTMSXZWIKH-XFSIEYDFSA-N 0.000 description 3
- FZUZDTBQBLPUKG-FLWNBWAVSA-N O=C1CCC(N2CC3=C(NC(C4=CC=CC=C4)=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(C4=CC=CC=C4)=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 FZUZDTBQBLPUKG-FLWNBWAVSA-N 0.000 description 3
- VNBGSVZNZJQZBS-QQTULTPQSA-N O=C1CCC(N2CC3=C(NC(CO)=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(CO)=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 VNBGSVZNZJQZBS-QQTULTPQSA-N 0.000 description 3
- PTSUBVMAEQLTED-GXZXSNFWSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(/C=C/C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(/C=C/C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 PTSUBVMAEQLTED-GXZXSNFWSA-N 0.000 description 3
- WGLHBSMCSHGKHK-PDGQHHTCSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C(=O)NC5=CC=C(Cl)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C(=O)NC5=CC=C(Cl)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 WGLHBSMCSHGKHK-PDGQHHTCSA-N 0.000 description 3
- DZGMNGOEPZJYIY-BOPFTXTBSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=C(F)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=C(F)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 DZGMNGOEPZJYIY-BOPFTXTBSA-N 0.000 description 3
- HQZHVIGKTCSDPL-PDGQHHTCSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=C6C=CNC6=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=C6C=CNC6=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 HQZHVIGKTCSDPL-PDGQHHTCSA-N 0.000 description 3
- KONMBNWCIIVQCY-UVTDQMKNSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=CC(F)=C5Cl)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=CC(F)=C5Cl)CC4=O)C=CC=C3C2=O)C(=O)N1 KONMBNWCIIVQCY-UVTDQMKNSA-N 0.000 description 3
- BRTKDBGSDBYPJB-BOPFTXTBSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=CC(O)=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=CC(O)=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 BRTKDBGSDBYPJB-BOPFTXTBSA-N 0.000 description 3
- RPUNTUAUUOPFHK-GDNBJRDFSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=CC6=C5C(C(F)(F)F)=CN6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=CC6=C5C(C(F)(F)F)=CN6)CC4=O)C=CC=C3C2=O)C(=O)N1 RPUNTUAUUOPFHK-GDNBJRDFSA-N 0.000 description 3
- CNTANVAWCJELNH-GDNBJRDFSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=CC6=C5C(Cl)=CN6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=CC6=C5C(Cl)=CN6)CC4=O)C=CC=C3C2=O)C(=O)N1 CNTANVAWCJELNH-GDNBJRDFSA-N 0.000 description 3
- HFBAXYPDTXAQRK-ATVHPVEESA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Br)C=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 HFBAXYPDTXAQRK-ATVHPVEESA-N 0.000 description 3
- GDBBBKXQBYNMTN-LCYFTJDESA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Cl)C(Cl)=CC(Cl)=C5F)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Cl)C(Cl)=CC(Cl)=C5F)CC4=O)C=CC=C3C2=O)C(=O)N1 GDBBBKXQBYNMTN-LCYFTJDESA-N 0.000 description 3
- UGJIEIBXQWSBBL-UVTDQMKNSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Cl)C(Cl)=CC=C5C(F)(F)F)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Cl)C(Cl)=CC=C5C(F)(F)F)CC4=O)C=CC=C3C2=O)C(=O)N1 UGJIEIBXQWSBBL-UVTDQMKNSA-N 0.000 description 3
- LJZFTVAYLGFUGX-PDGQHHTCSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Cl)C=C6C=CNC6=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Cl)C=C6C=CNC6=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 LJZFTVAYLGFUGX-PDGQHHTCSA-N 0.000 description 3
- JWFRZPWGDHPXEA-BOPFTXTBSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Cl)C=CC(C(F)(F)F)=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Cl)C=CC(C(F)(F)F)=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 JWFRZPWGDHPXEA-BOPFTXTBSA-N 0.000 description 3
- NCDTXGFMEXPARR-ATVHPVEESA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Cl)C=CC6=C5C=CN6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Cl)C=CC6=C5C=CN6)CC4=O)C=CC=C3C2=O)C(=O)N1 NCDTXGFMEXPARR-ATVHPVEESA-N 0.000 description 3
- WXRBXAQPQPGHEJ-PTNGSMBKSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Cl)C=CC=C5F)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(Cl)C=CC=C5F)CC4=O)C=CC=C3C2=O)C(=O)N1 WXRBXAQPQPGHEJ-PTNGSMBKSA-N 0.000 description 3
- SJQPJPWDWRZNTR-UVTDQMKNSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(F)C(Cl)=CC=C5C(F)(F)F)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(F)C(Cl)=CC=C5C(F)(F)F)CC4=O)C=CC=C3C2=O)C(=O)N1 SJQPJPWDWRZNTR-UVTDQMKNSA-N 0.000 description 3
- MUMQYDKLKDNNSA-ATVHPVEESA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(F)C=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C(F)C=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 MUMQYDKLKDNNSA-ATVHPVEESA-N 0.000 description 3
- JMVKUKZTWMTZHL-UQQQWYQISA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C6C=CC=CC6=CC6=C5C=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C6C=CC=CC6=CC6=C5C=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 JMVKUKZTWMTZHL-UQQQWYQISA-N 0.000 description 3
- KIMZHDYDUIPRTH-UYRXBGFRSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C6C=CNC6=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=C6C=CNC6=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 KIMZHDYDUIPRTH-UYRXBGFRSA-N 0.000 description 3
- AXUDRJNZWOBQMF-PDGQHHTCSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=C(C(F)(F)F)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=C(C(F)(F)F)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 AXUDRJNZWOBQMF-PDGQHHTCSA-N 0.000 description 3
- XIKURGUVKMGULZ-KQWNVCNZSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=C(C6=CC=NC=C6)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=C(C6=CC=NC=C6)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 XIKURGUVKMGULZ-KQWNVCNZSA-N 0.000 description 3
- PHXGALUNHIXNMQ-BOPFTXTBSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=C(Cl)C=C5F)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=C(Cl)C=C5F)CC4=O)C=CC=C3C2=O)C(=O)N1 PHXGALUNHIXNMQ-BOPFTXTBSA-N 0.000 description 3
- FLOTYIGXEQTSTO-PDGQHHTCSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=C(F)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=C(F)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 FLOTYIGXEQTSTO-PDGQHHTCSA-N 0.000 description 3
- LOQNFXBTRNRHIS-PDGQHHTCSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=C(O)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=C(O)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 LOQNFXBTRNRHIS-PDGQHHTCSA-N 0.000 description 3
- GFFKMPGEQBZZQC-PDGQHHTCSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=C(OC(F)(F)F)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=C(OC(F)(F)F)C=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 GFFKMPGEQBZZQC-PDGQHHTCSA-N 0.000 description 3
- FDAZUGGYHOJDOO-WJDWOHSUSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC(Cl)=C5Cl)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC(Cl)=C5Cl)CC4=O)C=CC=C3C2=O)C(=O)N1 FDAZUGGYHOJDOO-WJDWOHSUSA-N 0.000 description 3
- NQAUCDNKSUQSOS-WJDWOHSUSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC(Cl)=C5F)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC(Cl)=C5F)CC4=O)C=CC=C3C2=O)C(=O)N1 NQAUCDNKSUQSOS-WJDWOHSUSA-N 0.000 description 3
- JOWLJXRYRCHLQP-JCMHNJIXSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC6=C5C=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC6=C5C=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 JOWLJXRYRCHLQP-JCMHNJIXSA-N 0.000 description 3
- HGHHOBRSJFQVEG-UYRXBGFRSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC6=C5C=CS6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC6=C5C=CS6)CC4=O)C=CC=C3C2=O)C(=O)N1 HGHHOBRSJFQVEG-UYRXBGFRSA-N 0.000 description 3
- LLNDBZKRESNLBV-WQRHYEAKSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC6=C5C=NN6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC6=C5C=NN6)CC4=O)C=CC=C3C2=O)C(=O)N1 LLNDBZKRESNLBV-WQRHYEAKSA-N 0.000 description 3
- QCJWAXMOLBQJDQ-UHFFFAOYSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5)C(F)C4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5)C(F)C4=O)C=CC=C3C2=O)C(=O)N1 QCJWAXMOLBQJDQ-UHFFFAOYSA-N 0.000 description 3
- ACENAXRTSCGLNW-ATVHPVEESA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5C(F)(F)F)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5C(F)(F)F)CC4=O)C=CC=C3C2=O)C(=O)N1 ACENAXRTSCGLNW-ATVHPVEESA-N 0.000 description 3
- YHAMSEVDYLXSOI-BWAHOGKJSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5CC5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5CC5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 YHAMSEVDYLXSOI-BWAHOGKJSA-N 0.000 description 3
- MUBMWAZPIOBDPL-PGMHBOJBSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5N5CCOCC5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5N5CCOCC5)CC4=O)C=CC=C3C2=O)C(=O)N1 MUBMWAZPIOBDPL-PGMHBOJBSA-N 0.000 description 3
- BYVNOYLXLVWMEL-PTNGSMBKSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CS5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CS5)CC4=O)C=CC=C3C2=O)C(=O)N1 BYVNOYLXLVWMEL-PTNGSMBKSA-N 0.000 description 3
- VHNASTVCLNMFRN-ZHZULCJRSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=NC6=C5C=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=NC6=C5C=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 VHNASTVCLNMFRN-ZHZULCJRSA-N 0.000 description 3
- MJGRXQSPOMUKAZ-ATVHPVEESA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CNC6=C5C(Cl)=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CNC6=C5C(Cl)=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 MJGRXQSPOMUKAZ-ATVHPVEESA-N 0.000 description 3
- RFXFQXRWDGAMBV-ATVHPVEESA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CNC6=C5C(F)=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CNC6=C5C(F)=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 RFXFQXRWDGAMBV-ATVHPVEESA-N 0.000 description 3
- FWSUCQRGMVXBPC-UYRXBGFRSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CNC6=C5C=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CNC6=C5C=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 FWSUCQRGMVXBPC-UYRXBGFRSA-N 0.000 description 3
- PVSUFTOWIPEQMD-PDGQHHTCSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CSC6=C5C=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CSC6=C5C=CC=C6)CC4=O)C=CC=C3C2=O)C(=O)N1 PVSUFTOWIPEQMD-PDGQHHTCSA-N 0.000 description 3
- QLLHCXYIUYJRJG-YBEGLDIGSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=NC=NC6=C5C=CS6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=NC=NC6=C5C=CS6)CC4=O)C=CC=C3C2=O)C(=O)N1 QLLHCXYIUYJRJG-YBEGLDIGSA-N 0.000 description 3
- KKMFYEGSBKKZSY-UYRXBGFRSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(COC5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(COC5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 KKMFYEGSBKKZSY-UYRXBGFRSA-N 0.000 description 3
- KPKUAPWVZRGJFO-UHFFFAOYSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CCCC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CCCC4=O)C=CC=C3C2=O)C(=O)N1 KPKUAPWVZRGJFO-UHFFFAOYSA-N 0.000 description 3
- IALCJTBAZKCNKY-UHFFFAOYSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CN(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CN(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 IALCJTBAZKCNKY-UHFFFAOYSA-N 0.000 description 3
- ILDGOABBJZZQJZ-MXNGAVTRSA-N O=C1CCC(N2CC3=C(NCCOCCOCCOCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NCCOCCOCCOCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 ILDGOABBJZZQJZ-MXNGAVTRSA-N 0.000 description 3
- BHHKISUYVYYZOG-CLCOLTQESA-N O=C1CCC(N2CC3=C(NS(=O)(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NS(=O)(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 BHHKISUYVYYZOG-CLCOLTQESA-N 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125936 compound 42 Drugs 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 2
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 2
- UPPYKNLSSLIIAZ-UHFFFAOYSA-N 5-phenylcyclohexane-1,3-dione Chemical compound C1C(=O)CC(=O)CC1C1=CC=CC=C1 UPPYKNLSSLIIAZ-UHFFFAOYSA-N 0.000 description 2
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- HTLFVKHTWXXQBD-NTKFWRKTSA-N C=C1/C(=C/CC(C)(C)C)C(=O)CC(C2=CC=CC=C2)C1C.C=C1/C(=C/CC(C)(C)C)C(=O)CC(C2=CC=CC=C2)N1C.C=C1CC(/C=C/C2=CC=CC=C2)CC(=O)/C1=C\CC(C)(C)C.C=C1CN(C2=CC=CC=C2)CC(=O)/C1=C\CC(C)(C)C.C=C1NC(C2=CC=CC=C2)CC(=O)/C1=C\CC(C)(C)C.CC(C)(C)C/C=C1\C(=O)CC(CC2=CC=CC=C2)C1=O.CC(C)(C)C/C=C1\C(=O)CCC(C2=CC=CC=C2)CC1=O.CC(C)(C)OC=C1C(=O)CC(C2=CC=CC=C2)CC1=O.CC(C)(C)SC=C1C(=O)CC(C2=CC=CC=C2)CC1=O Chemical compound C=C1/C(=C/CC(C)(C)C)C(=O)CC(C2=CC=CC=C2)C1C.C=C1/C(=C/CC(C)(C)C)C(=O)CC(C2=CC=CC=C2)N1C.C=C1CC(/C=C/C2=CC=CC=C2)CC(=O)/C1=C\CC(C)(C)C.C=C1CN(C2=CC=CC=C2)CC(=O)/C1=C\CC(C)(C)C.C=C1NC(C2=CC=CC=C2)CC(=O)/C1=C\CC(C)(C)C.CC(C)(C)C/C=C1\C(=O)CC(CC2=CC=CC=C2)C1=O.CC(C)(C)C/C=C1\C(=O)CCC(C2=CC=CC=C2)CC1=O.CC(C)(C)OC=C1C(=O)CC(C2=CC=CC=C2)CC1=O.CC(C)(C)SC=C1C(=O)CC(C2=CC=CC=C2)CC1=O HTLFVKHTWXXQBD-NTKFWRKTSA-N 0.000 description 2
- ICDLUASKYOMLEV-JWMSHAKWSA-N C=C1C2=CC=C(C)C=C2NC(=O)/C1=C\NC(C)(C)C.C=C1CC(C2CCCCC2)CC(=O)/C1=C\CC(C)(C)C.C=C1CCCC(=O)/C1=C\CC(C)(C)C.CC(C)(C)C/C=C1\C(=O)NC2=C\C=C(C3=CC=CC=C3)/C=C\2C1=O.CC(C)(C)CC=C1C(=O)CC(C(=O)NC2=CC=C(Cl)C=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=C(Br)S2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=NC=NC3=C2C=CS3)CC1=O.CCOC(=O)C1CC(=O)C(=CCC(C)(C)C)C(=O)C1 Chemical compound C=C1C2=CC=C(C)C=C2NC(=O)/C1=C\NC(C)(C)C.C=C1CC(C2CCCCC2)CC(=O)/C1=C\CC(C)(C)C.C=C1CCCC(=O)/C1=C\CC(C)(C)C.CC(C)(C)C/C=C1\C(=O)NC2=C\C=C(C3=CC=CC=C3)/C=C\2C1=O.CC(C)(C)CC=C1C(=O)CC(C(=O)NC2=CC=C(Cl)C=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=C(Br)S2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=NC=NC3=C2C=CS3)CC1=O.CCOC(=O)C1CC(=O)C(=CCC(C)(C)C)C(=O)C1 ICDLUASKYOMLEV-JWMSHAKWSA-N 0.000 description 2
- OKLGNPHTDACZSP-HJHJZPBPSA-N C=C1CC(C2=CC=C(C3=CC=NC=C3)C=C2)CC(=O)/C1=C\CC(C)(C)C.C=C1CC(C2=CC=CN2CC(C)C)CC(=O)/C1=C\CC(C)(C)C.C=C1CC(C2=NC=CS2)CC(=O)/C1=C\CC(C)(C)C.C=C1NC(C2=CC=CC=C2)NC(=O)/C1=C\CC(C)(C)C.C=C1OC(C2=CC=CC=C2)CC(=O)/C1=C\CC(C)(C)C.CC(C)(C)C/C=C1\C(=O)CC(C2=CC=NC3=C2C=CC=C3)OC1=O.CC(C)(C)CC=C1C(=O)CC(COC2=CC=CC=C2)CC1=O.CCCNC(=O)C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.COCCOCCOC1=CC=CC=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1 Chemical compound C=C1CC(C2=CC=C(C3=CC=NC=C3)C=C2)CC(=O)/C1=C\CC(C)(C)C.C=C1CC(C2=CC=CN2CC(C)C)CC(=O)/C1=C\CC(C)(C)C.C=C1CC(C2=NC=CS2)CC(=O)/C1=C\CC(C)(C)C.C=C1NC(C2=CC=CC=C2)NC(=O)/C1=C\CC(C)(C)C.C=C1OC(C2=CC=CC=C2)CC(=O)/C1=C\CC(C)(C)C.CC(C)(C)C/C=C1\C(=O)CC(C2=CC=NC3=C2C=CC=C3)OC1=O.CC(C)(C)CC=C1C(=O)CC(COC2=CC=CC=C2)CC1=O.CCCNC(=O)C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.COCCOCCOC1=CC=CC=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1 OKLGNPHTDACZSP-HJHJZPBPSA-N 0.000 description 2
- MGLSKECEBGPDNB-UHFFFAOYSA-N C=C1CCC(N2C(=O)C3=CC=C(CC(C)(C)C)C=C3C2=O)C(=O)N1.C=C1CCC(N2C(=O)C3=CC=C(NC(C)(C)C)C=C3C2=O)C(=O)N1.C=C1CCC(N2C(=O)C3=CC=CC(N)=C3C2=O)C(=O)N1C(C)(C)C.C=C1CCC(N2C(=O)C3=CC=CC(NC(C)(C)C)=C3C2=O)C(=O)N1.C=C1CCC(N2CC3=C(N)C=CC=C3C2=O)C(=O)N1C(C)(C)C.C=C1CCC(N2CC3=C(NC(C)(C)C)C=CC=C3C2=O)C(=O)N1.C=C1CCC(N2CC3=CC(NC(C)(C)C)=CC=C3C2=O)C(=O)N1.C=C1CCC(N2CC3=CC=C(CC(C)(C)C)C=C3C2=O)C(=O)N1 Chemical compound C=C1CCC(N2C(=O)C3=CC=C(CC(C)(C)C)C=C3C2=O)C(=O)N1.C=C1CCC(N2C(=O)C3=CC=C(NC(C)(C)C)C=C3C2=O)C(=O)N1.C=C1CCC(N2C(=O)C3=CC=CC(N)=C3C2=O)C(=O)N1C(C)(C)C.C=C1CCC(N2C(=O)C3=CC=CC(NC(C)(C)C)=C3C2=O)C(=O)N1.C=C1CCC(N2CC3=C(N)C=CC=C3C2=O)C(=O)N1C(C)(C)C.C=C1CCC(N2CC3=C(NC(C)(C)C)C=CC=C3C2=O)C(=O)N1.C=C1CCC(N2CC3=CC(NC(C)(C)C)=CC=C3C2=O)C(=O)N1.C=C1CCC(N2CC3=CC=C(CC(C)(C)C)C=C3C2=O)C(=O)N1 MGLSKECEBGPDNB-UHFFFAOYSA-N 0.000 description 2
- ZIMPGTIWXULEQT-UHFFFAOYSA-N C=C1CCC(N2C(=O)C3=CC=CC(F)=C3C2=O)C(=O)N1C(C)(C)C.C=C1CCC(N2C(=O)C3=CC=CC(OC(C)(C)C)=C3C2=O)C(=O)N1.C=C1CCC(N2CC3=C(OC(C)(C)C)C=CC=C3C2=O)C(=O)N1.CC(C)(C)N1C(=O)CCC(N2C(=O)C3=CC=CC=C3C2=O)C1=O Chemical compound C=C1CCC(N2C(=O)C3=CC=CC(F)=C3C2=O)C(=O)N1C(C)(C)C.C=C1CCC(N2C(=O)C3=CC=CC(OC(C)(C)C)=C3C2=O)C(=O)N1.C=C1CCC(N2CC3=C(OC(C)(C)C)C=CC=C3C2=O)C(=O)N1.CC(C)(C)N1C(=O)CCC(N2C(=O)C3=CC=CC=C3C2=O)C1=O ZIMPGTIWXULEQT-UHFFFAOYSA-N 0.000 description 2
- QJXZPJOHMLQWLR-UHFFFAOYSA-N CC(=O)CC1=CC=CC=C1C(C)(C)C.CC(C)(C)C1=C(Br)C=C2C=CCC2=C1.CC(C)(C)C1=C(Br)C=CC(O)=C1.CC(C)(C)C1=C(Cl)C=C2C=CCC2=C1.CC(C)(C)C1=C(Cl)C=CC2=C1C=CN2.CC(C)(C)C1=CC=C(Cl)C=C1F.CC(C)(C)C1=CC=CC2=C1C=CS2.CC(C)(C)C1=CC=CC=C1N1CCCCC1.CC(C)(C)C1=CNC2=C1C(Cl)=CC=C2.CC(C)(C)C1=CNC2=C1C(F)=CC=C2.CC(C)(C)C1=CSC2=C1C=CC=C2.CC(C)(C)C1=NNC2=C1C=CC=C2.CC1=C(F)C(C(C)(C)C)=C(Cl)C(Cl)=C1.CC1=C(F)C(C(C)(C)C)=CC=C1.CC1=CC(C(C)(C)C)=C(Cl)C=C1.CC1=CC=CC(Cl)=C1C(C)(C)C.COC1=C(F)C(F)=C(C(C)(C)C)C=C1 Chemical compound CC(=O)CC1=CC=CC=C1C(C)(C)C.CC(C)(C)C1=C(Br)C=C2C=CCC2=C1.CC(C)(C)C1=C(Br)C=CC(O)=C1.CC(C)(C)C1=C(Cl)C=C2C=CCC2=C1.CC(C)(C)C1=C(Cl)C=CC2=C1C=CN2.CC(C)(C)C1=CC=C(Cl)C=C1F.CC(C)(C)C1=CC=CC2=C1C=CS2.CC(C)(C)C1=CC=CC=C1N1CCCCC1.CC(C)(C)C1=CNC2=C1C(Cl)=CC=C2.CC(C)(C)C1=CNC2=C1C(F)=CC=C2.CC(C)(C)C1=CSC2=C1C=CC=C2.CC(C)(C)C1=NNC2=C1C=CC=C2.CC1=C(F)C(C(C)(C)C)=C(Cl)C(Cl)=C1.CC1=C(F)C(C(C)(C)C)=CC=C1.CC1=CC(C(C)(C)C)=C(Cl)C=C1.CC1=CC=CC(Cl)=C1C(C)(C)C.COC1=C(F)C(F)=C(C(C)(C)C)C=C1 QJXZPJOHMLQWLR-UHFFFAOYSA-N 0.000 description 2
- FXZMNZFGHBMUKO-STZFKDTASA-N CC(=O)CC1=CC=CC=C1C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 Chemical compound CC(=O)CC1=CC=CC=C1C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 FXZMNZFGHBMUKO-STZFKDTASA-N 0.000 description 2
- FAVZNNUGTCUCRV-DMNPIWIWSA-N CC(C)(C)/C=C/C1=CC=CC=C1.CC(C)(C)C1=C(Cl)C=CC=C1C(F)(F)F.CC(C)(C)C1=C2C=CC=CC2=CC2=C1C=CC=C2.CC(C)(C)C1=CC(Cl)=CC=C1Cl.CC(C)(C)C1=CC=CC2=C1C(Cl)=CN2.CC(C)(C)C1=CC=CC2=C1C=CC=C2.CC(C)(C)C1=CC=CC2=C1C=CN2.CC(C)(C)C1=CC=NC2=C1C=CC=C2.CC(C)(C)C1=CNC2=C1C=CC=C2.CC(C)(C)CC1=CC=CC=C1.CC(C)(C)COC1=CC=CC=C1.CC(C)(C)OC1=CC=CC=C1.CC(C)(C)SC1=CC=CC=C1.CC1=C(C(C)(C)C)C2=C(C=C1)NC=C2Cl.CC1=CNC2=C1C(C(C)(C)C)=C(C)C=C2.CC1=CNC2=C1C(C(C)(C)C)=CC=C2.COCCOCCOC1=CC=CC=C1C(C)(C)C Chemical compound CC(C)(C)/C=C/C1=CC=CC=C1.CC(C)(C)C1=C(Cl)C=CC=C1C(F)(F)F.CC(C)(C)C1=C2C=CC=CC2=CC2=C1C=CC=C2.CC(C)(C)C1=CC(Cl)=CC=C1Cl.CC(C)(C)C1=CC=CC2=C1C(Cl)=CN2.CC(C)(C)C1=CC=CC2=C1C=CC=C2.CC(C)(C)C1=CC=CC2=C1C=CN2.CC(C)(C)C1=CC=NC2=C1C=CC=C2.CC(C)(C)C1=CNC2=C1C=CC=C2.CC(C)(C)CC1=CC=CC=C1.CC(C)(C)COC1=CC=CC=C1.CC(C)(C)OC1=CC=CC=C1.CC(C)(C)SC1=CC=CC=C1.CC1=C(C(C)(C)C)C2=C(C=C1)NC=C2Cl.CC1=CNC2=C1C(C(C)(C)C)=C(C)C=C2.CC1=CNC2=C1C(C(C)(C)C)=CC=C2.COCCOCCOC1=CC=CC=C1C(C)(C)C FAVZNNUGTCUCRV-DMNPIWIWSA-N 0.000 description 2
- FDIWGZOGYQRRMD-UHFFFAOYSA-N CC(C)(C)C(=O)NC1=CC=C(Cl)C=C1.CC(C)(C)C1=C(Cl)C=CC=C1Cl.CC(C)(C)C1=CC=C(Br)S1.CC(C)(C)C1=CC=CC(Cl)=C1Cl.CC(C)(C)C1=CC=CN=C1Br.CC(C)(C)C1=CC=CS1.CC(C)(C)C1=CSC(C2=CC=CC=C2)=C1.CC(C)(C)C1=NC=CS1.CC(C)(C)C1=NC=NC2=C1C=CS2.CC(C)CN1C=CC=C1C(C)(C)C.CC1=C(C(C)(C)C)C(Cl)=CC=C1.CC1=CC=C(C)C(C(C)(C)C)=C1.CC1=CC=C(Cl)C(Cl)=C1C(C)(C)C.CC1=CC=C(Cl)C(F)=C1C(C)(C)C.CCCNC(=O)C(C)(C)C.CN(C1=CC=CC=C1)C(C)(C)C.COC1=C(C)C=C(C(C)(C)C)C(C)=C1 Chemical compound CC(C)(C)C(=O)NC1=CC=C(Cl)C=C1.CC(C)(C)C1=C(Cl)C=CC=C1Cl.CC(C)(C)C1=CC=C(Br)S1.CC(C)(C)C1=CC=CC(Cl)=C1Cl.CC(C)(C)C1=CC=CN=C1Br.CC(C)(C)C1=CC=CS1.CC(C)(C)C1=CSC(C2=CC=CC=C2)=C1.CC(C)(C)C1=NC=CS1.CC(C)(C)C1=NC=NC2=C1C=CS2.CC(C)CN1C=CC=C1C(C)(C)C.CC1=C(C(C)(C)C)C(Cl)=CC=C1.CC1=CC=C(C)C(C(C)(C)C)=C1.CC1=CC=C(Cl)C(Cl)=C1C(C)(C)C.CC1=CC=C(Cl)C(F)=C1C(C)(C)C.CCCNC(=O)C(C)(C)C.CN(C1=CC=CC=C1)C(C)(C)C.COC1=C(C)C=C(C(C)(C)C)C(C)=C1 FDIWGZOGYQRRMD-UHFFFAOYSA-N 0.000 description 2
- OLFABXWPDVRKBV-UHFFFAOYSA-N CC(C)(C)C1=C(CC2=CC=CC=C2)C=CC=C1.CC(C)(C)C1=CC=C(C(F)(F)F)C=C1.CC(C)(C)C1=CC=C(C2=CC=NC=C2)C=C1.CC(C)(C)C1=CC=C(F)C=C1.CC(C)(C)C1=CC=C(O)C=C1.CC(C)(C)C1=CC=C(OC(F)(F)F)C=C1.CC(C)(C)C1=CC=CC=C1.CC1=C(C(C)(C)C)C(Cl)=CC=C1F.CC1=C(C(C)(C)C)C=C(N(C)C)C=C1.CC1=C(C(C)(C)C)C=CC(F)=C1.CC1=C(C(C)(C)C)C=CC=C1.CC1=C(C(C)(C)C)C=CC=C1.CC1=C(C(C)(C)C)C=CC=C1.CC1=C(C(C)(C)C)C=CC=C1.CC1=C(C(C)(C)C)C=CC=C1F.CC1=CC(C)=C(C(C)(C)C)C=C1.COC(=O)C1=CC=C(C(C)(C)C)C=C1.COC1=CC(C)=C(C(C)(C)C)C=C1.COC1=CC=C(C(C)(C)C)C=C1 Chemical compound CC(C)(C)C1=C(CC2=CC=CC=C2)C=CC=C1.CC(C)(C)C1=CC=C(C(F)(F)F)C=C1.CC(C)(C)C1=CC=C(C2=CC=NC=C2)C=C1.CC(C)(C)C1=CC=C(F)C=C1.CC(C)(C)C1=CC=C(O)C=C1.CC(C)(C)C1=CC=C(OC(F)(F)F)C=C1.CC(C)(C)C1=CC=CC=C1.CC1=C(C(C)(C)C)C(Cl)=CC=C1F.CC1=C(C(C)(C)C)C=C(N(C)C)C=C1.CC1=C(C(C)(C)C)C=CC(F)=C1.CC1=C(C(C)(C)C)C=CC=C1.CC1=C(C(C)(C)C)C=CC=C1.CC1=C(C(C)(C)C)C=CC=C1.CC1=C(C(C)(C)C)C=CC=C1.CC1=C(C(C)(C)C)C=CC=C1F.CC1=CC(C)=C(C(C)(C)C)C=C1.COC(=O)C1=CC=C(C(C)(C)C)C=C1.COC1=CC(C)=C(C(C)(C)C)C=C1.COC1=CC=C(C(C)(C)C)C=C1 OLFABXWPDVRKBV-UHFFFAOYSA-N 0.000 description 2
- ZMIHOZFJHVJSJU-WQBVGAKHSA-N CC(C)(C)CC(C1=CC=CC=C1)=C1C(=O)CC(C2=CC=CC=C2)CC1=O.CC(C)(C)CC(CO)=C1C(=O)CC(C2=CC=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C(Cl)=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=C(O)C=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CNC3=C2C(F)=CC=C3)CC1=O.CC(CC(C)(C)C)=C1C(=O)CC(C2=CC=CC=C2)CC1=O.CC1=C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=CC=C1.CN(C)C1=CC(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)=C(Br)C=C1.COC1=CC(OC)=C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=C1 Chemical compound CC(C)(C)CC(C1=CC=CC=C1)=C1C(=O)CC(C2=CC=CC=C2)CC1=O.CC(C)(C)CC(CO)=C1C(=O)CC(C2=CC=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C(Cl)=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=C(O)C=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CNC3=C2C(F)=CC=C3)CC1=O.CC(CC(C)(C)C)=C1C(=O)CC(C2=CC=CC=C2)CC1=O.CC1=C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=CC=C1.CN(C)C1=CC(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)=C(Br)C=C1.COC1=CC(OC)=C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=C1 ZMIHOZFJHVJSJU-WQBVGAKHSA-N 0.000 description 2
- WOBPXQIUOBSJRA-IWPZNRJESA-N CC(C)(C)CC=C1C(=O)CC(C2=C(Br)C=C(F)C=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C(Br)C=CC3=C2C(Cl)=CN3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C3C=CC=CC3=CC3=C2C=CC=C3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=C(F)C=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC3=C2C(Cl)=CN3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC3=C2C=CN3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC3=C2C=CS3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC=C2)C(F)C1=O.CC1=CNC2=C1C(C1CC(=O)C(=CCC(C)(C)C)C(=O)C1)=C(Br)C=C2.CC1=CNC2=C1C(C1CC(=O)C(=CCC(C)(C)C)C(=O)C1)=CC=C2 Chemical compound CC(C)(C)CC=C1C(=O)CC(C2=C(Br)C=C(F)C=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C(Br)C=CC3=C2C(Cl)=CN3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C3C=CC=CC3=CC3=C2C=CC=C3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=C(F)C=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC3=C2C(Cl)=CN3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC3=C2C=CN3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC3=C2C=CS3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC=C2)C(F)C1=O.CC1=CNC2=C1C(C1CC(=O)C(=CCC(C)(C)C)C(=O)C1)=C(Br)C=C2.CC1=CNC2=C1C(C1CC(=O)C(=CCC(C)(C)C)C(=O)C1)=CC=C2 WOBPXQIUOBSJRA-IWPZNRJESA-N 0.000 description 2
- YUQNTHJKSUDMSW-GCBZUDCQSA-N CC(C)(C)CC=C1C(=O)CC(C2=C(Br)C=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C(C(F)(F)F)C=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C(F)C=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=C(C(F)(F)F)C=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=C(OC(F)(F)F)C=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC=C2)CC1=O.CC1=CC(Br)=C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=C1.CC1C(=O)C(=CCC(C)(C)C)C(=O)CC1C1=C(Br)C=CC=C1.CC1C(=O)C(=CCC(C)(C)C)C(=O)CC1C1=CC=CC2=C1C=CN2 Chemical compound CC(C)(C)CC=C1C(=O)CC(C2=C(Br)C=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C(C(F)(F)F)C=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C(F)C=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=C(C(F)(F)F)C=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=C(OC(F)(F)F)C=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC=C2)CC1=O.CC1=CC(Br)=C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=C1.CC1C(=O)C(=CCC(C)(C)C)C(=O)CC1C1=C(Br)C=CC=C1.CC1C(=O)C(=CCC(C)(C)C)C(=O)CC1C1=CC=CC2=C1C=CN2 YUQNTHJKSUDMSW-GCBZUDCQSA-N 0.000 description 2
- LAUNVPVEWIMAIB-UQMNXODTSA-N CC(C)(C)CC=C1C(=O)CC(C2=C(CC3=CC=CC=C3)C=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C(F)C(F)=CC=C2Cl)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC3=C2C=CC=C3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CS2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CNC3=C2C=CC=C3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CSC(C3=CC=CC=C3)=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CSC3=C2C=CC=C3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=NNC3=C2C=CC=C3)CC1=O.COC(=O)C1=CC=C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=C1.COC1=CC=C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=C1 Chemical compound CC(C)(C)CC=C1C(=O)CC(C2=C(CC3=CC=CC=C3)C=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C(F)C(F)=CC=C2Cl)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC3=C2C=CC=C3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CS2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CNC3=C2C=CC=C3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CSC(C3=CC=CC=C3)=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CSC3=C2C=CC=C3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=NNC3=C2C=CC=C3)CC1=O.COC(=O)C1=CC=C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=C1.COC1=CC=C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=C1 LAUNVPVEWIMAIB-UQMNXODTSA-N 0.000 description 2
- HPYJQQHBDADMAB-MDVFONAFSA-N CC(C)(CC(=O)OCCN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C1=CC=CC=C1OC(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 Chemical compound CC(C)(CC(=O)OCCN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C1=CC=CC=C1OC(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 HPYJQQHBDADMAB-MDVFONAFSA-N 0.000 description 2
- XNKCZIGZYWERTG-UYRXBGFRSA-N CC(C)CN1C=CC=C1C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 Chemical compound CC(C)CN1C=CC=C1C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 XNKCZIGZYWERTG-UYRXBGFRSA-N 0.000 description 2
- GAKQLFJYRRVGDV-GZXXAQGXSA-N CC(C)[C@H](CC(=O)CN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 Chemical compound CC(C)[C@H](CC(=O)CN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 GAKQLFJYRRVGDV-GZXXAQGXSA-N 0.000 description 2
- ZSAANCBEQVSOLD-ULDRRJSHSA-N CC(C)[C@H](NC(=O)CCC(=O)OCCN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC1=CC=C(COC(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C=C1 Chemical compound CC(C)[C@H](NC(=O)CCC(=O)OCCN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC1=CC=C(COC(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C=C1 ZSAANCBEQVSOLD-ULDRRJSHSA-N 0.000 description 2
- PVWXAHWWSPUPBH-YSJPEAQMSA-N CC(C)[C@H](NC(=O)CN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC1=CC=C(COC(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C=C1 Chemical compound CC(C)[C@H](NC(=O)CN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC1=CC=C(COC(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C=C1 PVWXAHWWSPUPBH-YSJPEAQMSA-N 0.000 description 2
- UNTKYOVWPRIMRU-UCQKPKSFSA-N CC(NC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1)=C1C(=O)CC(C2=CC=CC=C2)CC1=O Chemical compound CC(NC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1)=C1C(=O)CC(C2=CC=CC=C2)CC1=O UNTKYOVWPRIMRU-UCQKPKSFSA-N 0.000 description 2
- WOXUKXZDVOKJRE-UHFFFAOYSA-N CC1=C(C(C)(C)C)C2=C(C)C(C)=C(C)C(C)=C2N1.CC1=C(C)C(C)=C(C(=O)NC(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(C(=O)OC(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(CC(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(CCC(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C2C(C)=C(C(C)(C)C)NC2=C1C.CC1=C(C)C2=C(C)C(C)=C(C)C(C(C)(C)C)=C2N1.CC1=CN(C)C2=C(C(C)(C)C)C(C)=C(C)C(C)=C12.CC1=CN(C)C2=C(C)C(C(C)(C)C)=C(C)C(C)=C12.CC1=CN(C)C2=C(C)C(C)=C(C(C)(C)C)C(C)=C12.CC1=CNC2=C(C)C(C)=C(C)C(C(C)(C)C)=C12 Chemical compound CC1=C(C(C)(C)C)C2=C(C)C(C)=C(C)C(C)=C2N1.CC1=C(C)C(C)=C(C(=O)NC(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(C(=O)OC(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(CC(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(CCC(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C2C(C)=C(C(C)(C)C)NC2=C1C.CC1=C(C)C2=C(C)C(C)=C(C)C(C(C)(C)C)=C2N1.CC1=CN(C)C2=C(C(C)(C)C)C(C)=C(C)C(C)=C12.CC1=CN(C)C2=C(C)C(C(C)(C)C)=C(C)C(C)=C12.CC1=CN(C)C2=C(C)C(C)=C(C(C)(C)C)C(C)=C12.CC1=CNC2=C(C)C(C)=C(C)C(C(C)(C)C)=C12 WOXUKXZDVOKJRE-UHFFFAOYSA-N 0.000 description 2
- OFGRGPWLAKSJIW-UHFFFAOYSA-N CC1=C(C)C(C(C)(C)C)=C2C(=C1C)N=CN2C.CC1=C(C)C(C(C)(C)C)=C2N=CN(C)C2=C1C.CC1=C(C)C2=C(C(C)(C)C)C(C)=C(C)C(C)=C2S1.CC1=C2N=CN(C)C2=C(C)C(C(C)(C)C)=C1C.CC1=C2N=CN(C)C2=C(C)C(C)=C1C(C)(C)C.CC1=NC2=C(C)C(C(C)(C)C)=C(C)C(C)=C2N1.CC1=NC2=C(C)C(C)=C(C(C)(C)C)C(C)=C2S1.CC1=NC2=C(C)C(C)=C(C)C(C(C)(C)C)=C2S1 Chemical compound CC1=C(C)C(C(C)(C)C)=C2C(=C1C)N=CN2C.CC1=C(C)C(C(C)(C)C)=C2N=CN(C)C2=C1C.CC1=C(C)C2=C(C(C)(C)C)C(C)=C(C)C(C)=C2S1.CC1=C2N=CN(C)C2=C(C)C(C(C)(C)C)=C1C.CC1=C2N=CN(C)C2=C(C)C(C)=C1C(C)(C)C.CC1=NC2=C(C)C(C(C)(C)C)=C(C)C(C)=C2N1.CC1=NC2=C(C)C(C)=C(C(C)(C)C)C(C)=C2S1.CC1=NC2=C(C)C(C)=C(C)C(C(C)(C)C)=C2S1 OFGRGPWLAKSJIW-UHFFFAOYSA-N 0.000 description 2
- OVQRGXFJLRYEGA-OFLTXZQISA-N CC1=C(C)C(C)=C(/C=C/C(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(C(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(NC(=O)C(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(NC(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(OC(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(SC(C)(C)C)C(C)=C1C.CC1=C(C)C2=C(C(C)(C)C)C(C)=C(C)C(C)=C2N1.CC1=C(C)C2=C(C)C(C(C)(C)C)=C(C)C(C)=C2N1.CC1=NC(C(C)(C)C)=C(C)C(C)=C1C.CC1=NC(C)=C(C(C)(C)C)C(C)=C1C.CC1=NC(C)=C(C)C(C(C)(C)C)=C1C Chemical compound CC1=C(C)C(C)=C(/C=C/C(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(C(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(NC(=O)C(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(NC(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(OC(C)(C)C)C(C)=C1C.CC1=C(C)C(C)=C(SC(C)(C)C)C(C)=C1C.CC1=C(C)C2=C(C(C)(C)C)C(C)=C(C)C(C)=C2N1.CC1=C(C)C2=C(C)C(C(C)(C)C)=C(C)C(C)=C2N1.CC1=NC(C(C)(C)C)=C(C)C(C)=C1C.CC1=NC(C)=C(C(C)(C)C)C(C)=C1C.CC1=NC(C)=C(C)C(C(C)(C)C)=C1C OVQRGXFJLRYEGA-OFLTXZQISA-N 0.000 description 2
- NUOIYJIKTRDPRA-UHFFFAOYSA-N CC1=C(C)C(C)=C(C(C)(C)C)S1.CC1=C(C)N(C(C)(C)C)C(C)=C1C.CC1=C(C)N(C)C(C(C)(C)C)=N1.CC1=NC(C(C)(C)C)=C(C)S1.CC1=NC(C)=C(C(C)(C)C)N1C.CC1=NC(C)=C(C(C)(C)C)S1 Chemical compound CC1=C(C)C(C)=C(C(C)(C)C)S1.CC1=C(C)N(C(C)(C)C)C(C)=C1C.CC1=C(C)N(C)C(C(C)(C)C)=N1.CC1=NC(C(C)(C)C)=C(C)S1.CC1=NC(C)=C(C(C)(C)C)N1C.CC1=NC(C)=C(C(C)(C)C)S1 NUOIYJIKTRDPRA-UHFFFAOYSA-N 0.000 description 2
- GXUGNZONBIFNGQ-UHFFFAOYSA-N CC1=C(C)C(C)=C2C(=C1C)C(C(C)(C)C)=NN2C.CC1=C(C)C(C)=C2C(=C1C)N=C(C(C)(C)C)N2C.CC1=C(C)C(C)=C2NC(C(C)(C)C)=NC2=C1C.CC1=NC2=C(C(C)(C)C)C(C)=C(C)C(C)=C2N1.CC1=NC2=C(C(C)(C)C)C(C)=C(C)C(C)=C2N1C.CC1=NC2=C(C)C(C(C)(C)C)=C(C)C(C)=C2N1C.CC1=NC2=C(C)C(C)=C(C(C)(C)C)C(C)=C2N1C.CC1=NC2=C(C)C(C)=C(C)C(C(C)(C)C)=C2N1C Chemical compound CC1=C(C)C(C)=C2C(=C1C)C(C(C)(C)C)=NN2C.CC1=C(C)C(C)=C2C(=C1C)N=C(C(C)(C)C)N2C.CC1=C(C)C(C)=C2NC(C(C)(C)C)=NC2=C1C.CC1=NC2=C(C(C)(C)C)C(C)=C(C)C(C)=C2N1.CC1=NC2=C(C(C)(C)C)C(C)=C(C)C(C)=C2N1C.CC1=NC2=C(C)C(C(C)(C)C)=C(C)C(C)=C2N1C.CC1=NC2=C(C)C(C)=C(C(C)(C)C)C(C)=C2N1C.CC1=NC2=C(C)C(C)=C(C)C(C(C)(C)C)=C2N1C GXUGNZONBIFNGQ-UHFFFAOYSA-N 0.000 description 2
- OFWBRTYUQSGXPX-PDGQHHTCSA-N CC1=CC=C(F)C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)=C1 Chemical compound CC1=CC=C(F)C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)=C1 OFWBRTYUQSGXPX-PDGQHHTCSA-N 0.000 description 2
- NOVAIXKYFYNSEE-UYRXBGFRSA-N CC1C(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C(C)C1C1CCCCC1 Chemical compound CC1C(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C(C)C1C1CCCCC1 NOVAIXKYFYNSEE-UYRXBGFRSA-N 0.000 description 2
- AHRUWSPDLSELNR-PTNGSMBKSA-N CCCNC(=O)C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 Chemical compound CCCNC(=O)C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 AHRUWSPDLSELNR-PTNGSMBKSA-N 0.000 description 2
- AWCSVDWVAOYGIW-UHFFFAOYSA-N CN1C(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)CC1C1=CC=CC=C1 Chemical compound CN1C(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)CC1C1=CC=CC=C1 AWCSVDWVAOYGIW-UHFFFAOYSA-N 0.000 description 2
- USFZMHCRNYIHBT-PDGQHHTCSA-N COC1=C(C)C=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C(Br)=C1 Chemical compound COC1=C(C)C=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C(Br)=C1 USFZMHCRNYIHBT-PDGQHHTCSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- NQFKLEGTXGYTTG-UHFFFAOYSA-N Cc1cc(Br)c(C(CC(C2=CNc3cccc4c3CN(C(CCC(N3)=O)C3=O)C4=O)=O)CC2=O)cc1 Chemical compound Cc1cc(Br)c(C(CC(C2=CNc3cccc4c3CN(C(CCC(N3)=O)C3=O)C4=O)=O)CC2=O)cc1 NQFKLEGTXGYTTG-UHFFFAOYSA-N 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- PVHODPDKIVYOQM-UHFFFAOYSA-N O=C(c1c(C2)c(NCCN3CCN(CCNC=C(C(CC(C4)c5ccccc5)=O)C4=O)CC3)ccc1)N2C(CCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(NCCN3CCN(CCNC=C(C(CC(C4)c5ccccc5)=O)C4=O)CC3)ccc1)N2C(CCC(N1)=O)C1=O PVHODPDKIVYOQM-UHFFFAOYSA-N 0.000 description 2
- CFOWUIOELRAJSH-UHFFFAOYSA-N O=C(c1c2c(OCCOCCOCCOCCN3CCN(CCNC=C(C(CC(C4)c5ccccc5)=O)C4=O)CC3)ccc1)N(C(CCC(N1)=O)C1=O)C2=O Chemical compound O=C(c1c2c(OCCOCCOCCOCCN3CCN(CCNC=C(C(CC(C4)c5ccccc5)=O)C4=O)CC3)ccc1)N(C(CCC(N1)=O)C1=O)C2=O CFOWUIOELRAJSH-UHFFFAOYSA-N 0.000 description 2
- HFBAXYPDTXAQRK-UHFFFAOYSA-N O=C(c1cccc(NC=C(C(CC(C2)c3ccccc3Br)=O)C2=O)c1C1)N1C(CCC(N1)=O)C1=O Chemical compound O=C(c1cccc(NC=C(C(CC(C2)c3ccccc3Br)=O)C2=O)c1C1)N1C(CCC(N1)=O)C1=O HFBAXYPDTXAQRK-UHFFFAOYSA-N 0.000 description 2
- FEFBWFJPVAKBRS-QOMWVZHYSA-N O=C1CC(C2=CC=CC=C2)CC(=O)C1=CNCCN1CCC(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1 Chemical compound O=C1CC(C2=CC=CC=C2)CC(=O)C1=CNCCN1CCC(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1 FEFBWFJPVAKBRS-QOMWVZHYSA-N 0.000 description 2
- ITKXNOOBDPHPKM-UYRXBGFRSA-N O=C1CCC(N2C(=O)C3=CC=C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=C3C2=O)C(=O)N1 ITKXNOOBDPHPKM-UYRXBGFRSA-N 0.000 description 2
- CHZAFPSIXCDXMH-CLCOLTQESA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)CN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)CN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 CHZAFPSIXCDXMH-CLCOLTQESA-N 0.000 description 2
- CCYVLEMOFBYFSF-AQTBWJFISA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)CNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)CNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 CCYVLEMOFBYFSF-AQTBWJFISA-N 0.000 description 2
- XPBIILGCZBUJBO-AQTBWJFISA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)COC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 XPBIILGCZBUJBO-AQTBWJFISA-N 0.000 description 2
- LTPMFCBPKLZRSE-AQTBWJFISA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)CSC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)CSC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 LTPMFCBPKLZRSE-AQTBWJFISA-N 0.000 description 2
- STCLZHHNELCQHH-JWGURIENSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)OCC4=CC=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=C4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)OCC4=CC=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=C4)=C3C2=O)C(=O)N1 STCLZHHNELCQHH-JWGURIENSA-N 0.000 description 2
- YKYFCRCLXCJSGT-PDDAPORNSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)[C@@H]4C[C@H](O)CN4CCCC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)[C@@H]4C[C@H](O)CN4CCCC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 YKYFCRCLXCJSGT-PDDAPORNSA-N 0.000 description 2
- SREJBTNYYRSCOJ-CLCOLTQESA-N O=C1CCC(N2C(=O)C3=CC=CC(OCC(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(OCC(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 SREJBTNYYRSCOJ-CLCOLTQESA-N 0.000 description 2
- BMUZWUMVFDMZBP-QGOAFFKASA-N O=C1CCC(N2CC3=C(N/C=C4\C(=O)CC(CC5=CC=CC=C5)C4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(N/C=C4\C(=O)CC(CC5=CC=CC=C5)C4=O)C=CC=C3C2=O)C(=O)N1 BMUZWUMVFDMZBP-QGOAFFKASA-N 0.000 description 2
- HGQGQVKZUHTRSH-XMHGGMMESA-N O=C1CCC(N2CC3=C(N/C=C4\C(=O)CCC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(N/C=C4\C(=O)CCC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 HGQGQVKZUHTRSH-XMHGGMMESA-N 0.000 description 2
- PKTLXGWGDRTLRY-QJOMJCCJSA-N O=C1CCC(N2CC3=C(NC(=O)C4=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)C=CC=C4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)C4=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)C=CC=C4)C=CC=C3C2=O)C(=O)N1 PKTLXGWGDRTLRY-QJOMJCCJSA-N 0.000 description 2
- OKHTVFPXQURYDH-SXBRIOAWSA-N O=C1CCC(N2CC3=C(NC(=O)C4=CC=C(CN5CCN(CCNC=C6C(=O)CC(C7=CC=CC=C7)CC6=O)CC5)C=C4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)C4=CC=C(CN5CCN(CCNC=C6C(=O)CC(C7=CC=CC=C7)CC6=O)CC5)C=C4)C=CC=C3C2=O)C(=O)N1 OKHTVFPXQURYDH-SXBRIOAWSA-N 0.000 description 2
- UBMZATAHZPQJCM-ULJHMMPZSA-N O=C1CCC(N2CC3=C(NC(=O)C4=CC=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)C=C4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)C4=CC=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)C=C4)C=CC=C3C2=O)C(=O)N1 UBMZATAHZPQJCM-ULJHMMPZSA-N 0.000 description 2
- CQYRQGAPBPQKGS-PLRJNAJWSA-N O=C1CCC(N2CC3=C(NC(=O)C4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)C4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 CQYRQGAPBPQKGS-PLRJNAJWSA-N 0.000 description 2
- XFDFMGKSVJLKBD-QLYXXIJNSA-N O=C1CCC(N2CC3=C(NC(=O)CCC(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)CCC(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 XFDFMGKSVJLKBD-QLYXXIJNSA-N 0.000 description 2
- ZKXXFQIWZUEQOF-KRUMMXJUSA-N O=C1CCC(N2CC3=C(NC(=O)CCC(=O)OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)C1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)CCC(=O)OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)C1 ZKXXFQIWZUEQOF-KRUMMXJUSA-N 0.000 description 2
- MSXMTZFOZIMYKZ-KSEXSDGBSA-N O=C1CCC(N2CC3=C(NC(=O)CCCCCC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)CCCCCC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 MSXMTZFOZIMYKZ-KSEXSDGBSA-N 0.000 description 2
- PKTRPLSDUADOLT-MOHJPFBDSA-N O=C1CCC(N2CC3=C(NC(=O)CN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6Br)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)CN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6Br)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 PKTRPLSDUADOLT-MOHJPFBDSA-N 0.000 description 2
- YGYKKVFZUXWYJB-AFPJDJCSSA-N O=C1CCC(N2CC3=C(NC(=O)COCCCC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)COCCCC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 YGYKKVFZUXWYJB-AFPJDJCSSA-N 0.000 description 2
- HHRCLRLHPAURSU-HKWRFOASSA-N O=C1CCC(N2CC3=C(NC(=O)NCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)NCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 HHRCLRLHPAURSU-HKWRFOASSA-N 0.000 description 2
- NPWCKCDKMOIBDR-KQWNVCNZSA-N O=C1CCC(N2CC3=C(NC(=O)OCC4=CC=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=C4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)OCC4=CC=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=C4)C=CC=C3C2=O)C(=O)N1 NPWCKCDKMOIBDR-KQWNVCNZSA-N 0.000 description 2
- ZCQQLINGRWVBOG-YYEQGNIJSA-N O=C1CCC(N2CC3=C(NC(=O)[C@@H]4C[C@H](O)CN4CCCC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)[C@@H]4C[C@H](O)CN4CCCC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 ZCQQLINGRWVBOG-YYEQGNIJSA-N 0.000 description 2
- GWOLIOFSGYSUCC-BOPFTXTBSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC6=C5C(C(F)(F)F)=CN6)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC6=C5C(C(F)(F)F)=CN6)CC4=O)C=CC=C3C2=O)C(=O)N1 GWOLIOFSGYSUCC-BOPFTXTBSA-N 0.000 description 2
- HYGRNQPKDZBZMO-AQTBWJFISA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 HYGRNQPKDZBZMO-AQTBWJFISA-N 0.000 description 2
- FEVRDCCTMBYSJC-UVTDQMKNSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=NC=CS5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=NC=CS5)CC4=O)C=CC=C3C2=O)C(=O)N1 FEVRDCCTMBYSJC-UVTDQMKNSA-N 0.000 description 2
- RVTDHFMMNIGHGS-PTNGSMBKSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)NC(C5=CC=CC=C5)NC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)NC(C5=CC=CC=C5)NC4=O)C=CC=C3C2=O)C(=O)N1 RVTDHFMMNIGHGS-PTNGSMBKSA-N 0.000 description 2
- DGRZIIRRKHGAPL-MOSHPQCFSA-N O=C1CCC(N2CC3=CC(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=CC(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=CC=C3C2=O)C(=O)N1 DGRZIIRRKHGAPL-MOSHPQCFSA-N 0.000 description 2
- FRNLJHXOTOZHKD-MOSHPQCFSA-N O=C1CCC(N2CC3=CC=C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=CC=C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=C3C2=O)C(=O)N1 FRNLJHXOTOZHKD-MOSHPQCFSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000534944 Thia Species 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 201000003663 Vici syndrome Diseases 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QSNONXQMKXTNQH-UHFFFAOYSA-N benzyl n-(2-oxoethyl)carbamate Chemical compound O=CCNC(=O)OCC1=CC=CC=C1 QSNONXQMKXTNQH-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000011903 deuterated solvents Substances 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 2
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 125000003838 furazanyl group Chemical group 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000005917 in vivo anti-tumor Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KPIVDNYJNOPGBE-UHFFFAOYSA-N 2-aminonicotinic acid Chemical compound NC1=NC=CC=C1C(O)=O KPIVDNYJNOPGBE-UHFFFAOYSA-N 0.000 description 1
- CSTIZSQKHUSKHU-UHFFFAOYSA-N 2-azidoethanamine Chemical compound NCCN=[N+]=[N-] CSTIZSQKHUSKHU-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 102000003954 Autophagy-Related Proteins Human genes 0.000 description 1
- 108010082399 Autophagy-Related Proteins Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CGIWMPNZLIWLNG-MCZLFMOPSA-N C=C1CC(C2=C(F)C(F)=C(OC)C=C2)CC(=O)/C1=C\CC(C)(C)C.CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C(Cl)=CC(Cl)=C2F)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C=CC3=C2C=CN3)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=C(Br)C=C3C=CCC3=C2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=C(Br)C=CC(O)=C2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=C(Cl)C=C3C=CCC3=C2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=CNC3=C2C(Cl)=CC=C3)CC1=O.CC1=CC=CC(Cl)=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1 Chemical compound C=C1CC(C2=C(F)C(F)=C(OC)C=C2)CC(=O)/C1=C\CC(C)(C)C.CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C(Cl)=CC(Cl)=C2F)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C=CC3=C2C=CN3)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=C(Br)C=C3C=CCC3=C2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=C(Br)C=CC(O)=C2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=C(Cl)C=C3C=CCC3=C2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=CNC3=C2C(Cl)=CC=C3)CC1=O.CC1=CC=CC(Cl)=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1 CGIWMPNZLIWLNG-MCZLFMOPSA-N 0.000 description 1
- BMIJBIDSRPRJMN-DCXBDMLBSA-N C=C1CC(C2=C(F)C(F)=C(OC)C=C2)CC(=O)/C1=C\CC(C)(C)C.CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C=CC3=C2C=CN3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC(Cl)=C2F)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=C(Br)C=C3C=CCC3=C2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=C(Br)C=CC(O)=C2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=C(Cl)C=C3C=CCC3=C2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=CNC3=C2C(Cl)=CC=C3)CC1=O.CC1=CC=CC(Cl)=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1 Chemical compound C=C1CC(C2=C(F)C(F)=C(OC)C=C2)CC(=O)/C1=C\CC(C)(C)C.CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C=CC3=C2C=CN3)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC(Cl)=C2F)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=C(Br)C=C3C=CCC3=C2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=C(Br)C=CC(O)=C2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=C(Cl)C=C3C=CCC3=C2)CC1=O.CC(C)(C)NC=C1C(=O)CC(C2=CNC3=C2C(Cl)=CC=C3)CC1=O.CC1=CC=CC(Cl)=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1 BMIJBIDSRPRJMN-DCXBDMLBSA-N 0.000 description 1
- MNJOYVZZUOTVIF-SQRVJWAMSA-N C=C1CCC(N2CC3=C(NC(C)=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.CC(=O)C1C(=O)CC(C2=CC=CC=C2)CC1=O.CC(=O)Cl.O=C1CC(=O)CC(C2=CC=CC=C2)C1 Chemical compound C=C1CCC(N2CC3=C(NC(C)=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.CC(=O)C1C(=O)CC(C2=CC=CC=C2)CC1=O.CC(=O)Cl.O=C1CC(=O)CC(C2=CC=CC=C2)C1 MNJOYVZZUOTVIF-SQRVJWAMSA-N 0.000 description 1
- GTOBGLIFJHUUJL-NFGOXDESSA-N CC(=O)CC1=CC=CC=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C(Cl)=CC(Cl)=C2F)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC=C2N2CCCCC2)CC1=O.CC(C)(C)CC=C1C(=O)CC(CC2=CC=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(NC(=O)C2=CC=CC=C2)CC1=O.CC1=CC=C(NC(=O)C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=C1 Chemical compound CC(=O)CC1=CC=CC=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C(Cl)=CC(Cl)=C2F)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC=C2N2CCCCC2)CC1=O.CC(C)(C)CC=C1C(=O)CC(CC2=CC=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(NC(=O)C2=CC=CC=C2)CC1=O.CC1=CC=C(NC(=O)C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=C1 GTOBGLIFJHUUJL-NFGOXDESSA-N 0.000 description 1
- ZKKQZJXTYVFBMX-MTUURBKFSA-N CC(=O)CC1=CC=CC=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC=C2N2CCCCC2)CC1=O.CC(C)(C)CC=C1C(=O)CC(CC2=CC=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(NC(=O)C2=CC=CC=C2)CC1=O.CC1=CC=C(NC(=O)C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=C1 Chemical compound CC(=O)CC1=CC=CC=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC=C2N2CCCCC2)CC1=O.CC(C)(C)CC=C1C(=O)CC(CC2=CC=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(NC(=O)C2=CC=CC=C2)CC1=O.CC1=CC=C(NC(=O)C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)C=C1 ZKKQZJXTYVFBMX-MTUURBKFSA-N 0.000 description 1
- HYLHQGCKSNLLFU-ALDKTEAASA-N CC(=O)COC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.O=C(CO)OCC1=CC=CC=C1.O=C(O)COC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.O=C1CCC(N2C(=O)C3=CC=CC(O)=C3C2=O)C(=O)N1.O=C1CCC(N2C(=O)C3=CC=CC(OCC(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1.[N-]=[N+]=NCCN1CCN(C(=O)COC2=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)CC1.[N-]=[N+]=NCCN1CCNCC1 Chemical compound CC(=O)COC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.O=C(CO)OCC1=CC=CC=C1.O=C(O)COC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.O=C1CCC(N2C(=O)C3=CC=CC(O)=C3C2=O)C(=O)N1.O=C1CCC(N2C(=O)C3=CC=CC(OCC(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1.[N-]=[N+]=NCCN1CCN(C(=O)COC2=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)CC1.[N-]=[N+]=NCCN1CCNCC1 HYLHQGCKSNLLFU-ALDKTEAASA-N 0.000 description 1
- VBTFONIHEHSEFK-UYRXBGFRSA-N CC(=O)NC1=CC=CC=C1C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 Chemical compound CC(=O)NC1=CC=CC=C1C1CC(=O)C(=CNC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 VBTFONIHEHSEFK-UYRXBGFRSA-N 0.000 description 1
- QWFPVZYHZUHGCP-MGBFBDGPSA-N CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C=CC(C(F)(F)F)=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC(Cl)=C2F)CC1=O.CC1=CC(Cl)=CC=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC1=CC=C(Cl)C(Cl)=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC1=CC=C(Cl)C(F)=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC1=CC=C(F)C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)=C1.CN1C(=O)/C(=C\NC(C)(C)C)C(=O)CC1C1=CC=CC=C1.COC1=C(C)C=C(C2CC(=O)C(=CNC(C)(C)C)C(=O)C2)C(C)=C1 Chemical compound CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C=CC(C(F)(F)F)=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(C2=CC=CC(Cl)=C2F)CC1=O.CC1=CC(Cl)=CC=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC1=CC=C(Cl)C(Cl)=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC1=CC=C(Cl)C(F)=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC1=CC=C(F)C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)=C1.CN1C(=O)/C(=C\NC(C)(C)C)C(=O)CC1C1=CC=CC=C1.COC1=C(C)C=C(C2CC(=O)C(=CNC(C)(C)C)C(=O)C2)C(C)=C1 QWFPVZYHZUHGCP-MGBFBDGPSA-N 0.000 description 1
- RYZSPRUCYQEXCU-DSXJRAJCSA-N CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C=CC(C(F)(F)F)=C2)CC1=O.CC1=CC(Cl)=CC=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC1=CC=C(C)C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)=C1.CC1=CC=C(Cl)C(Cl)=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC1=CC=C(Cl)C(F)=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CN(C1=CC=CC=C1)C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CN1C(=O)/C(=C\NC(C)(C)C)C(=O)CC1C1=CC=CC=C1.COC1=C(C)C=C(C2CC(=O)C(=CNC(C)(C)C)C(=O)C2)C(C)=C1 Chemical compound CC(C)(C)CC=C1C(=O)CC(C2=C(Cl)C=CC(C(F)(F)F)=C2)CC1=O.CC1=CC(Cl)=CC=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC1=CC=C(C)C(C2CC(=O)C(=CCC(C)(C)C)C(=O)C2)=C1.CC1=CC=C(Cl)C(Cl)=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CC1=CC=C(Cl)C(F)=C1C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CN(C1=CC=CC=C1)C1CC(=O)C(=CCC(C)(C)C)C(=O)C1.CN1C(=O)/C(=C\NC(C)(C)C)C(=O)CC1C1=CC=CC=C1.COC1=C(C)C=C(C2CC(=O)C(=CNC(C)(C)C)C(=O)C2)C(C)=C1 RYZSPRUCYQEXCU-DSXJRAJCSA-N 0.000 description 1
- XKZYCLSZKCGRTR-TZRGMIDDSA-N CC(C)(C)CC=C1C(=O)CC(OC2=CC=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(SC2=CC=CC=C2)CC1=O.CC(C)(C)N/C=C1/C(=O)CC(C2=CC=CC=C2)C(C)(C)C1=O.CC(C)(C)N/C=C1/C(=O)NC2=C(C=CC3=CC=CC=C32)C1=O.CC1=CC=C(Cl)C=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CC1=CC=CC(Cl)=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CC1=CC=CC(Cl)=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CC1=NC=CC=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1 Chemical compound CC(C)(C)CC=C1C(=O)CC(OC2=CC=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(SC2=CC=CC=C2)CC1=O.CC(C)(C)N/C=C1/C(=O)CC(C2=CC=CC=C2)C(C)(C)C1=O.CC(C)(C)N/C=C1/C(=O)NC2=C(C=CC3=CC=CC=C32)C1=O.CC1=CC=C(Cl)C=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CC1=CC=CC(Cl)=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CC1=CC=CC(Cl)=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CC1=NC=CC=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1 XKZYCLSZKCGRTR-TZRGMIDDSA-N 0.000 description 1
- MVUWEJJRMOOORJ-DYPCUADKSA-N CC(C)(C)CC=C1C(=O)CC(OC2=CC=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(SC2=CC=CC=C2)CC1=O.CC(C)(C)N/C=C1/C(=O)CC(C2=CC=CC=C2)C(C)(C)C1=O.CC(C)(C)N/C=C1/C(=O)NC2=C(C=CC3=CC=CC=C32)C1=O.CC1=CC=C(Cl)C=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CC1=CC=CC(Cl)=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CC1=CC=CC(Cl)=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CC1=NC=CC=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CN(C1=CC=CC=C1)C1CC(=O)C(=CCC(C)(C)C)C(=O)C1 Chemical compound CC(C)(C)CC=C1C(=O)CC(OC2=CC=CC=C2)CC1=O.CC(C)(C)CC=C1C(=O)CC(SC2=CC=CC=C2)CC1=O.CC(C)(C)N/C=C1/C(=O)CC(C2=CC=CC=C2)C(C)(C)C1=O.CC(C)(C)N/C=C1/C(=O)NC2=C(C=CC3=CC=CC=C32)C1=O.CC1=CC=C(Cl)C=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CC1=CC=CC(Cl)=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CC1=CC=CC(Cl)=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CC1=NC=CC=C1C1CC(=O)C(=CNC(C)(C)C)C(=O)C1.CN(C1=CC=CC=C1)C1CC(=O)C(=CCC(C)(C)C)C(=O)C1 MVUWEJJRMOOORJ-DYPCUADKSA-N 0.000 description 1
- XALQCRXRYCRCIP-WDGPOBMRSA-N CC(C)(C)OC(=O)NCC(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.O=C1CCC(N2CC3=C(NC(=O)CNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound CC(C)(C)OC(=O)NCC(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.O=C1CCC(N2CC3=C(NC(=O)CNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 XALQCRXRYCRCIP-WDGPOBMRSA-N 0.000 description 1
- ZMGDAQLAPVKQLD-MDVFONAFSA-N CC(C)(CC(=O)OCCN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C1=CC=CC=C1NC(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 Chemical compound CC(C)(CC(=O)OCCN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C1=CC=CC=C1NC(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 ZMGDAQLAPVKQLD-MDVFONAFSA-N 0.000 description 1
- ZMGDAQLAPVKQLD-UHFFFAOYSA-N CC(C)(CC(OCCN1CCN(CCNC=C(C(CC(C2)c3ccccc3)=O)C2=O)CC1)=O)c1ccccc1NC(Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O)=O Chemical compound CC(C)(CC(OCCN1CCN(CCNC=C(C(CC(C2)c3ccccc3)=O)C2=O)CC1)=O)c1ccccc1NC(Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O)=O ZMGDAQLAPVKQLD-UHFFFAOYSA-N 0.000 description 1
- SPPWGCYEYAMHDT-UHFFFAOYSA-N CC(C)C1=CC=C(C(C)C)C=C1 Chemical compound CC(C)C1=CC=C(C(C)C)C=C1 SPPWGCYEYAMHDT-UHFFFAOYSA-N 0.000 description 1
- DNIOFGQPEGHMLA-SFQUDFHCSA-N CC(C)CN1C=CC=C1C1CC(=O)/C(=C\NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)O1 Chemical compound CC(C)CN1C=CC=C1C1CC(=O)/C(=C\NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)O1 DNIOFGQPEGHMLA-SFQUDFHCSA-N 0.000 description 1
- PVWXAHWWSPUPBH-UPBPYTAZSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(COC(Nc2cccc3c2CN(C(CCC(N2)=O)C2=O)C3=O)=O)cc1)=O)=O)NC(CN1CCN(CCNC=C(C(CC(C2)c3ccccc3)=O)C2=O)CC1)=O Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(COC(Nc2cccc3c2CN(C(CCC(N2)=O)C2=O)C3=O)=O)cc1)=O)=O)NC(CN1CCN(CCNC=C(C(CC(C2)c3ccccc3)=O)C2=O)CC1)=O PVWXAHWWSPUPBH-UPBPYTAZSA-N 0.000 description 1
- JGYCHQZWKSUNJO-IIKWSDBPSA-N CC(C)[C@H](CC(=O)CN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)CC1=CC=C(COC(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C=C1 Chemical compound CC(C)[C@H](CC(=O)CN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)CC1=CC=C(COC(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C=C1 JGYCHQZWKSUNJO-IIKWSDBPSA-N 0.000 description 1
- CWLZMDUEAZHGKC-ILZWKZQQSA-N CC(C)[C@H](NC(=O)CCC(=O)OCCN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC1=CC=C(COC(=O)NC2=C3CN(C4CCC(=O)CC4=O)C(=O)C3=CC=C2)C=C1 Chemical compound CC(C)[C@H](NC(=O)CCC(=O)OCCN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC1=CC=C(COC(=O)NC2=C3CN(C4CCC(=O)CC4=O)C(=O)C3=CC=C2)C=C1 CWLZMDUEAZHGKC-ILZWKZQQSA-N 0.000 description 1
- UXRQKRLQAFTIGC-VTXCCIQCSA-N CC(C)[C@H](NC(=O)CN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 Chemical compound CC(C)[C@H](NC(=O)CN1CCN(CCNC=C2C(=O)CC(C3=CC=CC=C3)CC2=O)CC1)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1 UXRQKRLQAFTIGC-VTXCCIQCSA-N 0.000 description 1
- KTFKRVMXIVSARW-UHFFFAOYSA-N CC(c1ccc(C=O)cc1)=O Chemical compound CC(c1ccc(C=O)cc1)=O KTFKRVMXIVSARW-UHFFFAOYSA-N 0.000 description 1
- ZBDWKZRIAWZANW-QJOMJCCJSA-N CC1=C(Cl)C(C2CC(=O)C(=CNCCN3CCN(CC(=O)NC4=C5CN(C6CCC(=O)NC6=O)C(=O)C5=CC=C4)CC3)C(=O)C2)=C(Cl)C=C1 Chemical compound CC1=C(Cl)C(C2CC(=O)C(=CNCCN3CCN(CC(=O)NC4=C5CN(C6CCC(=O)NC6=O)C(=O)C5=CC=C4)CC3)C(=O)C2)=C(Cl)C=C1 ZBDWKZRIAWZANW-QJOMJCCJSA-N 0.000 description 1
- OGSSDCQHHBQEHR-UHFFFAOYSA-N CC=C(C(CC(C1)c2ccccc2)=O)C1=O Chemical compound CC=C(C(CC(C1)c2ccccc2)=O)C1=O OGSSDCQHHBQEHR-UHFFFAOYSA-N 0.000 description 1
- QDJDBBWHXBNVCS-CYVLTUHYSA-N CCC(=O)/C(=C/NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1)C(=O)CCC1=CC=CC=C1 Chemical compound CCC(=O)/C(=C/NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1)C(=O)CCC1=CC=CC=C1 QDJDBBWHXBNVCS-CYVLTUHYSA-N 0.000 description 1
- PICAPHVIRKQSEQ-VLXHHWTLSA-N CCCN1CCN(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1.CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.O=C(Cl)N1CCN(C(=O)OCC2=CC=CC=C2)CC1.O=C(OCC1=CC=CC=C1)N1CCN(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1.O=C1CC(C2=CC=CC=C2)CC(=O)C1=CNCCN1CCN(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1.O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1 Chemical compound CCCN1CCN(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1.CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.O=C(Cl)N1CCN(C(=O)OCC2=CC=CC=C2)CC1.O=C(OCC1=CC=CC=C1)N1CCN(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1.O=C1CC(C2=CC=CC=C2)CC(=O)C1=CNCCN1CCN(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1.O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1 PICAPHVIRKQSEQ-VLXHHWTLSA-N 0.000 description 1
- JNFASCRMVZGVKE-KAMYIIQDSA-N CCCNC(=O)C1CC(=O)C(=CNC2=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 Chemical compound CCCNC(=O)C1CC(=O)C(=CNC2=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C(=O)C1 JNFASCRMVZGVKE-KAMYIIQDSA-N 0.000 description 1
- RIHVNYOZQLQIMR-QTVNNTRDSA-N CCCNC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.O=C1CCC(N2CC3=C(NCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.O=CCNC(=O)OCC1=CC=CC=C1 Chemical compound CCCNC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.O=C1CCC(N2CC3=C(NCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.O=CCNC(=O)OCC1=CC=CC=C1 RIHVNYOZQLQIMR-QTVNNTRDSA-N 0.000 description 1
- OVWQTCNDWKFSKP-ILLVPBFUSA-N CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.COC1=CC=C(C(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C=C1.COC1=CC=C(C(=O)O)C=C1.NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.O=C1CCC(N2CC3=C(NC(=O)C4=CC=C(CN5CCN(CCNC=C6C(=O)CC(C7=CC=CC=C7)CC6=O)CC5)C=C4)C=CC=C3C2=O)C(=O)N1.[N-]=[N+]=NCCN1CCN(CC2=CC=C(C(=O)NC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C=C2)CC1.[N-]=[N+]=NCCN1CCNCC1 Chemical compound CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.COC1=CC=C(C(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C=C1.COC1=CC=C(C(=O)O)C=C1.NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.O=C1CCC(N2CC3=C(NC(=O)C4=CC=C(CN5CCN(CCNC=C6C(=O)CC(C7=CC=CC=C7)CC6=O)CC5)C=C4)C=CC=C3C2=O)C(=O)N1.[N-]=[N+]=NCCN1CCN(CC2=CC=C(C(=O)NC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C=C2)CC1.[N-]=[N+]=NCCN1CCNCC1 OVWQTCNDWKFSKP-ILLVPBFUSA-N 0.000 description 1
- YEZMSXZOXMVVHI-AZCAKMLDSA-N CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.NC1=NC=CC=C1C(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.NC1=NC=CC=C1C(=O)O.O=C1CCC(N2CC3=C(NC(=O)C4=CC=CN=C4CC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.NC1=NC=CC=C1C(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.NC1=NC=CC=C1C(=O)O.O=C1CCC(N2CC3=C(NC(=O)C4=CC=CN=C4CC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 YEZMSXZOXMVVHI-AZCAKMLDSA-N 0.000 description 1
- XSBKVLKDLAVRJZ-IBQIFKITSA-N CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.O=C1CCC(=O)O1.O=C1CCC(N2CC3=C(NC(=O)CCC(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1.[N-]=[N+]=NCCN1CCN(C(=O)CCC(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)CC1.[N-]=[N+]=NCCN1CCN(C(=O)CCC(=O)O)CC1.[N-]=[N+]=NCCN1CCNCC1 Chemical compound CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.O=C1CCC(=O)O1.O=C1CCC(N2CC3=C(NC(=O)CCC(=O)N4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1.[N-]=[N+]=NCCN1CCN(C(=O)CCC(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)CC1.[N-]=[N+]=NCCN1CCN(C(=O)CCC(=O)O)CC1.[N-]=[N+]=NCCN1CCNCC1 XSBKVLKDLAVRJZ-IBQIFKITSA-N 0.000 description 1
- BSGGMXKZRRNWQJ-UUQJKBTFSA-N CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.O=C1CCC(N2C(=O)C3=CC=CC(F)=C3C2=O)C(=O)N1.O=C1CCC(N2C(=O)C3=CC=CC(NCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1.[N-]=[N+]=NCCN1CCN(CCN)CC1.[N-]=[N+]=NCCN1CCN(CCNC2=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)CC1 Chemical compound CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.O=C1CCC(N2C(=O)C3=CC=CC(F)=C3C2=O)C(=O)N1.O=C1CCC(N2C(=O)C3=CC=CC(NCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1.[N-]=[N+]=NCCN1CCN(CCN)CC1.[N-]=[N+]=NCCN1CCN(CCNC2=C3C(=O)N(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)CC1 BSGGMXKZRRNWQJ-UUQJKBTFSA-N 0.000 description 1
- GBSDKUIXOFHKBG-LMAFNLKMSA-N CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.O=C1CCC(N2CC3=C(NC(=O)CCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.[N-]=[N+]=NCCCC(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.[N-]=[N+]=NCCN Chemical compound CN(C)C=C1C(=O)CC(C2=CC=CC=C2)CC1=O.O=C1CCC(N2CC3=C(NC(=O)CCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.[N-]=[N+]=NCCCC(=O)NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.[N-]=[N+]=NCCN GBSDKUIXOFHKBG-LMAFNLKMSA-N 0.000 description 1
- JYYBEFUOCDPDHE-ATVHPVEESA-N COC1=C(OC)C=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C(Br)=C1 Chemical compound COC1=C(OC)C=C(C2CC(=O)C(=CNC3=C4CN(C5CCC(=O)NC5=O)C(=O)C4=CC=C3)C(=O)C2)C(Br)=C1 JYYBEFUOCDPDHE-ATVHPVEESA-N 0.000 description 1
- ZDRMNZSYUWWUCV-UHFFFAOYSA-N COCCOCCOc1c(C(CC(C2=CNc3c(CN(C(CCC(N4)=O)C4=O)C4=O)c4ccc3)=O)CC2=O)cccc1 Chemical compound COCCOCCOc1c(C(CC(C2=CNc3c(CN(C(CCC(N4)=O)C4=O)C4=O)c4ccc3)=O)CC2=O)cccc1 ZDRMNZSYUWWUCV-UHFFFAOYSA-N 0.000 description 1
- HAJJECVHWIQUFH-UHFFFAOYSA-N COc1ccc(C(CC(C2=CNc3cccc4c3CN(C(CCC(N3)=O)C3=O)C4=O)=O)CC2=O)cc1 Chemical compound COc1ccc(C(CC(C2=CNc3cccc4c3CN(C(CCC(N3)=O)C3=O)C4=O)=O)CC2=O)cc1 HAJJECVHWIQUFH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GXGHWKKPIXKOMK-UHFFFAOYSA-N Cc1cc(C(Nc2cccc3c2CN(C(CCC(N2)=O)C2=O)C3=O)=O)ccc1NC=C(C(CC(C1)c2ccccc2)=O)C1=O Chemical compound Cc1cc(C(Nc2cccc3c2CN(C(CCC(N2)=O)C2=O)C3=O)=O)ccc1NC=C(C(CC(C1)c2ccccc2)=O)C1=O GXGHWKKPIXKOMK-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- SQYKWFAPLFSGNM-RSGTUZHMSA-N NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.NC1=CC=C(C(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C=C1.O=C(O)C1=CC=C([N+](=O)[O-])C=C1.O=C1CCC(N2CC3=C(NC(=O)C4=CC=C(CC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)C=C4)C=CC=C3C2=O)C(=O)N1.O=C1CCC(N2CC3=C(NC(=O)C4=CC=C([N+](=O)[O-])C=C4)C=CC=C3C2=O)C(=O)N1 Chemical compound NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1.NC1=CC=C(C(=O)NC2=C3CN(C4CCC(=O)NC4=O)C(=O)C3=CC=C2)C=C1.O=C(O)C1=CC=C([N+](=O)[O-])C=C1.O=C1CCC(N2CC3=C(NC(=O)C4=CC=C(CC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)C=C4)C=CC=C3C2=O)C(=O)N1.O=C1CCC(N2CC3=C(NC(=O)C4=CC=C([N+](=O)[O-])C=C4)C=CC=C3C2=O)C(=O)N1 SQYKWFAPLFSGNM-RSGTUZHMSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- WGLHBSMCSHGKHK-UHFFFAOYSA-N O=C(C(CC(C1=CNc2c(CN(C(CCC(N3)=O)C3=O)C3=O)c3ccc2)=O)CC1=O)Nc(cc1)ccc1Cl Chemical compound O=C(C(CC(C1=CNc2c(CN(C(CCC(N3)=O)C3=O)C3=O)c3ccc2)=O)CC1=O)Nc(cc1)ccc1Cl WGLHBSMCSHGKHK-UHFFFAOYSA-N 0.000 description 1
- CCYVLEMOFBYFSF-UHFFFAOYSA-N O=C(CNC=C(C(CC(C1)c2ccccc2)=O)C1=O)Nc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound O=C(CNC=C(C(CC(C1)c2ccccc2)=O)C1=O)Nc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O CCYVLEMOFBYFSF-UHFFFAOYSA-N 0.000 description 1
- XPBIILGCZBUJBO-UHFFFAOYSA-N O=C(COC=C(C(CC(C1)c2ccccc2)=O)C1=O)Nc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound O=C(COC=C(C(CC(C1)c2ccccc2)=O)C1=O)Nc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O XPBIILGCZBUJBO-UHFFFAOYSA-N 0.000 description 1
- GSANERHRXBCQFZ-UHFFFAOYSA-N O=C(COC=C(C(CC(C1)c2ccccc2)=O)C1=O)Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O Chemical compound O=C(COC=C(C(CC(C1)c2ccccc2)=O)C1=O)Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O GSANERHRXBCQFZ-UHFFFAOYSA-N 0.000 description 1
- WXUKLUVXEJNCDQ-UHFFFAOYSA-N O=C(Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)OCc1cnc(NC=C(C(CC(C2)c3ccccc3)=O)C2=O)[s]1 Chemical compound O=C(Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)OCc1cnc(NC=C(C(CC(C2)c3ccccc3)=O)C2=O)[s]1 WXUKLUVXEJNCDQ-UHFFFAOYSA-N 0.000 description 1
- NPWCKCDKMOIBDR-UHFFFAOYSA-N O=C(Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O)OCc1ccc(NC=C(C(CC(C2)c3ccccc3)=O)C2=O)nc1 Chemical compound O=C(Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O)OCc1ccc(NC=C(C(CC(C2)c3ccccc3)=O)C2=O)nc1 NPWCKCDKMOIBDR-UHFFFAOYSA-N 0.000 description 1
- MQCHYOPYZKFHSO-UHFFFAOYSA-N O=C(OCCOCCN1CCN(CCNC=C(C(CC(C2)c3ccccc3)=O)C2=O)CC1)Oc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound O=C(OCCOCCN1CCN(CCNC=C(C(CC(C2)c3ccccc3)=O)C2=O)CC1)Oc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O MQCHYOPYZKFHSO-UHFFFAOYSA-N 0.000 description 1
- DGRZIIRRKHGAPL-UHFFFAOYSA-N O=C(c(c(C1)c2)ccc2NC=C(C(CC(C2)c3ccccc3)=O)C2=O)N1C(CCC(N1)=O)C1=O Chemical compound O=C(c(c(C1)c2)ccc2NC=C(C(CC(C2)c3ccccc3)=O)C2=O)N1C(CCC(N1)=O)C1=O DGRZIIRRKHGAPL-UHFFFAOYSA-N 0.000 description 1
- QCJWAXMOLBQJDQ-SFQUDFHCSA-N O=C(c1c(C2)c(N/C=C(\C(CC(C3F)c4ccccc4)=O)/C3=O)ccc1)N2C(CCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(N/C=C(\C(CC(C3F)c4ccccc4)=O)/C3=O)ccc1)N2C(CCC(N1)=O)C1=O QCJWAXMOLBQJDQ-SFQUDFHCSA-N 0.000 description 1
- GWOLIOFSGYSUCC-UHFFFAOYSA-N O=C(c1c(C2)c(NC=C(C(CC(C3)c4c(c(C(F)(F)F)c[nH]5)c5ccc4)=O)C3=O)ccc1)N2C(CCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(NC=C(C(CC(C3)c4c(c(C(F)(F)F)c[nH]5)c5ccc4)=O)C3=O)ccc1)N2C(CCC(N1)=O)C1=O GWOLIOFSGYSUCC-UHFFFAOYSA-N 0.000 description 1
- JOWLJXRYRCHLQP-UHFFFAOYSA-N O=C(c1c(C2)c(NC=C(C(CC(C3)c4cccc5ccccc45)=O)C3=O)ccc1)N2C(CCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(NC=C(C(CC(C3)c4cccc5ccccc45)=O)C3=O)ccc1)N2C(CCC(N1)=O)C1=O JOWLJXRYRCHLQP-UHFFFAOYSA-N 0.000 description 1
- CWYGHSHQUSTGTJ-UHFFFAOYSA-N O=C(c1c2c(NC=C(C(CC(C3)c4c(c(C(F)(F)F)c[nH]5)c5ccc4)=O)C3=O)ccc1)N(C(CCC(N1)=O)C1=O)C2=O Chemical compound O=C(c1c2c(NC=C(C(CC(C3)c4c(c(C(F)(F)F)c[nH]5)c5ccc4)=O)C3=O)ccc1)N(C(CCC(N1)=O)C1=O)C2=O CWYGHSHQUSTGTJ-UHFFFAOYSA-N 0.000 description 1
- DTCBVKXBKQHHQP-UHFFFAOYSA-N O=C(c1c2c(NS(N3CCN(CCNC=C(C(CC(C4)c5ccccc5)=O)C4=O)CC3)(=O)=O)ccc1)N(C(CCC(N1)=O)C1=O)C2=O Chemical compound O=C(c1c2c(NS(N3CCN(CCNC=C(C(CC(C4)c5ccccc5)=O)C4=O)CC3)(=O)=O)ccc1)N(C(CCC(N1)=O)C1=O)C2=O DTCBVKXBKQHHQP-UHFFFAOYSA-N 0.000 description 1
- CNTANVAWCJELNH-UHFFFAOYSA-N O=C(c1cccc(NC=C(C(CC(C2)c3c(c(Cl)c[nH]4)c4ccc3Br)=O)C2=O)c1C1)N1C(CCC(N1)=O)C1=O Chemical compound O=C(c1cccc(NC=C(C(CC(C2)c3c(c(Cl)c[nH]4)c4ccc3Br)=O)C2=O)c1C1)N1C(CCC(N1)=O)C1=O CNTANVAWCJELNH-UHFFFAOYSA-N 0.000 description 1
- TUCSYLYMBDZFNN-UHFFFAOYSA-N O=C(c1cccc(NC=C(C(CC(C2)c3c(cc[nH]4)c4ccc3)=O)C2=O)c11)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(c1cccc(NC=C(C(CC(C2)c3c(cc[nH]4)c4ccc3)=O)C2=O)c11)N(C(CCC(N2)=O)C2=O)C1=O TUCSYLYMBDZFNN-UHFFFAOYSA-N 0.000 description 1
- RFXFQXRWDGAMBV-UHFFFAOYSA-N O=C(c1cccc(NC=C(C(CC(C2)c3c[nH]c4c3c(F)ccc4)=O)C2=O)c1C1)N1C(CCC(N1)=O)C1=O Chemical compound O=C(c1cccc(NC=C(C(CC(C2)c3c[nH]c4c3c(F)ccc4)=O)C2=O)c1C1)N1C(CCC(N1)=O)C1=O RFXFQXRWDGAMBV-UHFFFAOYSA-N 0.000 description 1
- JEKBYZSMVUSHQP-UHFFFAOYSA-N O=C(c1cccnc1NC=C(C(CC(C1)c2ccccc2)=O)C1=O)Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O Chemical compound O=C(c1cccnc1NC=C(C(CC(C1)c2ccccc2)=O)C1=O)Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O JEKBYZSMVUSHQP-UHFFFAOYSA-N 0.000 description 1
- VDGDSWLRZVGYIX-PPDIBHTLSA-N O=C1CC(C2=CC=CC=C2)CC(=O)C1=CCCCN1CCC(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1 Chemical compound O=C1CC(C2=CC=CC=C2)CC(=O)C1=CCCCN1CCC(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1 VDGDSWLRZVGYIX-PPDIBHTLSA-N 0.000 description 1
- WZVPHFAOJOZSIG-ZRGSRPPYSA-N O=C1CC(C2=CC=CC=C2)CC(=O)C1=CCCCN1CCN(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1 Chemical compound O=C1CC(C2=CC=CC=C2)CC(=O)C1=CCCCN1CCN(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1 WZVPHFAOJOZSIG-ZRGSRPPYSA-N 0.000 description 1
- BHSSVMOLKALQBZ-DDCXCOFVSA-N O=C1CC(C2=CC=CC=C2)CC(=O)C1=CNC1=C2CN(C3CCC(O)=NC3=O)C(=O)C2=CC=C1.O=C1CCC(N2CC3=C(/N=C/C4=C(O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.O=C1CCC(N2CC3=C(/N=C/C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.O=C1CCC(N2CC3=C(CC=C/C3=N/C=C3C(=O)CC(C4=CC=CC=C4)CC3=O)C2=O)C(=O)N1.O=C1CCC(N2CC3=C(N/C=C4/C(=O)CC(C5=CC=CC=C5)C=C4O)C=CC=C3C2=O)C(=O)N1.O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(O)=N1.O=C1CCC(N2CC3=C(NC=C4C(O)=CC(C5=CC=CC=C5)C=C4O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CC(C2=CC=CC=C2)CC(=O)C1=CNC1=C2CN(C3CCC(O)=NC3=O)C(=O)C2=CC=C1.O=C1CCC(N2CC3=C(/N=C/C4=C(O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.O=C1CCC(N2CC3=C(/N=C/C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.O=C1CCC(N2CC3=C(CC=C/C3=N/C=C3C(=O)CC(C4=CC=CC=C4)CC3=O)C2=O)C(=O)N1.O=C1CCC(N2CC3=C(N/C=C4/C(=O)CC(C5=CC=CC=C5)C=C4O)C=CC=C3C2=O)C(=O)N1.O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(O)=N1.O=C1CCC(N2CC3=C(NC=C4C(O)=CC(C5=CC=CC=C5)C=C4O)C=CC=C3C2=O)C(=O)N1 BHSSVMOLKALQBZ-DDCXCOFVSA-N 0.000 description 1
- YCAQBCXAVKTPLD-QQTULTPQSA-N O=C1CC(C2=CC=CC=C2)CC(=O)C1=CNCCN1CCN(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1 Chemical compound O=C1CC(C2=CC=CC=C2)CC(=O)C1=CNCCN1CCN(C(=O)N2C(=O)CCC(N3C(=O)C4=CC=CC=C4C3=O)C2=O)CC1 YCAQBCXAVKTPLD-QQTULTPQSA-N 0.000 description 1
- SQLOKLQOWQTBSC-NTCAYCPXSA-N O=C1CCC(N2C(=O)C3=CC=CC(N/C=C4\C(=O)CC(C5=CC=CC=C5)OC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(N/C=C4\C(=O)CC(C5=CC=CC=C5)OC4=O)=C3C2=O)C(=O)N1 SQLOKLQOWQTBSC-NTCAYCPXSA-N 0.000 description 1
- BQAHIPIYRMDRHC-PGMHBOJBSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)C4=CN=C(C(=O)NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)C=C4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)C4=CN=C(C(=O)NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)C=C4)=C3C2=O)C(=O)N1 BQAHIPIYRMDRHC-PGMHBOJBSA-N 0.000 description 1
- DLXZZQBOATVJJZ-SILNSSARSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)CN4CCN(CCNC=C5C(=O)CC(C6=C(Cl)C=CC(C(F)(F)F)=C6Cl)CC5=O)CC4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)CN4CCN(CCNC=C5C(=O)CC(C6=C(Cl)C=CC(C(F)(F)F)=C6Cl)CC5=O)CC4)=C3C2=O)C(=O)N1 DLXZZQBOATVJJZ-SILNSSARSA-N 0.000 description 1
- HGGZAOLXAFIDFT-NKFKGCMQSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)CN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6Br)CC5=O)CC4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)CN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6Br)CC5=O)CC4)=C3C2=O)C(=O)N1 HGGZAOLXAFIDFT-NKFKGCMQSA-N 0.000 description 1
- HSHRTEZIMWMTJR-ULJHMMPZSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)OCC4=CC=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=C4)=C3C2=O)C(=O)C1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)OCC4=CC=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=C4)=C3C2=O)C(=O)C1 HSHRTEZIMWMTJR-ULJHMMPZSA-N 0.000 description 1
- IFPVRTVYQWPNSG-BCSGMDHLSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)[C@@H]4C[C@H](O)CN4CCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC(=O)[C@@H]4C[C@H](O)CN4CCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 IFPVRTVYQWPNSG-BCSGMDHLSA-N 0.000 description 1
- CWYGHSHQUSTGTJ-WJDWOHSUSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=CC=CC6=C5C(C(F)(F)F)=CN6)CC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=CC=CC6=C5C(C(F)(F)F)=CN6)CC4=O)=C3C2=O)C(=O)N1 CWYGHSHQUSTGTJ-WJDWOHSUSA-N 0.000 description 1
- DGBJOZXKQSMQMY-RAXLEYEMSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=NC=CS5)CC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)CC(C5=NC=CS5)CC4=O)=C3C2=O)C(=O)N1 DGBJOZXKQSMQMY-RAXLEYEMSA-N 0.000 description 1
- PEKSHULFTXPGHA-KAMYIIQDSA-N O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)NC(C5=CC=CC=C5)NC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NC=C4C(=O)NC(C5=CC=CC=C5)NC4=O)=C3C2=O)C(=O)N1 PEKSHULFTXPGHA-KAMYIIQDSA-N 0.000 description 1
- YXQVYNUGHWBKGO-DAFNUICNSA-N O=C1CCC(N2C(=O)C3=CC=CC(NCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 YXQVYNUGHWBKGO-DAFNUICNSA-N 0.000 description 1
- BCGJTBBFVLBFDN-CYVLTUHYSA-N O=C1CCC(N2C(=O)C3=CC=CC(NCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C3C2=O)C(=O)N1 BCGJTBBFVLBFDN-CYVLTUHYSA-N 0.000 description 1
- BLMNSHUGNPZYQN-MDVFONAFSA-N O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)C1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)C1 BLMNSHUGNPZYQN-MDVFONAFSA-N 0.000 description 1
- JKUUPCSMFPCQAU-QVTSOHHYSA-N O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)=C3C2=O)C(=O)N1 JKUUPCSMFPCQAU-QVTSOHHYSA-N 0.000 description 1
- ZFAJUIVZXKYXBB-STZFKDTASA-N O=C1CCC(N2C(=O)C3=C\C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C/C=C\3C2=O)C(=O)C1 Chemical compound O=C1CCC(N2C(=O)C3=C\C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C/C=C\3C2=O)C(=O)C1 ZFAJUIVZXKYXBB-STZFKDTASA-N 0.000 description 1
- CWJQYUFVNXYLLS-KSEXSDGBSA-N O=C1CCC(N2CC3=C(NC(=O)C4=C(CC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=CC=C4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)C4=C(CC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=CC=C4)C=CC=C3C2=O)C(=O)N1 CWJQYUFVNXYLLS-KSEXSDGBSA-N 0.000 description 1
- DYYZKVYSQIWOTC-BWAHOGKJSA-N O=C1CCC(N2CC3=C(NC(=O)C4=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)C=CC=C4)C=CC=C3C2=O)C(=O)C1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)C4=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)C=CC=C4)C=CC=C3C2=O)C(=O)C1 DYYZKVYSQIWOTC-BWAHOGKJSA-N 0.000 description 1
- JEKBYZSMVUSHQP-JWGURIENSA-N O=C1CCC(N2CC3=C(NC(=O)C4=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=CC=C4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)C4=C(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=CC=C4)C=CC=C3C2=O)C(=O)N1 JEKBYZSMVUSHQP-JWGURIENSA-N 0.000 description 1
- KNKYXWBBOYEUFD-JWGURIENSA-N O=C1CCC(N2CC3=C(NC(=O)C4=CN=C(C(=O)NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)C=C4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)C4=CN=C(C(=O)NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)C=C4)C=CC=C3C2=O)C(=O)N1 KNKYXWBBOYEUFD-JWGURIENSA-N 0.000 description 1
- DHBJFJQPFJODMZ-KQWNVCNZSA-N O=C1CCC(N2CC3=C(NC(=O)C4=CN=CC(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)=C4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)C4=CN=CC(NC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)=C4)C=CC=C3C2=O)C(=O)N1 DHBJFJQPFJODMZ-KQWNVCNZSA-N 0.000 description 1
- RKSGXSUIBONNAM-WMDMUMDLSA-N O=C1CCC(N2CC3=C(NC(=O)C4CCN(CCCC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)C4CCN(CCCC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 RKSGXSUIBONNAM-WMDMUMDLSA-N 0.000 description 1
- VXLAFQDHYKROHO-NFFVHWSESA-N O=C1CCC(N2CC3=C(NC(=O)CCC(=O)OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)CCC(=O)OCCN4CCN(CCNC=C5C(=O)CC(C6=CC=CC=C6)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 VXLAFQDHYKROHO-NFFVHWSESA-N 0.000 description 1
- ZQLMDWRJJWGEHU-XLNRJJMWSA-N O=C1CCC(N2CC3=C(NC(=O)CCCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)CCCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 ZQLMDWRJJWGEHU-XLNRJJMWSA-N 0.000 description 1
- GNINOXSXLOXUJG-PGMHBOJBSA-N O=C1CCC(N2CC3=C(NC(=O)CN4CCN(CCNC=C5C(=O)CC(C6=C(Cl)C=CC(C(F)(F)F)=C6Cl)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)CN4CCN(CCNC=C5C(=O)CC(C6=C(Cl)C=CC(C(F)(F)F)=C6Cl)CC5=O)CC4)C=CC=C3C2=O)C(=O)N1 GNINOXSXLOXUJG-PGMHBOJBSA-N 0.000 description 1
- GSANERHRXBCQFZ-ZHZULCJRSA-N O=C1CCC(N2CC3=C(NC(=O)COC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)COC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 GSANERHRXBCQFZ-ZHZULCJRSA-N 0.000 description 1
- GDSWWHDDYNWDHU-QNGOZBTKSA-N O=C1CCC(N2CC3=C(NC(=O)COCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)COCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 GDSWWHDDYNWDHU-QNGOZBTKSA-N 0.000 description 1
- LXHGMDRKPLTJAH-ZHZULCJRSA-N O=C1CCC(N2CC3=C(NC(=O)CSC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)CSC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 LXHGMDRKPLTJAH-ZHZULCJRSA-N 0.000 description 1
- HUOONFSRFRFCES-KULFSUQXSA-N O=C1CCC(N2CC3=C(NC(=O)OCC4=CC=C(/N=C/C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=C4)C=CC=C3C2=O)C(=O)C1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)OCC4=CC=C(/N=C/C5C(=O)CC(C6=CC=CC=C6)CC5=O)N=C4)C=CC=C3C2=O)C(=O)C1 HUOONFSRFRFCES-KULFSUQXSA-N 0.000 description 1
- RQYCDBGTXQUMKG-BZBNNRNISA-N O=C1CCC(N2CC3=C(NC(=O)[C@@H]4C[C@H](O)CN4CCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)[C@@H]4C[C@H](O)CN4CCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 RQYCDBGTXQUMKG-BZBNNRNISA-N 0.000 description 1
- SSWHCQNZQQNZHM-ZSVZTZMJSA-N O=C1CCC(N2CC3=C(NC(=O)[C@H](CCCCC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)[C@H](CCCCC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 SSWHCQNZQQNZHM-ZSVZTZMJSA-N 0.000 description 1
- XFVHUDYJIBLCLY-BMXBRTATSA-M O=C1CCC(N2CC3=C(NC(=O)[C@H](CCCCC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.[SH-] Chemical compound O=C1CCC(N2CC3=C(NC(=O)[C@H](CCCCC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1.[SH-] XFVHUDYJIBLCLY-BMXBRTATSA-M 0.000 description 1
- QDWUPRFFLAPBHS-IIHMOPPUSA-N O=C1CCC(N2CC3=C(NC(=O)[C@H](CCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC(=O)[C@H](CCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 QDWUPRFFLAPBHS-IIHMOPPUSA-N 0.000 description 1
- BBSVVTLPUCHISW-BOPFTXTBSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC(C(F)(F)F)=CC=C5F)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC(C(F)(F)F)=CC=C5F)CC4=O)C=CC=C3C2=O)C(=O)N1 BBSVVTLPUCHISW-BOPFTXTBSA-N 0.000 description 1
- XFZWRFGRKBKDKG-UHFFFAOYSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5)NC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5=CC=CC=C5)NC4=O)C=CC=C3C2=O)C(=O)N1 XFZWRFGRKBKDKG-UHFFFAOYSA-N 0.000 description 1
- FGYTYLDVJSTMFV-AQTBWJFISA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5CCCCC5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(C5CCCCC5)CC4=O)C=CC=C3C2=O)C(=O)N1 FGYTYLDVJSTMFV-AQTBWJFISA-N 0.000 description 1
- BMUZWUMVFDMZBP-UHFFFAOYSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CC(CC5=CC=CC=C5)C4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CC(CC5=CC=CC=C5)C4=O)C=CC=C3C2=O)C(=O)N1 BMUZWUMVFDMZBP-UHFFFAOYSA-N 0.000 description 1
- HGQGQVKZUHTRSH-UHFFFAOYSA-N O=C1CCC(N2CC3=C(NC=C4C(=O)CCC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NC=C4C(=O)CCC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 HGQGQVKZUHTRSH-UHFFFAOYSA-N 0.000 description 1
- ZZDTYYNFSSYXAC-HKWRFOASSA-N O=C1CCC(N2CC3=C(NCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=C(NCCNC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=CC=C3C2=O)C(=O)N1 ZZDTYYNFSSYXAC-HKWRFOASSA-N 0.000 description 1
- GSIRBKMNEKXEOM-UKWGHVSLSA-N O=C1CCC(N2CC3=CC=C(CC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=C3C2=O)C(=O)N1 Chemical compound O=C1CCC(N2CC3=CC=C(CC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)C=C3C2=O)C(=O)N1 GSIRBKMNEKXEOM-UKWGHVSLSA-N 0.000 description 1
- IZQZSEVZKXBCIC-HMAPJEAMSA-N O=C1CCC(N2CC3=C\C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C/C=C\3C2=O)C(=O)C1 Chemical compound O=C1CCC(N2CC3=C\C(NC=C4C(=O)CC(C5=CC=CC=C5)CC4=O)=C/C=C\3C2=O)C(=O)C1 IZQZSEVZKXBCIC-HMAPJEAMSA-N 0.000 description 1
- VNBGSVZNZJQZBS-UHFFFAOYSA-N OCC(Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O)=C(C(CC(C1)c2ccccc2)=O)C1=O Chemical compound OCC(Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O)=C(C(CC(C1)c2ccccc2)=O)C1=O VNBGSVZNZJQZBS-UHFFFAOYSA-N 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 201000007902 Primary cutaneous amyloidosis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004642 autophagic pathway Effects 0.000 description 1
- 239000012822 autophagy inhibitor Substances 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- VPYJBEIOKFRWQZ-UHFFFAOYSA-N benzyl 2-hydroxyacetate Chemical compound OCC(=O)OCC1=CC=CC=C1 VPYJBEIOKFRWQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 150000003951 lactams Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 125000000686 lactone group Chemical group 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000005494 pyridonyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to the field of biomedicine, and in particular to an autophagy modulator, particularly a mammalian ATG8 homolog modulator, and a preparation method, a pharmaceutical composition and use thereof.
- Autophagy is a cellular degradative pathway whereby dysfunctional proteins or organelles are transported to lysosome and then digested and degraded. It is a universal and conservative process amongst yeast, plants and mammals.
- the diseases associated with autophagy include liver cancer, lung cancer, pancreatic cancer, breast cancer, cervical cancer, endometrial cancer, colorectal cancer, gastric cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, prostate cancer, leukemia, lymphoma, myeloma, and the other relevant diseases include cardiovascular diseases, autoimmune diseases, neurodegenerative diseases, hypertension, bone tissue cell and bone diseases, Crohn's disease, acute kidney injury, cerebral ischemia, retinal disease, bronchial asthma, Vici syndrome, amyotrophic lateral sclerosis and various infectious diseases.
- Lenalidomide as an immunomodulator, has been approved for use in multiple myeloma, myelodysplastic syndrome and mantle cell lymphoma. Indications for clinical studies also include non-Hodgkin's lymphoma, large B lymphoma, follicular lymphoma, T-cell lymphoma, mucosa-associated lymphoid tumors, plasma cell myeloma, chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), non-small cell lung cancer, liver cancer, renal cancer, ovarian cancer, squamous cell carcinoma, spongioblastoma, thyroid tumor, POEMS syndrome, neurofibomatosis-1, prostatic cancer, carcinoma of urinary bladder, systemic lupus erythematosus, anemia, HIV-1 infection, autism, primary cutaneous amyloidosis, Crohn's disease, and pain syndrome-1 and the like.
- the present invention provides an autophagy modulator, particularly a mammalian ATG8 homolog modulator, and a preparation method, a pharmaceutical composition and use thereof.
- the present invention provides a compound of General Formula (I) below or a pharmaceutically acceptable salt thereof:
- Ar is an isoindolinone-imide group represented by Formula (II):
- a and B are C ⁇ O, and the other is C ⁇ O or CH 2 ;
- R 1 is selected from hydrogen, deuterium, halo, and C1-C4 alkyl
- R 6 , R 7 , R 8 and R 9 is a divalent group selected from O, S, SO 2 , and NH, which is attached to L or directly to X, and the remaining three of R 6 , R 7 , R 8 and R 9 are each independently selected from the group consisting of hydrogen, deuterium, halo, C1-C4 alkyl, unsubstituted or substituted phenyl, and unsubstituted or substituted 5-10 membered heteroaryl; and R 10 is hydrogen; or
- R 6 , R 7 , R 8 and R 9 are each independently selected from the group consisting of hydrogen, deuterium, halo, C1-C4 alkyl, unsubstituted or substituted phenyl, unsubstituted or substituted 5-10 membered heteroaryl, and NR b1 R b′ , in which R b1 and R b′ are each independently selected from the group consisting of hydrogen, C1-C4 alkyl, unsubstituted or substituted phenyl, and unsubstituted or substituted 5-10 membered heteroaryl; and R 10 is absent, and the nitrogen attached to R 10 is directly attached to L or X;
- L is absent, or is a divalent, trivalent or tetravalent linking group, where when L is absent or is a divalent linking group, p is 1; when L is a trivalent linking group, p is 2; when L is a tetravalent linking group, p is 3; and when p is 2 or 3, the 2 or 3 Xs linked to L are the same or different; and
- X is a group represented by General Formula (III):
- R 2 is selected from hydrogen, deuterium, halo, C1-C6 alkyl, unsubstituted or substituted phenyl, and unsubstituted or substituted 5-10 membered heteroaryl;
- W and T are each independently absent, —C(R a1 )(R a1′ )—, —C(R a1 )(R a1′ ) C(R a2 )(R a2′ ))—, —O—, —S— or —NR a3 —, where R a1 , R a1′ , R a2 , R a2′ and R a3 are each independently selected from the group consisting of hydrogen, deuterium, hydroxyl, amino, halo, CN, CO 2 R a4′ , CONR a5 R a5′ , C1-C6 alkyl, C1-C10 heteroalkyl, C2-C4 alkenyl, C2-C4 alkynyl, unsubstituted or substituted —CONH—(C6-C10) aryl, unsubstituted or substituted —CH ⁇ CH—(C6-C10) aryl, unsubsti
- Z is selected from N, O or CR d , in which R d is hydrogen, deuterium, halo, C1-C4 alkyl or C6-C12 aryl; and when Z is O, R 3 is absent;
- R 3 is selected from the group consisting of hydrogen, deuterium, hydroxyl, amino, halo, CN, CO 2 R e1′ , CONR e2 R e2′ , C1-C6 alkyl, C1-C10 heteroalkyl, C2-C4 alkenyl, C2-C4 alkynyl, —O(C6-C10) aryl, unsubstituted or substituted —S(C6-C10) aryl, unsubstituted or substituted —NH(C6-C10) aryl, unsubstituted or substituted —NHC( ⁇ O)(C6-C10) aryl, unsubstituted or substituted —CONH—(C6-C10) aryl, unsubstituted or substituted —CH ⁇ CH—(C6-C10) aryl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl
- Q is absent, O, N(R f ), S or SO 2 , where R f is selected from hydrogen or C1-C4 alkyl,
- unsubstituted or substituted indicates that the group is unsubstituted or substituted with one or more substituents selected from hydroxyl, amino, cyano, nitro, carboxyl, halo, C1-C6 alkyl, C1-C6 haloalkyl and C1-C6 hydroxyalkyl;
- Ar is a group represented by General Formula (IIa):
- B is C ⁇ O or CH 2 ;
- R 1 is selected from hydrogen, deuterium, halo, and C1-C4 alkyl
- R 10 is H, and Y 1 is NH or O, and is attached to L or directly to X; or
- R 10 is absent, and the N attached to R 10 is directly attached to L or X; and Y 1 is H, NH 2 or halo; or
- Ar is selected from the groups of:
- X is selected from the groups represented by General Formulas (IIIa) and (IIIb):
- R 2 is selected from hydrogen, deuterium, halo, C1-C4 alkyl, and unsubstituted or substituted phenyl;
- Q is absent, or selected from NH, or O;
- W is selected from CR g1 R g1′ , O, and NR g2 , in which R g1 , R g1′ and R g2 are each independently hydrogen, C1-C6 alkyl, CO 2 R g3 or CONR g4 R g4′ ; where R g3 , R g4 and R g4′ are each independently hydrogen or C1-C6 alkyl;
- R 3 is selected from the group consisting of unsubstituted or substituted —CONH—(C6-C10) aryl, —CO 2 —(C6-C10) aryl, unsubstituted or substituted —CH ⁇ CH—(C6-C10) aryl, unsubstituted or substituted C6-C10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted 3-10 membered heterocycloalkyl, unsubstituted or substituted 3-7 membered heterocycloalkenyl, unsubstituted or substituted C1-C6 alkyl-C6-C10 aryl, unsubstituted or substituted —O(C6-C10) aryl, unsubstituted or substituted —S(C6-C10) aryl, unsubstituted or substitute
- Z is selected from CR e3 and N, in which R e3 is selected from hydrogen, C1-C6 alkyl, C1-C10 heteroalkyl, C2-C4 alkenyl, C2-C4 alkynyl, and unsubstituted or substituted C6-C10 aryl; and
- the ring C is unsubstituted or substituted C6-C10 aryl, or unsubstituted or substituted 5-10 membered heteroaryl;
- unsubstituted or substituted indicates that the group is unsubstituted or substituted with one or more substituents selected from hydroxyl, amino, cyano, nitro, carboxyl, halo, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 hydroxyl alkyl, and
- R 3 is selected from the following groups:
- X 1 is hydrogen, halo or CF 3 ;
- X 2 is hydrogen, halo or CF 3 ;
- R c1 , R c2 , R c3 , R c4 , R c5 and R c6 are each independently selected from the group consisting of hydrogen, deuterium, hydroxyl, halo, cyano, nitro, formyl, CO 2 R h , CONR h1 R h1′ , NR h2 R h2′ , C1-C4 alkyl, C1-C10 heteroalkyl, C2-C4 alkenyl, C2-C4 alkynyl, unsubstituted or substituted C6-C10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted 3-10 membered heterocycloalkyl, unsubstituted or substituted 3-7 membered heterocycloalkenyl, unsubstituted or substituted C6-C10 aryl
- R c1 and R c2 , or R c2 and R c3 , or R c3 and R c4 , or R c5 and R c6 form, together with the ring atoms in the ring to which they are attached, unsubstituted or substituted C6-10 aryl, or unsubstituted or substituted 5-10 membered heteroaryl,
- unsubstituted or substituted indicates that the group is unsubstituted or substituted with one or more substituents selected from hydroxyl, amino, cyano, nitro, carboxyl, halo, C1-C6 alkyl, C1-C6 haloalkyl and C1-C6hydroxyl alkyl; or
- R 3 is selected from the groups of:
- X is selected from the groups of:
- L is absent or is a divalent group represented by General Formula (IV) or a trivalent group represented by General Formula (V):
- J and M are each independently absent, NR i , O, S, SO 2 , C( ⁇ O) or C( ⁇ S), in which R i is hydrogen, C1-C4 alkyl or C6-C10 aryl;
- K is absent, C1-C10 alkylene, C3-C10 cycloalkylene, C1-C6 heteroalkylene, C2-C6 alkenylene, C2-C6 alkynylene, unsubstituted or substituted C6-C10 arylene, unsubstituted or substituted 5-10 membered heteroarylene, unsubstituted or substituted C3-C8 cycloalkylene, unsubstituted or substituted 3-10 membered non-aromatic heterocyclylene, peptidylene consisting of 2 to 8 identical or different amino acids, or any combination of two, three, or four identical or different groups thereof; and
- K 1 is a trivalent group, selected from the group consisting of C1-C10 alkyl, C3-C10 cycloalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, unsubstituted or substituted C6-C10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-C8 cycloalkyl, unsubstituted or substituted 3-10 membered non-aromatic heterocyclyl, peptidyl consisting of 2 to 8 identical or different amino acids, and any combination of two, three, or four identical or different groups thereof;
- unsubstituted or substituted indicates that the group is unsubstituted or substituted with one or more substituents selected from hydroxyl, amino, cyano, nitro, carboxyl, halo, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 hydroxyalkyl.
- the divalent and trivalent groups represented by General Formulas (IV) and (V) are selected from the following groups or any combinations of identical or different groups thereof:
- n are each independently 0, 1, 2, 3, 4 or 5;
- X b , X c , X h and X i are each independently absent, O, S or NH;
- R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 29 , R 32 , R 33 and R 34 are each independently absent, C1-C10 alkylene, C3-C10 cycloalkylene, C1-C6 heteroalkylene, C2-C6 alkenylene, C2-C6 alkynylene, unsubstituted or substituted C6-C10 arylene, unsubstituted or substituted 5-10 membered heteroarylene, unsubstituted or substituted C3-C8 cycloalkylene, unsubstituted or substituted 3-10 membered non-aromatic heterocyclylene, or any combination of two, three, or four identical or different groups thereof;
- R 30 and R 31 are each independently H, C1-C10 alkyl, C3-C10 cycloalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, unsubstituted or substituted C6-C10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-C8 cycloalkyl, unsubstituted or substituted 3-10 membered non-aromatic heterocyclyl, or any combination of two, three, or four identical or different groups thereof;
- Ar 1 and Ar 2 are each independently unsubstituted or substituted C6-C10 arylene, or unsubstituted or substituted 5-10 membered heteroarylene;
- rings D and E are each independently unsubstituted or substituted 3-10 membered nitrogen-containing heterocyclic ring
- unsubstituted or substituted indicates that the group is unsubstituted or substituted with one or more substituents selected from hydroxyl, amino, cyano, nitro, carboxyl, halo, C1-C6 alkyl, C1-C6 haloalkyl or C1-C6hydroxylalkyl.
- divalent and trivalent groups represented by General Formulas IV and V are selected from the groups of:
- the compound of General Formula (I) is selected from the compounds of General Formulas (VI), (VII), (VIII), (IX), (X) and (XI):
- Y 2 is H, NH 2 or halo
- Y 3 is NH or O.
- the compound of General Formula (I) is selected from:
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof of the present invention, and optionally a pharmaceutically acceptable excipient.
- the present invention also provides the use of the compound or a pharmaceutically acceptable salt thereof of the present invention in the preparation of an autophagy modulator, particularly a mammalian ATG8 homolog modulator, for preventing or treating a disease associated with autophagy.
- an autophagy modulator particularly a mammalian ATG8 homolog modulator
- the present invention also provides a method for modulating autophagy, comprising administering, to a subject in need thereof, the compound or a pharmaceutically acceptable salt thereof according to the present invention, or the pharmaceutical composition according to the present invention.
- the present invention also provides a method for modulating a mammalian ATG8 homolog, comprising administering, to a subject in need thereof, the compound or a pharmaceutically acceptable salt thereof according to the present invention, or the pharmaceutical composition according to the present invention.
- the present invention also provides a method for preventing or treating a disease associated with autophagy, comprising administering, to a subject in need thereof, the compound or a pharmaceutically acceptable salt thereof according to the present invention, or the pharmaceutical composition according to the present invention.
- the diseases associated with autophagy are selected from the group consisting of tumors, cancers, cardiovascular diseases, autoimmune diseases, neurodegenerative diseases, hypertension, bone tissue cell and bone diseases, Crohn's disease, acute kidney injury, cerebral ischemia, retinal disease, bronchial asthma, Vici syndrome, amyotrophic lateral sclerosis and infectious diseases
- the cancers are selected from the group consisting of liver cancer, lung cancer, pancreatic cancer, breast cancer, cervical cancer, endometrial cancer, colorectal cancer, gastric cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, prostate cancer, leukemia, lymphoma, myeloma, and preferably lymphoma, multiple myeloma, leukemia, lung cancer, breast cancer and pancreatic cancer.
- FIG. 1 shows the body weight vs time of each group of mice in the in-vivo pharmacodynamic test in Example 25 of the present invention
- FIG. 2 shows the changes in body weight vs time of each group of mice in the in-vivo pharmacodynamic test in Example 25 of the present invention
- FIG. 3 shows the tumor volume vs time of each group of mice in the in-vivo pharmacodynamic test in Example 25 of the present invention.
- FIG. 4 shows the changes in tumor volume vs time of each group of mice in the in-vivo pharmacodynamic test in Example 25 of the present invention.
- alkyl refers to the “alkyl” and the “alkyl” moiety of “hydroxyl alkyl”, “haloalkyl”, “aryl alkyl”, “alkyl aryl”, “alkoxy” and the like.
- “Pharmaceutical composition” means a composition suitable for administration to a patient.
- the composition may contain a single compound of the present invention, a mixture of the compounds of the present invention, a salt, a solvate, a prodrug, an isomer or a tautomer of the compound of the present invention, or the compound of the present invention in combination with one or more pharmaceutically acceptable carriers or excipients.
- the “subjects” include humans and non-human animals.
- the pharmaceutical composition may be in various forms such as tablets, capsules, powders, syrups, solutions, suspensions, aerosols, and the like, and may be present in a suitable solid or liquid carrier or diluent and in a sterilized container suitable for injection or infusion.
- compositions of the present invention can be prepared according to conventional preparation methods in the pharmaceutical field.
- the formulation of the preparation comprises, in a unit dosage, 0.05-200 mg of the compound of General Formula (I), and preferably 0.1-100 mg of the compound of General Formula (I).
- the compound and pharmaceutical composition of the present invention can be used clinically in mammals, including humans and animals, and can be given through the routes of administration including oral, intranasal, transdermal, transpulmonary, or gastrointestinal tract administration, and most preferably oral administration.
- the most preferred daily dose is 0.01-200 mg/kg body weight in a single dose, or 0.01-100 mg/kg body weight in divided doses. Regardless of the route of administration, the optimal dosage for an individual depends on the particular treatment. Generally, the most suitable dose is found by starting with a small dose, and then gradually increasing the dose.
- Halo refers to fluoro, chloro, bromo, or iodo.
- Alkyl refers to an aliphatic saturated hydrocarbon group, and is preferably a linear or branched alkyl group having 1 to 10 carbon atoms, preferably a linear or branched alkyl group having 1 to 6 carbon atoms, and more preferably a linear or branched alkyl group having 1 to 4 carbon atoms. “Branched” means that one or more alkyl groups having 1 to 4 carbon atoms such as methyl, ethyl or propyl is/are attached to a linear alkyl group. Preferred alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl groups and the like.
- Haloalkyl refers to an alkyl group as defined above, where one or more hydrogen atoms in the alkyl group are substituted with halo as defined above.
- Heteroalkyl means an alkyl group as defined above, where one or more carbon atoms in the alkyl group are replaced by groups independently selected from —O—, —S—, —(S ⁇ O)—, —(O ⁇ S ⁇ O)—, —N(H) and —N—.
- Preferably heteroalkyl groups include, but are not limited to, —O— alkyl, —S— alkyl, —(S ⁇ O)— alkyl, —(O ⁇ S ⁇ O)— alkyl, —N(H) alkyl, —N(alkyl) 2 , and the like.
- Alkenyl means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond, which may be linear or branched and comprises 2 to 10 carbon atoms, preferably 2 to 6 carbon atoms, and more preferably 2 to 4 carbon atoms in a linear or branched chain. “Branched” means that one or more lower alkyl groups is/are attached to a linear alkenyl chain. Preferably alkenyl groups include, but are not limited to, ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl, and decenyl, and the like.
- Alkylene refers to a divalent group obtained by removing a hydrogen atom from the alkyl group defined above.
- alkylene groups include, but are not limited to, methylene, ethylene, propylene, and the like. In general, they can be optionally and equivalently represented herein as -(alkyl)-, for example —CH 2 CH 2 — is ethylene.
- Alkynyl refers to an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond, which may be linear or branched and contains 2 to 10 carbon atoms, preferably 2 to 6 carbon atoms, and more preferably 2 to 4 carbon atoms in the chain. “Branched” means that one or more alkyl groups having 2 to 4 carbon atoms is/are attached to a linear alkynyl group.
- alkynyl groups include, but are not limited to, ethynyl, propynyl, 2-butynyl, and 3-methyl butynyl.
- alkenylene refers to a difunctional group obtained by removing a hydrogen atom from the above-defined alkenyl group.
- alkenylene groups include, but are not limited to, —CH ⁇ CH—, —C(CH 3 ) ⁇ CH—, —CH ⁇ CHCH 2 —, and the like.
- Aryl refers to a carbocyclic aromatic monocyclic or polycyclic ring system having 6 to 14 carbon atoms, and preferably 6 to 10 carbon atoms in the ring.
- the aryl may be optionally substituted with one or more identical or different “substituents” as defined herein.
- Preferably aryl groups include, but are not limited to, phenyl and naphthyl.
- the “monocyclic aryl” means phenyl.
- “Arylene” refers to a divalent functional group obtained by removing a hydrogen atom from the above-defined aryl group.
- Heteroaryl refers to an aromatic monocyclic or polycyclic ring system having 5 to 14 ring atoms and preferably 5 to 10 ring atoms in the ring, where one or more ring atoms are elements other than carbon, such as nitrogen, oxygen, or sulfur, used alone or in combination. Preferably heteroaryl groups contain 5 to 6 ring atoms. “Heteroaryl” may be optionally substituted with one or more substituents as defined herein which may be the same or different. The prefix aza, oxa or thia before the root name heteroaryl means containing at least one nitrogen, oxygen or sulfur atom independently acting as a ring atom.
- heteroaryl also includes a heteroaryl as defined above, which is fused to an aryl as defined above.
- heteroaryl groups include, but are not limited to, pyridyl, pyrazinyl, furyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridone), isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, pyrazolyl, furazanyl, pyrrolyl, triazolyl, 1,2,4-thiadiazolyl, pyridazinyl, quinoxalinyl, phthalazinyl, hydroxyindolyl, imidazo[1,2-a]pyridyl, imidazo[2,1-b]thiazo
- heteroaryl also refers to partially saturated heteroaryl groups, such as tetrahydroisoquinolyl, tetrahydroquinolinyl and the like.
- monocyclic heteroaryl refers to a monocyclic form of a heterocycle as described above, and includes 4- to 7-membered monocyclic heteroaryl groups having from 1 to 4 ring heteroatoms independently selected from N, O and S and oxides thereof. The point of attachment to the parent moiety is any available ring carbon atom or ring heteroatom.
- monocyclic heteroaryl groups include, but are not limited to, pyridyl, pyrazinyl, furyl, thienyl, pyrimidinyl, pyridazinyl, pyridonyl, thiazolyl, isothiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, thiadiazolyl (e.g. 1,2,4-thiadiazolyl), imidazolyl, triazinyl (e.g. 1,2,4-triazinyl) and oxides thereof
- Cycloalkyl refers to a non-aromatic monocyclic or polycyclic ring system containing from 3 to 10 carbon atoms, and preferably from 3 to 6 carbon atoms.
- the cycloalkyl may be optionally substituted with one or more substituents as described in the present invention which are the same or different.
- Monocyclic cycloalkyl refers to a monocyclic form of the cycloalkyl described in the present invention.
- Preferably monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- polycyclic cycloalkyl groups include, but are not limited to, [1.1.1]-bicyclopentyl, 1-decanoyl, norbornyl, adamantyl and the like.
- Cycloalkenyl refers to a non-aromatic monocyclic or polycyclic ring system having from 3 to 10 carbon atoms and containing at least one cyclic carbon-carbon double bond. Preferably cycloalkenyl rings contain from 3 to 7 ring atoms. The cycloalkenyl may be optionally substituted with one or more substituents as described in the present invention, which may be the same or different.
- the term “monocyclic cycloalkenyl” refers to a monocyclic form of the cycloalkenyl as described in the present invention and includes non-aromatic 3- to 7-membered monocyclic cycloalkenyl groups containing one or more carbon-carbon double bonds.
- monocyclic cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptane-1,3-dienyl, and the like.
- polycyclic cycloalkenyl groups include, but are not limited to, norbornenyl.
- Heterocycloalkyl refers to a non-aromatic saturated monocyclic or polycyclic ring system containing from 3 to 10 ring atoms and preferably from 5 to 10 ring atoms, where one or more atoms in the ring system are elements other than carbon, such as nitrogen, oxygen or sulfur, alone or a combination thereof. No adjacent oxygen and/or sulfur atoms are present in the ring system.
- Preferably heterocyclyl groups contain from 5 to 6 ring atoms.
- the heterocyclyl may be optionally substituted with one or more substituents as described in the present invention, which are the same or different.
- heterocyclyl also includes a group in which two available hydrogen atoms on the same carbon atom of the ring system are replaced by a single group ⁇ O (e.g., carbonyl), which may be referred to as “oxo” in the present invention.
- monocyclic heterocycloalkyl refers to a monocyclic form of the heterocycloalkyl group described in the present invention, including 4 to 7 membered monocyclic heterocycloalkyl groups having from 1 to 4 ring heteroatoms independently selected from N, N-oxide, O, S, S-oxide, S(O) and S(O) 2 .
- monocyclic heterocycloalkyl groups include, but are not limited to, piperidinyl, oxetanyl, pyrrolyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuryl, tetrahydrothiophenyl, a lactam group (such as pyrrolidinonyl), a lactone group and oxides thereof
- Heterocycloalkenyl refers to a non-aromatic monocyclic or polycyclic ring system containing from 3 to 10 ring atoms and preferably from 3 to 7 ring atoms, where one or more atoms in the ring system are elements other than carbon, for example, nitrogen, oxygen or sulfur, alone or a combination thereof; and containing at least one carbon-carbon double bond or carbon-nitrogen double bond. No adjacent oxygen and/or sulfur atoms are present in the ring system.
- Preferably heterocycloalkenyl groups contain from 5 to 6 ring atoms.
- heterocycloalkenyl means containing at least one nitrogen, oxygen or sulfur atom independently acting as a ring atom.
- the heterocycloalkenyl may be optionally substituted with one or more substituents as described in the present invention, which are the same or different.
- the nitrogen or sulfur atom in the heterocycloalkenyl group can be optionally oxidized into the corresponding N-oxide, S-oxide or S,S-dioxide.
- heterocycloalkenyl groups include, but are not limited to, 1,2,3,4-tetrahydropyridyl, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridyl, 1,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazolyl, dihydroxazolyl, dihydroxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyl, dihydrofuranyl, fluorodihydrofuranyl and the like.
- Heterocycloalkenyl may also be a substituted ring system where two available hydrogen atoms on the same carbon atom are replaced by a single group ⁇ O (e.g., carbonyl).
- the term “monocyclic heterocycloalkenyl” refers to a monocyclic form of the heterocycloalkenyl group as described in the present invention, including 4- to 7-membered monocyclic heterocycloalkenyl groups having from 1 to 4 ring heteroatoms independently selected from N,N-dioxide, O, S, S-oxide, S(O), and S(O) 2 .
- monocyclic heterocycloalkenyl groups include, but are not limited to, 1,2,3,4-tetrahydropyridyl, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridyl, 1,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazolyl, dihydroxazolyl, dihydroxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyl, dihydrofuranyl, fluorodihydrofuranyl, dihydrothiophenyl, dihydrothiopyranyl and oxides thereof.
- Arylalkyl refers to an aryl-alkyl- group in which the aryl and alkyl are as defined above. Unless otherwise stated, the alkyl group in the definition “arylalkyl” (or “-alkyl-aryl”) refers to a linear or branched lower alkyl group. Preferably, the arylalkyl includes a lower alkyl group. Preferably arylalkyl groups include, but are not limited to, benzyl, 2-phenethyl and naphthylmethyl. The group is attached to the parent moiety via the alkyl group.
- arylalkyl (or “-alkyl-aryl”), to indicate the point of attachment to the parent moiety.
- heteroaryl alkyl “cycloalkyl alkyl”, “cycloalkenyl alkyl”, “heterocycloalkyl alkyl”, “heterocycloalkenyl alkyl” and the like refer to the heteroaryl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl and the like as described in the present invention, which are attached to the parent moiety via the alkyl group.
- Alkylaryl refers to an alkyl-aryl group where the alkyl and aryl are as described above.
- the alkylaryl group comprises a lower alkyl group.
- alkylaryl includes, but is not limited to, tolyl. The group is attached to the parent moiety via the aryl group.
- Heteroaralkyl refers to a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as described above.
- the heteroaralkyl contains a lower alkyl group.
- aralkyl groups include, but are not limited to, pyridylmethyl and quinolin-3-ylmethyl. The group is attached to the parent moiety via the alkyl group.
- “Hydroxyalkyl” refers to a HO-alkyl- group in which the alkyl group is as defined above. Preferably, the hydroxyalkyl contains a lower alkyl group. Preferably hydroxylalkyl groups include, but are not limited to, hydroxymethyl and 2-hydroxyethyl. “Alkoxy” refers to an alkyl-O— group in which the alkyl is as defined above. Preferably alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The group is attached to the parent moiety via oxygen. “Alkoxyalkyl” refers to a group derived from an alkoxy group and an alkyl group as defined in the present invention. The group is attached to the parent moiety via the alkyl group.
- any of the foregoing functional groups mentioned in the present invention may be unsubstituted or substituted with the substituents described in the present invention.
- substituted or substitution means that one or more hydrogen atoms on a given atom is/are replaced by a group selected from specified groups, provided that the normal valence of the given atom is not exceeded and that the substitution results in a stable compound.
- the combination of the substituents and/or variables is permissible only when the combination results in a stable compound.
- “Stable compound” or “stable structure” means a compound having stability sufficient to be separated from the reaction mixture to a useful purity and prepared into an effective therapeutic agent.
- unsubstituted or substituted means that a particular group is unsubstituted or substituted with one or more substituents.
- substitutions on groups such as cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, and aryl fused cycloalkylalkyl include substitutions on any of the ring moieties and/or alkyl moieties of the groups.
- a tautomer refers to a compound produced by the transfer of a proton from one atom to another atom in a molecule.
- the tautomer also refers to two or more isomeric forms in equilibrium that trend to convert from one isomeric form to another.
- One of ordinary skill in the art will recognize the possibility of all tautomeric ring atom arrangements. All such isomeric forms of these compounds are expressly embraced in the disclosure of the present invention.
- the compound of the present invention includes all tautomers thereof, such as keto-enol tautomers.
- tautomers thereof such as keto-enol tautomers.
- a stereoisomer refers to an isomer of a compound having the same molecular formula and having the same joining order, but different spatial arrangement of atoms in the molecule.
- Stereoisomerism includes cis-trans isomerism, conformational isomerism, enantiomerism and diastereomerism, etc.
- the cis-trans isomerism is caused by the inability of two carbon atoms connected by a double bond to rotate relatively freely around a sigma bond, and generally refers to the cis-trans isomerism of a double bond of an olefin and also a C ⁇ N double bond, a N ⁇ N double bond, and a cyclic compound.
- Enantiomers refer to stereoisomers that are mirror images of each other.
- Diastereomers refer to stereoisomers in which the molecule has two or more chiral centers and the molecules are in a non-mirror relationship. Unless otherwise indicated, the specification is intended to include individual stereoisomers and mixtures thereof.
- the compound of the present invention includes all isomers thereof, such as diastereomers and cis/trans (Z/E) isomers.
- the compound of the present invention can form a metal chelate with one or more metal ions, including, but not limited to, copper, iron, magnesium, calcium, zinc, nickel, and platinum.
- the compound of the present invention includes all metal chelates.
- pharmaceutically acceptable salt refers to a substance that is suitable for use in humans and/or animals without undue adverse side effects (e.g., toxicity, irritation, and allergies), i.e., having a reasonable benefit/risk ratio.
- Pharmaceutically acceptable salts include inorganic and organic salts that can be obtained during the final separation and purification of the compound of the present invention, or by reaction of the free acid or base functional group with a suitable base or acid.
- Acids suitable for salt formation include, but are not limited to, inorganic acids such as hydrochloric acid, phosphoric acid or sulfuric acid, or organic acids such as citric acid, ascorbic acid, tartaric acid, lactic acid, maleic acid, malonic acid, fumaric acid, glycolic acid, succinic acid, propionic acid, acetic acid or methanesulfonic acid.
- Bases suitable for salt formation include, but are not limited to, inorganic bases such as sodium carbonate, sodium hydroxide, potassium carbonate, potassium hydroxide, lithium hydroxide, calcium acetate, calcium chloride or magnesium chloride, and organic bases such as aminoethanol.
- an effective amount means that the amount of the compound of present invention contained in the administered composition is sufficient to modulate (e.g., inhibit or activate) a mammalian ATG8 homolog.
- the compound of the present invention can be prepared by various similar known methods in the art, and the following reaction schemes are an alternative to the preparation of the compound of the present invention. Those skilled in the art will readily appreciate that these compounds can be prepared using known variations of the conditions and procedures in the following preparative methods.
- the starting reactants used in the present invention are commercially available unless otherwise stated.
- the compound of the present invention can be synthesized using one of the following general synthesis methods:
- NMR Nuclear magnetic resonance
- TAA triethylamine
- MS mass spectrometry
- DMF dimethylformamide
- DMF-DMA N,N-dimethylformamide dimethylacetal
- DIPEA diisopropyl ethylamine
- NMP N-methylpyrrolidone
- Lenalidomide benzyl formate (Cbz); sodium sulfate (Na 2 SO 4 ); tert-butyl formate (Boc); 2-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU)
- LCMS Liquid chromatography-mass spectrometry
- TLC thin layer chromatography
- the liquid chromatograph-mass spectrometer is an Agilent 6120B single quadrupole liquid chromatograph-mass spectrometer. Gradient of solvent system: 2 to 98% B over 1.5 min, flow rate 1.2 mL/min; eluent A: water/0.1% TFA, eluent B: ACN/0.1% TFA. Column: Kinetex C18 2.6 ⁇ m 2.1 ⁇ 50 mm (Phenomenex), column temperature: 50° C. LC/MS UPLC system (column: Acquity C18 BEH 1.7 ⁇ m, 2.1 ⁇ 50 mm at 50° C.; eluent A: water+0.1% formic acid; eluent B: ACN. Gradient: 2 to 98% B over 1.4 min, flow rate 1.0 mL/min. HPLC: method group: 10 to 95%; run time: 10 min.
- Nuclear magnetic resonance (NMR) spectra (such as hydrogen spectrum ( 1 H), carbon spectrum ( 13 C), phosphorus spectrum ( 31 P) and fluorine spectrum ( 19 F)) are recorded on Bruker AMX-400, Gemini-300 or AMX-600 NMR Spectrometer, in a deuterated solvent such as deuterated chloroform, deuterated methanol, deuterated water or deuterated dimethyl sulfoxide, with the deuterated solvent peaks as a reference.
- a deuterated solvent such as deuterated chloroform, deuterated methanol, deuterated water or deuterated dimethyl sulfoxide
- the chemical shift ⁇ is in ppm
- the coupling constant (J or J) is in Hertz (Hz)
- the coupling and split peaks in the NMR spectrum are expressed as: broad singlet (brs), singlet (s), doublet (d), doublet of doublets (dd), triplet (t), quartet (q) and multiplet (m).
- Step 1 5-phenyl-1,3-cyclohexandione (30.0 g, 159.4 mmol) was dissolved in chloroform (100 mL). N, N-dimethylformamide dimethyl acetal (DMFDMA, 20 mL) was added slowly at room temperature and stirred for 1 hr, until TLC showed the reaction was complete. The reaction solution was poured into iced water, the chloroform phase was separated, and the aqueous phase was extracted with dichloromethane. The combined organic phase was washed with water and brine, dried (Na 2 SO 4 ), and concentrated. The crude product was separated by column chromatography to afford the target intermediate 1-1 (30.4 g, yield 78.4%).
- DMFDMA N, N-dimethylformamide dimethyl acetal
- Step 2 Lenalidomide (910 mg, 3.5 mmol) and the intermediate 1-1 (1.10 g, 4.5 mmol) were dissolved in a mixture of ethanol (20 mL)/dichloromethane (15 mL). The reaction solution was heated and refluxed for 1 hr, until TLC showed the reaction was complete. The reaction solution was filtered while hot, and the solid was washed with ethanol (10 mL ⁇ 3), dried under suction, beaten in methanol (20 mL), and stirred for 2 hrs. After filtering, the crude product was dissolved in dichloromethane (20 mL), beaten for 1 hr, filtered, and dried to obtain the target compound 1 (1.42 g, yield 89%).
- Example 2 Synthesis of Compounds 2-41, 110-121, 124, 126-128, 130-132, and 134-156
- Step 1 N-Boc-glycine (405 mg, 2.31 mmol) was dissolved in dry DMF (10 ml). HATU (1.10 g, 2.9 mmol) and DIPEA (516 mg, 4 mmol) were added at room temperature, and stirred for 20 min. Then lenalidomide (500 mg, 1.93 mmol) was added and stirred for another 2 hrs until TLC showed the raw materials were completely reacted. The reaction solution was poured into water, and extracted with EtOAc. The organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 42-1 (511 mg, 64%).
- Step 2 The intermediate 42-1 (500 mg, 1.2 mmol) was dissolved in dichloromethane (DCM, 10 ml). Trifluoroacetic acid (TFA, 10 ml) was added and the reaction was stirred at room temperature for 1 hr, until TLC showed the reaction was complete. The TFA was distilled off under reduced pressure, and the crude product was dissolved in ethanol (30 ml). After dissolution, an appropriate amount of N,N-diisopropylethylamine (DIPEA) was added to adjust the pH to be basic. Then, the intermediate 1-1 (365 mg, 1.5 mmol) was added, and stirred at room temperature for 1 hr, until TLC showed that the reaction was almost complete. The reaction solution was poured into iced water, and a solid was precipitated out and filtered with suction. The filter cake was washed 3 times with ethanol and then 3 times with water, and dried to give the compound 42 (150 mg, 24.3%).
- DIPEA N,N-d
- Step 1 The synthesis method was the same as that in Step 1 of Example 3.
- Step 2 The intermediate 50-1 (500 mg, 1.22 mmol) was dissolved in ethanol (20 ml)/water (10 ml). Saturated ammonium chloride (3 mL) and reduced iron powder (560 mg, 10 mmol) were added and refluxed at 80° C. for 1 hr, until TLC showed the reaction was complete. The reaction solution was filtered through diatomaceous earth under sunction while hot. The filter cake was washed with EtOAc. The organic phase was separated, and the aqueous phase was extracted with EtOAc. The combined organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 50-2 (200 mg, 43%).
- Step 3 This step was the same as Step 2 in Example 1.
- Step 1 5-phenyl-1,3-cyclohexandione (10 g, 53.1 mmol), DIPEA (7.11 g, 55 mmol) and 4-dimethylaminopyridine (2.0 g, 16.4 mmol) were dissolved in 1,2-dichloroethane (140 ml). Acetyl chloride (4.32 g, 55 mmol) was slowly added dropwise at RT, and then reacted at 60° C. for 2 hrs, until TLC showed the reaction was complete. The reaction solution was poured into iced water, the organic layer was separated, and the aqueous phase was extracted with dichloromethane. The organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 73-1 (7.31 g, yield 60%).
- Step 2 The intermediate 73-1 (360 mg, 1.56 mmol) and lenalidomide (200 mg, 0.77 mmol) were dissolved in ethanol/chloroform (10 mL/10 mL), and reacted for 2 hrs under reflux by heating, until TLC showed the reaction was complete. The reaction solution was dried by rotation. The crude product was separated by column chromatography on silica gel to give the compound 73 (90 mg, 25%).
- Step 1 Triphosgene (1.14 g, 3.84 mmol) was dissolved in dichloromethane (20 ml). After cooling to ⁇ 10° C., 2-azidoethylamine (1.0 g, 11.61 mmol) was slowly added dropwise, and stirred at ⁇ 10° C. for half an hour. Then, TEA (2.34 g, 23 mmol) was added and reacted for an additional 1 hr. The reaction solution was slowly added dropwise to a solution of lenalidomide (2.0 g, 7.7 mmol) in N,N-dimethylacetamide (20 ml), and then reacted at 65° C. for 1 hr.
- Step 2 The intermediate 77-1 (2.0 g, 5.38 mmol) was dissolved in ethanol (50 ml), and then 10% Pd/C (200 mg) was added, and stirred for 1 hr while hydrogen was introduced at RT, until TLC showed the reaction was complete. The Pd/C was filtered off. Then, the intermediate 1-1 (423 mg, 1.74 mmol) was added, and stirred for another 1 hr at room temperature. A solid was precipitated out, which was filtered under suction, washed 3 times with ethanol and dried to give the compound 77 (533 mg, 68%).
- Step 1 2-aminonicotinic acid (5.00 g, 36.2 mmol) was slowly added to thionyl chloride (50 mL). After stirring at 80° C. for 2 hrs, the thionyl chloride was directly removed under reduced pressure. At RT, The acyl chloride crude product was added in portions to a solution of lenalidomide (2.00 g, 7.72 mmol) and DIPEA (3.8 mL) in N,N-dimethylacetamide (20 mL), and the reaction solution was stirred at room temperature for 2 hrs. The reaction solution was poured into iced water, and extracted with ethyl acetate. The organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 67-1 (620 mg, 21%).
- Step 2 The intermediate 67-1 (200 mg, 0.526 mmol), the intermediate 1-1 (300 mg, 1.23 mmol) and acetic acid (60 mg, 1 mmol) were dissolved in methanol (20 mL)/dichloromethane (20 ml). The reaction solution was heated to 45° C. and reacted overnight. A solid was precipitated out, washed with ethanol and then with dichloromethane, and dried to obtain the compound 67 (32 mg, 10%).
- Step 1 1-(2-azidoethyl)piperazine (0.93 g, 6.0 mmol) was dissolved in tetrahydrofuran (20 mL), succinic anhydride (0.5 g, 5.0 mmol) was added and stirred for 3 hrs at room temperature until the raw materials were detected to disappear by TLC. The reaction solution was concentrated to obtain the intermediate 91-1 (1.46 g, crude) which was directly used in the next step.
- Step 2 The intermediate 91-1 (1.46 g, crude), DIPEA (1.6 mL, 10.0 mmol), and lenalidomide (1.00 g, 3.86 mmol) were dissolved in dry DMF (20 mL), and then HATU (2.8 g, 7.5 mmol) was added and stirred overnight at RT. The reaction solution was poured into iced water, and extracted with EtOAc. The organic phase was washed with water and brine, dried and concentrated. The crude product was separated by column chromatography to afford the intermediate 91-2 (615 mg, 32%).
- Step 3 The synthesis method was the same as that in Step 2 of Example 10.
- Step 1 4-formyl benzoic acid (1.50 g, 10.0 mmol), DIPEA (3.87 g, 30.0 mmol), and lenalidomide (2.10 g, 8.1 mmol) were dissolved in dry DMF (20 mL), and then HATU (5.70 g, 15.0 mmol) was added and stirred overnight at RT. The reaction solution was poured into iced water, and extracted with ethyl acetate. The organic phase was washed with water and brine, dried and concentrated. The crude product was separated by column chromatography to afford the intermediate 92-1 (613 mg, 20%).
- Step 2 The intermediate 92-1 (400 mg, 1.02 mmol) 1-(2-azidoethyl)piperazine (174 mg, 1.13 mmol), and acetic acid (90 mg, 1.5 mmol) were dissolved in dichloromethane (50 mL)/methanol (10 mL), and stirred at room temperature for half an hour. Sodium cyanoborohydride (126 mg, 2.04 mmol) was added, and continuously stirred overnight at room temperature. The reaction solution was poured into iced water, and extracted with dichloromethane. The organic phase was washed with water and brine, dried and concentrated. The crude product was separated by column chromatography to afford the intermediate 92-2 (140 mg, 26%).
- Step 3 The synthesis method was same as that in Step 2 of Example 12.
- Step 1 Thalidomide (2.58 g, 10 mmol) was dissolved in anhydrous DMF (100 mL), and sodium-hydrogen (60%, 440 mg, 11 mmol) was slowly added portionwise in an iced water bath and then stirred for 30 min at room temperature.
- the raw material 101-1 (3.67 g, 13 mmol) was added, and the reaction solution was stirred at room temperature overnight.
- the reaction solution was poured into iced water, and extracted with ethyl acetate. The organic phase was washed with water and brine, dried and concentrated.
- the crude product was separated by column chromatography to afford the intermediate 101-2 (807 mg, 16%).
- Step 2 101-2 (807 mg, 1.6 mmol) was dissolved in methanol (35 ml), 10% Pd/C (80 mg) was added, and stirred for 24 hrs at room temperature under a hydrogen atmosphere (0.2 MPa), until TLC showed the reaction was complete. Pd/C was removed by filtration, and N-Cbz-aminoacetaldehyde (710 mg, 3.6 mmol) and acetic acid (120 mg, 2.0 mmol) were added to the filtrate. After stirring at room temperature for 10 min, sodium cyanoborohydride (302 mg, 4.8 mmol) was added, and stirred at room temperature for 2 hrs. The reaction solution was poured into iced water, and extracted with EtOAc. The organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 95-3 (271 mg, 31%).
- Step 3 The synthesis method was the same as that in Step 2 of Example 12.
- Step 1 The raw materials 105-1 (4.414 g, 16.10 mmol), triphenylphosphine (6.33 g, 24.13 mmol) and benzyl hydroxyacetate (2.51 mL, 17.7 mmol) were dissolved in anhydrous tetrahydrofuran (180 mL), and diisopropyl azodicarboxylate (3.49 mL, 17.7 mmol) was slowly added at 0° C. After stirring for 5 min, the reaction solution was slowly warmed to room temperature and stirred overnight. The reaction solution was poured into iced water, and extracted with dichloromethane. The organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 105-2 (4.1 g, 60%).
- Step 2 The intermediate 105-2 (4.1 g, 9.71 mmol) was dissolved in 5:2 ethyl acetate/dichloromethane (200 mL). 10% Pd/C (460 mg) was added, and the reaction solution was stirred for 3 hrs under a hydrogen atmosphere, until TLC showed the reaction was complete. Methanol (200 mL) was added, and heated to reflux to dissolve the product. Pd/C was removed by filtration, and the filtrate was washed with hot methanol. The organic phase was concentrated to give the intermediate 105-3 (3.23 g, 100%).
- Step 3 The intermediate 105-3 (1.0 g, 3.0 mmol), 1-(2-azidoethyl)piperazine (620 mg, 4.0 mmol), and DIPEA (1.03 g, 8.0 mmol) were dissolved in anhydrous DMF (25 mL). HATU (1.9 g, 5.0 mmol) was added at RT, and the reaction solution was stirred overnight. The reaction solution was poured into iced water, and extracted with EtOAc. The organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 105-4 (720 mg, 51%).
- Step 4 The synthesis method was the same as that in the Step 2 of Example 10.
- Step 1 Lenalidomide (780 mg, 3.0 mmol), N-Cbz-aminoacetaldehyde (770 mg, 4 mmol) were dissolved in anhydrous DMF (25 mL), heated to 80° C., stirred for 6 hrs, and then cooled to RT. Sodium borohydride (190 mg, 5 mmol) was added portionwise, and then stirred for 30 min. The reaction solution was poured into iced water, and extracted with ethyl acetate. The organic phase was washed water and then with brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 108-2 (360 mg, 27%).
- Step 2 The synthesis method was the same as that in Step 2 of Example 10.
- Step 1 The raw material 109-1 (830 mg, 3 mmol), the raw material 109-2 (1.0 g, 5 mmol), and DIPEA (775 mg, 6 mmol) were dissolved in anhydrous NMP (20 ml), heated to 90° C. and reacted overnight. The reaction solution was poured into iced water, and extracted with EtOAc. The organic phase was washed with water and then with brine, dried and concentrated. The crude product was separated by column chromatography to afford the intermediate 109-3 (340 mg, 25%)
- Step 2 The synthesis method was the same as that in Step 2 of Example 10.
- Example 23 Molecular Level Experiments of Targeting LC3B of Example Compounds 1-67, 71-94, and 100-158 or their Salts
- the LC3B protein was successfully expressed and purified, and a preliminary screening and verification platform was established using fluorescence polarization experiments to determine the activity of purchased and synthesized small compound libraries.
- the recombinant protein GST-LC3B (final concentration 180 nM) (SEQ ID NO: 1) and N-terminal FITC-labeled peptide (SEQ ID NO: 2, final concentration 18 nM) were placed in the FP buffer (50 mM HEPES pH 7.5, 0.1 mg/ml BSA and 1 mM DTT), to which a compound serially diluted with the FP buffer was added. Then the mixture was incubated at 25° C. in the dark.
- the fluorescence polarization value PerkinElmer Envision, emission wavelength 480 nm; absorption wavelength 535 nm
- the test results are shown in Table 11.
- the inhibitory activity data of the example compounds for LC3B is summarized (where 1 mM ⁇ IC 50 >100 ⁇ M, the compound is considered to be less active (+) for LC3B; where 15 ⁇ M ⁇ IC 50 ⁇ 100 ⁇ M, the compound is considered to be moderately active for LC3B (+ +); where 3 ⁇ M ⁇ IC 50 ⁇ 15 ⁇ M, the compound is considered to be highly active for LC3B (+++); and where IC 50 ⁇ 3 ⁇ M, the compound is considered to be highly active for LC3B (++++)).
- Example 24 Inhibition of Compounds 1-68, 71-94, and 100-158 or Salts Thereof on Proliferation of Tumor Cells
- the inhibitory effects of the compounds 1-68, 71-94, and 100-158 on proliferation of lymphoma, multiple myeloma, leukemia, lung cancer, breast cancer, pancreatic cancer and other tumor cells were investigated.
- the corresponding complete medium was used, and culture was carried out in an incubator at 37° C. with 5% CO 2 .
- the cells were counted, and inoculated into a 96-well plate at 2000-10000 cells/100 ⁇ l per well according to the cell volume and growth rate.
- the suspended cells were treated immediately, and the adherent cells were treated after adherence.
- Example 25 Pharmacodynamic Study of Compound 1 in a Mouse Model of Multiple Myeloma Xenograft Tumor
- the test animals were female CB17 SCID mice.
- Human RPMI8226 cells were cultured in RPMI1640 medium containing 10% heat-inactivated fetal bovine serum and 1% penicillin-streptomycin double antibody in an incubator with 5% CO 2 at 37° C. When the cells were in an exponential growth phase, the cells were harvested, counted, and subcutaneously inoculated into the right dorsal portion of each mouse. The mice were grouped and administered when the average tumor volume reached about 150 mm 3 . Grouping method: the animals were weighed and measured for the tumor volume before administration, and grouped by block design according to the tumor volume. The dosage regimen is shown in Table 13.
- the diameter of the tumor was measured by a vernier caliper.
- TGI Inhibition rate on tumor weight
- the compound 1 at a dosage of 17.7 mg/kg (1/3 of the molar dose of lenalidomide) has a tumor inhibition effect comparable to that of lenalidomide at a dosage of 30 mg/kg.
- the anti-tumor effect is significantly higher than lenalidomide.
- the compound 1 when used in combination with dexamethasone, the compound 1 also shows a stronger tumor inhibition effect than lenalidomide. Therefore, the compound 1 has significant in-vivo anti-tumor efficacy in human multiple myeloma RPMI8226 cell xenograft tumor model, and is more potent than the commercially available drug lenalidomide.
- RTBW body weight
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hematology (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
- The present invention relates to the field of biomedicine, and in particular to an autophagy modulator, particularly a mammalian ATG8 homolog modulator, and a preparation method, a pharmaceutical composition and use thereof.
- Autophagy is a cellular degradative pathway whereby dysfunctional proteins or organelles are transported to lysosome and then digested and degraded. It is a universal and conservative process amongst yeast, plants and mammals.
- Current studies demonstrate that autophagy plays an important role in maintaining physiological functions, such as providing nutrients during hunger, eliminating cell contents, antigen presentation.
- The diseases associated with autophagy include liver cancer, lung cancer, pancreatic cancer, breast cancer, cervical cancer, endometrial cancer, colorectal cancer, gastric cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, prostate cancer, leukemia, lymphoma, myeloma, and the other relevant diseases include cardiovascular diseases, autoimmune diseases, neurodegenerative diseases, hypertension, bone tissue cell and bone diseases, Crohn's disease, acute kidney injury, cerebral ischemia, retinal disease, bronchial asthma, Vici syndrome, amyotrophic lateral sclerosis and various infectious diseases.
- Currently, there are about 30 clinical trials about autophagy regulation, for example, using hydroxychloroquine alone, chloroquine alone or combined with other anti-tumor drugs to assess the therapeutic effects of autophagy inhibition mainly on refractory or relapsed solid tumors. Relevant results can be retrieved on the clinicaltrial.gov website. However, the side effects of antilysosomal agents and undetermined directions of chemical space optimization may severely limit further development of these types of autophagy inhibitors, because of a lack of definite molecular targets. There is an urgent need to develop a new modulator which directly acts on important proteins on autophagy pathway for treating related diseases, particularly the development prospect of the modulator of mammalian ATG8 homologous proteins targeting LC3B is promising.
- Lenalidomide, as an immunomodulator, has been approved for use in multiple myeloma, myelodysplastic syndrome and mantle cell lymphoma. Indications for clinical studies also include non-Hodgkin's lymphoma, large B lymphoma, follicular lymphoma, T-cell lymphoma, mucosa-associated lymphoid tumors, plasma cell myeloma, chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), non-small cell lung cancer, liver cancer, renal cancer, ovarian cancer, squamous cell carcinoma, spongioblastoma, thyroid tumor, POEMS syndrome, neurofibomatosis-1, prostatic cancer, carcinoma of urinary bladder, systemic lupus erythematosus, anemia, HIV-1 infection, autism, primary cutaneous amyloidosis, Crohn's disease, and pain syndrome-1 and the like.
- Since the indications for autophagy regulators and the indications for lenalidomide cover a wide range, and are overlapped considerably, the development of a small molecule inhibitor having the activity of lenalidomide and its analogues and the activity of autophagy-related proteins, such as mammalian ATG8 homologous family proteins, may have a wide range of application and promising prospect.
- The present invention provides an autophagy modulator, particularly a mammalian ATG8 homolog modulator, and a preparation method, a pharmaceutical composition and use thereof.
- In an aspect, the present invention provides a compound of General Formula (I) below or a pharmaceutically acceptable salt thereof:
-
Ar-L(-X)p (I) - where p is 1, 2 or 3;
- Ar is an isoindolinone-imide group represented by Formula (II):
- wherein one of A and B is C═O, and the other is C═O or CH2;
- R1 is selected from hydrogen, deuterium, halo, and C1-C4 alkyl;
- one of R6, R7, R8 and R9 is a divalent group selected from O, S, SO2, and NH, which is attached to L or directly to X, and the remaining three of R6, R7, R8 and R9 are each independently selected from the group consisting of hydrogen, deuterium, halo, C1-C4 alkyl, unsubstituted or substituted phenyl, and unsubstituted or substituted 5-10 membered heteroaryl; and R10 is hydrogen; or
- R6, R7, R8 and R9 are each independently selected from the group consisting of hydrogen, deuterium, halo, C1-C4 alkyl, unsubstituted or substituted phenyl, unsubstituted or substituted 5-10 membered heteroaryl, and NRb1Rb′, in which Rb1 and Rb′ are each independently selected from the group consisting of hydrogen, C1-C4 alkyl, unsubstituted or substituted phenyl, and unsubstituted or substituted 5-10 membered heteroaryl; and R10 is absent, and the nitrogen attached to R10 is directly attached to L or X;
- L is absent, or is a divalent, trivalent or tetravalent linking group, where when L is absent or is a divalent linking group, p is 1; when L is a trivalent linking group, p is 2; when L is a tetravalent linking group, p is 3; and when p is 2 or 3, the 2 or 3 Xs linked to L are the same or different; and
- X is a group represented by General Formula (III):
- wherein
- R2 is selected from hydrogen, deuterium, halo, C1-C6 alkyl, unsubstituted or substituted phenyl, and unsubstituted or substituted 5-10 membered heteroaryl;
- W and T are each independently absent, —C(Ra1)(Ra1′)—, —C(Ra1)(Ra1′) C(Ra2)(Ra2′))—, —O—, —S— or —NRa3—, where Ra1, Ra1′, Ra2, Ra2′ and Ra3 are each independently selected from the group consisting of hydrogen, deuterium, hydroxyl, amino, halo, CN, CO2Ra4′, CONRa5Ra5′, C1-C6 alkyl, C1-C10 heteroalkyl, C2-C4 alkenyl, C2-C4 alkynyl, unsubstituted or substituted —CONH—(C6-C10) aryl, unsubstituted or substituted —CH═CH—(C6-C10) aryl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-10 cycloalkyl, unsubstituted or substituted 3-10 membered heterocycloalkyl, unsubstituted or substituted 3-7 membered heterocycloalkenyl, unsubstituted or substituted C6-C10 aryl-C1-C6 alkyl, unsubstituted or substituted C1-C6 alkyl-C6-C10 aryl, unsubstituted or substituted 5-10 membered heteroaryl-C1-C6 alkyl or unsubstituted or substituted C1-C6 alkyl-5-10 membered heteroaryl;
- Z is selected from N, O or CRd, in which Rd is hydrogen, deuterium, halo, C1-C4 alkyl or C6-C12 aryl; and when Z is O, R3 is absent;
- R3 is selected from the group consisting of hydrogen, deuterium, hydroxyl, amino, halo, CN, CO2Re1′, CONRe2Re2′, C1-C6 alkyl, C1-C10 heteroalkyl, C2-C4 alkenyl, C2-C4 alkynyl, —O(C6-C10) aryl, unsubstituted or substituted —S(C6-C10) aryl, unsubstituted or substituted —NH(C6-C10) aryl, unsubstituted or substituted —NHC(═O)(C6-C10) aryl, unsubstituted or substituted —CONH—(C6-C10) aryl, unsubstituted or substituted —CH═CH—(C6-C10) aryl, unsubstituted or substituted C6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted 3-10 membered heterocycloalkyl, unsubstituted or substituted 3-7 membered heterocycloalkenyl, unsubstituted or substituted C6-C10 aryl-C1-6 alkyl, unsubstituted or substituted C1-6 alkyl-C6-C10 aryl, unsubstituted or substituted 5-10 membered heteroaryl-C1-C6 alkyl or unsubstituted or substituted C1-C6 alkyl-5-10 membered heteroaryl; and R3 may form, together with the adjacent W and T, unsubstituted or substituted C6-C10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, 5-10 membered cycloalkyl or 5-10 membered heterocycloalkyl, where Re1, Re1′ and Re2′ are each independently hydrogen, hydroxyl, and C1-C6 alkyl; and
- Q is absent, O, N(Rf), S or SO2, where Rf is selected from hydrogen or C1-C4 alkyl,
- where “unsubstituted or substituted” indicates that the group is unsubstituted or substituted with one or more substituents selected from hydroxyl, amino, cyano, nitro, carboxyl, halo, C1-C6 alkyl, C1-C6 haloalkyl and C1-C6 hydroxyalkyl; and
- represents me point or attachment.
- In a specific embodiment, in General Formula (I), Ar is a group represented by General Formula (IIa):
- where
- B is C═O or CH2;
- R1 is selected from hydrogen, deuterium, halo, and C1-C4 alkyl;
- R10 is H, and Y1 is NH or O, and is attached to L or directly to X; or
- R10 is absent, and the N attached to R10 is directly attached to L or X; and Y1 is H, NH2 or halo; or
- Ar is selected from the groups of:
- wherein
- represents the point of attachment.
- In another specific embodiment, in General Formula (I), X is selected from the groups represented by General Formulas (IIIa) and (IIIb):
- wherein
- R2 is selected from hydrogen, deuterium, halo, C1-C4 alkyl, and unsubstituted or substituted phenyl;
- Q is absent, or selected from NH, or O;
- W is selected from CRg1Rg1′, O, and NRg2, in which Rg1, Rg1′ and Rg2 are each independently hydrogen, C1-C6 alkyl, CO2Rg3 or CONRg4Rg4′; where Rg3, Rg4 and Rg4′ are each independently hydrogen or C1-C6 alkyl;
- R3 is selected from the group consisting of unsubstituted or substituted —CONH—(C6-C10) aryl, —CO2—(C6-C10) aryl, unsubstituted or substituted —CH═CH—(C6-C10) aryl, unsubstituted or substituted C6-C10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted 3-10 membered heterocycloalkyl, unsubstituted or substituted 3-7 membered heterocycloalkenyl, unsubstituted or substituted C1-C6 alkyl-C6-C10 aryl, unsubstituted or substituted —O(C6-C10) aryl, unsubstituted or substituted —S(C6-C10) aryl, unsubstituted or substituted —NH(C6-C10) aryl, unsubstituted or substituted —NHC(═O)(C6-C10) aryl, or unsubstituted or substituted C1-C6 alkyl-5-10 membered heteroaryl;
- Z is selected from CRe3 and N, in which Re3 is selected from hydrogen, C1-C6 alkyl, C1-C10 heteroalkyl, C2-C4 alkenyl, C2-C4 alkynyl, and unsubstituted or substituted C6-C10 aryl; and
- the ring C is unsubstituted or substituted C6-C10 aryl, or unsubstituted or substituted 5-10 membered heteroaryl;
- where “unsubstituted or substituted” indicates that the group is unsubstituted or substituted with one or more substituents selected from hydroxyl, amino, cyano, nitro, carboxyl, halo, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 hydroxyl alkyl, and
- represents the point of attachment.
- In another specific embodiment, in General Formula (I), R3 is selected from the following groups:
- wherein
- X1 is hydrogen, halo or CF3;
- X2 is hydrogen, halo or CF3;
- Rc1, Rc2, Rc3, Rc4, Rc5 and Rc6 are each independently selected from the group consisting of hydrogen, deuterium, hydroxyl, halo, cyano, nitro, formyl, CO2Rh, CONRh1Rh1′, NRh2Rh2′, C1-C4 alkyl, C1-C10 heteroalkyl, C2-C4 alkenyl, C2-C4 alkynyl, unsubstituted or substituted C6-C10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted 3-10 membered heterocycloalkyl, unsubstituted or substituted 3-7 membered heterocycloalkenyl, unsubstituted or substituted C6-C10 aryl-C1-6 alkyl, unsubstituted or substituted C1-6 alkyl-C6-C10 aryl, unsubstituted or substituted 5-10 membered heteroaryl-C1-C6 alkyl, and unsubstituted or substituted C1-C6 alkyl-5-10 membered heteroaryl, in which Rh, Rh1, Rh1′, Rh2 and Rh2′ are each independently selected from hydrogen and C1-C4 alkyl; or
- Rc1 and Rc2, or Rc2 and Rc3, or Rc3 and Rc4, or Rc5 and Rc6 form, together with the ring atoms in the ring to which they are attached, unsubstituted or substituted C6-10 aryl, or unsubstituted or substituted 5-10 membered heteroaryl,
- where “unsubstituted or substituted” indicates that the group is unsubstituted or substituted with one or more substituents selected from hydroxyl, amino, cyano, nitro, carboxyl, halo, C1-C6 alkyl, C1-C6 haloalkyl and C1-C6hydroxyl alkyl; or
- R3 is selected from the groups of:
- wherein
- represents the point of attachment.
- In another specific embodiment, in General Formula (I), X is selected from the groups of:
- wherein
- represents the point of attachment.
- In another specific embodiment, in General Formula (I), L is absent or is a divalent group represented by General Formula (IV) or a trivalent group represented by General Formula (V):
- wherein
- J and M are each independently absent, NRi, O, S, SO2, C(═O) or C(═S), in which Ri is hydrogen, C1-C4 alkyl or C6-C10 aryl;
- K is absent, C1-C10 alkylene, C3-C10 cycloalkylene, C1-C6 heteroalkylene, C2-C6 alkenylene, C2-C6 alkynylene, unsubstituted or substituted C6-C10 arylene, unsubstituted or substituted 5-10 membered heteroarylene, unsubstituted or substituted C3-C8 cycloalkylene, unsubstituted or substituted 3-10 membered non-aromatic heterocyclylene, peptidylene consisting of 2 to 8 identical or different amino acids, or any combination of two, three, or four identical or different groups thereof; and
- K1 is a trivalent group, selected from the group consisting of C1-C10 alkyl, C3-C10 cycloalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, unsubstituted or substituted C6-C10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-C8 cycloalkyl, unsubstituted or substituted 3-10 membered non-aromatic heterocyclyl, peptidyl consisting of 2 to 8 identical or different amino acids, and any combination of two, three, or four identical or different groups thereof;
- where “unsubstituted or substituted” indicates that the group is unsubstituted or substituted with one or more substituents selected from hydroxyl, amino, cyano, nitro, carboxyl, halo, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 hydroxyalkyl.
- Preferably, the divalent and trivalent groups represented by General Formulas (IV) and (V) are selected from the following groups or any combinations of identical or different groups thereof:
- where m and n are each independently 0, 1, 2, 3, 4 or 5;
- Xb, Xc, Xh and Xi are each independently absent, O, S or NH;
- R22, R23, R24, R25, R26, R27, R29, R32, R33 and R34 are each independently absent, C1-C10 alkylene, C3-C10 cycloalkylene, C1-C6 heteroalkylene, C2-C6 alkenylene, C2-C6 alkynylene, unsubstituted or substituted C6-C10 arylene, unsubstituted or substituted 5-10 membered heteroarylene, unsubstituted or substituted C3-C8 cycloalkylene, unsubstituted or substituted 3-10 membered non-aromatic heterocyclylene, or any combination of two, three, or four identical or different groups thereof;
- R30 and R31 are each independently H, C1-C10 alkyl, C3-C10 cycloalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, unsubstituted or substituted C6-C10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C3-C8 cycloalkyl, unsubstituted or substituted 3-10 membered non-aromatic heterocyclyl, or any combination of two, three, or four identical or different groups thereof;
- Ar1 and Ar2 are each independently unsubstituted or substituted C6-C10 arylene, or unsubstituted or substituted 5-10 membered heteroarylene; and
- the rings D and E are each independently unsubstituted or substituted 3-10 membered nitrogen-containing heterocyclic ring,
- where “unsubstituted or substituted” indicates that the group is unsubstituted or substituted with one or more substituents selected from hydroxyl, amino, cyano, nitro, carboxyl, halo, C1-C6 alkyl, C1-C6 haloalkyl or C1-C6hydroxylalkyl.
- Preferably, the divalent and trivalent groups represented by General Formulas IV and V are selected from the groups of:
- where the group is attached to Ar at the end
- and to the fragment X at the end
- In another specific embodiment, the compound of General Formula (I) is selected from the compounds of General Formulas (VI), (VII), (VIII), (IX), (X) and (XI):
- where A, B, R1, R2, R3, Q, L, W, T, and Z are as defined in corresponding claims;
- Y2 is H, NH2 or halo; and
- Y3 is NH or O.
- In another specific embodiment, the compound of General Formula (I) is selected from:
-
Compound 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 - The present invention also provides a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof of the present invention, and optionally a pharmaceutically acceptable excipient.
- The present invention also provides the use of the compound or a pharmaceutically acceptable salt thereof of the present invention in the preparation of an autophagy modulator, particularly a mammalian ATG8 homolog modulator, for preventing or treating a disease associated with autophagy.
- The present invention also provides a method for modulating autophagy, comprising administering, to a subject in need thereof, the compound or a pharmaceutically acceptable salt thereof according to the present invention, or the pharmaceutical composition according to the present invention.
- The present invention also provides a method for modulating a mammalian ATG8 homolog, comprising administering, to a subject in need thereof, the compound or a pharmaceutically acceptable salt thereof according to the present invention, or the pharmaceutical composition according to the present invention.
- The present invention also provides a method for preventing or treating a disease associated with autophagy, comprising administering, to a subject in need thereof, the compound or a pharmaceutically acceptable salt thereof according to the present invention, or the pharmaceutical composition according to the present invention.
- The diseases associated with autophagy are selected from the group consisting of tumors, cancers, cardiovascular diseases, autoimmune diseases, neurodegenerative diseases, hypertension, bone tissue cell and bone diseases, Crohn's disease, acute kidney injury, cerebral ischemia, retinal disease, bronchial asthma, Vici syndrome, amyotrophic lateral sclerosis and infectious diseases, where the cancers are selected from the group consisting of liver cancer, lung cancer, pancreatic cancer, breast cancer, cervical cancer, endometrial cancer, colorectal cancer, gastric cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, prostate cancer, leukemia, lymphoma, myeloma, and preferably lymphoma, multiple myeloma, leukemia, lung cancer, breast cancer and pancreatic cancer.
-
FIG. 1 shows the body weight vs time of each group of mice in the in-vivo pharmacodynamic test in Example 25 of the present invention; -
FIG. 2 shows the changes in body weight vs time of each group of mice in the in-vivo pharmacodynamic test in Example 25 of the present invention; -
FIG. 3 shows the tumor volume vs time of each group of mice in the in-vivo pharmacodynamic test in Example 25 of the present invention; and -
FIG. 4 shows the changes in tumor volume vs time of each group of mice in the in-vivo pharmacodynamic test in Example 25 of the present invention. - The present invention will be described in detail below. Of course, various corresponding changes and modifications can be made by those skilled in the art based on the disclosure of the present invention without departing from the spirit and the essence of the present invention, which are contemplated in the scope of protection as defined by the appended claims of the present invention.
- The terms used in the present invention have their general meaning in the art, and in the case of conflict, the definitions in this application apply. The chemical names, generic names and chemical structures are used interchangeably to describe the same structure. These definitions apply regardless of whether they are used alone or in combination with other terms. Thus, the definition of “alkyl” applies to the “alkyl” and the “alkyl” moiety of “hydroxyl alkyl”, “haloalkyl”, “aryl alkyl”, “alkyl aryl”, “alkoxy” and the like.
- “Pharmaceutical composition” means a composition suitable for administration to a patient. The composition may contain a single compound of the present invention, a mixture of the compounds of the present invention, a salt, a solvate, a prodrug, an isomer or a tautomer of the compound of the present invention, or the compound of the present invention in combination with one or more pharmaceutically acceptable carriers or excipients. The “subjects” include humans and non-human animals. The pharmaceutical composition may be in various forms such as tablets, capsules, powders, syrups, solutions, suspensions, aerosols, and the like, and may be present in a suitable solid or liquid carrier or diluent and in a sterilized container suitable for injection or infusion.
- Various dosage forms of the pharmaceutical composition of the present invention can be prepared according to conventional preparation methods in the pharmaceutical field. The formulation of the preparation comprises, in a unit dosage, 0.05-200 mg of the compound of General Formula (I), and preferably 0.1-100 mg of the compound of General Formula (I).
- The compound and pharmaceutical composition of the present invention can be used clinically in mammals, including humans and animals, and can be given through the routes of administration including oral, intranasal, transdermal, transpulmonary, or gastrointestinal tract administration, and most preferably oral administration. The most preferred daily dose is 0.01-200 mg/kg body weight in a single dose, or 0.01-100 mg/kg body weight in divided doses. Regardless of the route of administration, the optimal dosage for an individual depends on the particular treatment. Generally, the most suitable dose is found by starting with a small dose, and then gradually increasing the dose.
- “Halo” refers to fluoro, chloro, bromo, or iodo.
- “Alkyl” refers to an aliphatic saturated hydrocarbon group, and is preferably a linear or branched alkyl group having 1 to 10 carbon atoms, preferably a linear or branched alkyl group having 1 to 6 carbon atoms, and more preferably a linear or branched alkyl group having 1 to 4 carbon atoms. “Branched” means that one or more alkyl groups having 1 to 4 carbon atoms such as methyl, ethyl or propyl is/are attached to a linear alkyl group. Preferred alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl groups and the like.
- “Haloalkyl” refers to an alkyl group as defined above, where one or more hydrogen atoms in the alkyl group are substituted with halo as defined above.
- “Heteroalkyl” means an alkyl group as defined above, where one or more carbon atoms in the alkyl group are replaced by groups independently selected from —O—, —S—, —(S═O)—, —(O═S═O)—, —N(H) and —N—. Preferably heteroalkyl groups include, but are not limited to, —O— alkyl, —S— alkyl, —(S═O)— alkyl, —(O═S═O)— alkyl, —N(H) alkyl, —N(alkyl)2, and the like.
- “Alkenyl” means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond, which may be linear or branched and comprises 2 to 10 carbon atoms, preferably 2 to 6 carbon atoms, and more preferably 2 to 4 carbon atoms in a linear or branched chain. “Branched” means that one or more lower alkyl groups is/are attached to a linear alkenyl chain. Preferably alkenyl groups include, but are not limited to, ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl, and decenyl, and the like.
- “Alkylene” refers to a divalent group obtained by removing a hydrogen atom from the alkyl group defined above. Preferably alkylene groups include, but are not limited to, methylene, ethylene, propylene, and the like. In general, they can be optionally and equivalently represented herein as -(alkyl)-, for example —CH2CH2— is ethylene.
- “Alkynyl” refers to an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond, which may be linear or branched and contains 2 to 10 carbon atoms, preferably 2 to 6 carbon atoms, and more preferably 2 to 4 carbon atoms in the chain. “Branched” means that one or more alkyl groups having 2 to 4 carbon atoms is/are attached to a linear alkynyl group. Preferably alkynyl groups include, but are not limited to, ethynyl, propynyl, 2-butynyl, and 3-methyl butynyl.
- “Alkenylene” refers to a difunctional group obtained by removing a hydrogen atom from the above-defined alkenyl group. Preferably alkenylene groups include, but are not limited to, —CH═CH—, —C(CH3)═CH—, —CH═CHCH2—, and the like.
- “Aryl” refers to a carbocyclic aromatic monocyclic or polycyclic ring system having 6 to 14 carbon atoms, and preferably 6 to 10 carbon atoms in the ring. The aryl may be optionally substituted with one or more identical or different “substituents” as defined herein. Preferably aryl groups include, but are not limited to, phenyl and naphthyl. The “monocyclic aryl” means phenyl.
- “Arylene” refers to a divalent functional group obtained by removing a hydrogen atom from the above-defined aryl group. For example,
- is p-phenylene.
- “Heteroaryl” refers to an aromatic monocyclic or polycyclic ring system having 5 to 14 ring atoms and preferably 5 to 10 ring atoms in the ring, where one or more ring atoms are elements other than carbon, such as nitrogen, oxygen, or sulfur, used alone or in combination. Preferably heteroaryl groups contain 5 to 6 ring atoms. “Heteroaryl” may be optionally substituted with one or more substituents as defined herein which may be the same or different. The prefix aza, oxa or thia before the root name heteroaryl means containing at least one nitrogen, oxygen or sulfur atom independently acting as a ring atom. The nitrogen atom in the heteroaryl group can be optionally oxidized into the corresponding N-oxide. The term “heteroaryl” also includes a heteroaryl as defined above, which is fused to an aryl as defined above. Preferably heteroaryl groups include, but are not limited to, pyridyl, pyrazinyl, furyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridone), isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, pyrazolyl, furazanyl, pyrrolyl, triazolyl, 1,2,4-thiadiazolyl, pyridazinyl, quinoxalinyl, phthalazinyl, hydroxyindolyl, imidazo[1,2-a]pyridyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidinyl, pyrrolopyridyl, imidazopyridine, isoquinolinyl, benzoazinyl, 1,2,4-triazinyl, benzothiazolyl, and the like. The term “heteroaryl” also refers to partially saturated heteroaryl groups, such as tetrahydroisoquinolyl, tetrahydroquinolinyl and the like. The term “monocyclic heteroaryl” refers to a monocyclic form of a heterocycle as described above, and includes 4- to 7-membered monocyclic heteroaryl groups having from 1 to 4 ring heteroatoms independently selected from N, O and S and oxides thereof. The point of attachment to the parent moiety is any available ring carbon atom or ring heteroatom. Preferably monocyclic heteroaryl groups include, but are not limited to, pyridyl, pyrazinyl, furyl, thienyl, pyrimidinyl, pyridazinyl, pyridonyl, thiazolyl, isothiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, thiadiazolyl (e.g. 1,2,4-thiadiazolyl), imidazolyl, triazinyl (e.g. 1,2,4-triazinyl) and oxides thereof
- “Cycloalkyl” refers to a non-aromatic monocyclic or polycyclic ring system containing from 3 to 10 carbon atoms, and preferably from 3 to 6 carbon atoms. The cycloalkyl may be optionally substituted with one or more substituents as described in the present invention which are the same or different. Monocyclic cycloalkyl refers to a monocyclic form of the cycloalkyl described in the present invention. Preferably monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Preferably polycyclic cycloalkyl groups include, but are not limited to, [1.1.1]-bicyclopentyl, 1-decanoyl, norbornyl, adamantyl and the like.
- “Cycloalkenyl” refers to a non-aromatic monocyclic or polycyclic ring system having from 3 to 10 carbon atoms and containing at least one cyclic carbon-carbon double bond. Preferably cycloalkenyl rings contain from 3 to 7 ring atoms. The cycloalkenyl may be optionally substituted with one or more substituents as described in the present invention, which may be the same or different. The term “monocyclic cycloalkenyl” refers to a monocyclic form of the cycloalkenyl as described in the present invention and includes non-aromatic 3- to 7-membered monocyclic cycloalkenyl groups containing one or more carbon-carbon double bonds. Preferably monocyclic cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptane-1,3-dienyl, and the like. Preferably polycyclic cycloalkenyl groups include, but are not limited to, norbornenyl.
- “Heterocycloalkyl” (or “heterocyclyl”) refers to a non-aromatic saturated monocyclic or polycyclic ring system containing from 3 to 10 ring atoms and preferably from 5 to 10 ring atoms, where one or more atoms in the ring system are elements other than carbon, such as nitrogen, oxygen or sulfur, alone or a combination thereof. No adjacent oxygen and/or sulfur atoms are present in the ring system. Preferably heterocyclyl groups contain from 5 to 6 ring atoms. The heterocyclyl may be optionally substituted with one or more substituents as described in the present invention, which are the same or different. The nitrogen or sulfur atom in the heterocyclyl group can be optionally oxidized into the corresponding N-oxide, S-oxide or S,S-dioxide. Thus the term “oxide” in the present invention refers to the corresponding N-oxide, S-oxide or S, S-dioxide. “Heterocyclyl” also includes a group in which two available hydrogen atoms on the same carbon atom of the ring system are replaced by a single group ═O (e.g., carbonyl), which may be referred to as “oxo” in the present invention. The term “monocyclic heterocycloalkyl” refers to a monocyclic form of the heterocycloalkyl group described in the present invention, including 4 to 7 membered monocyclic heterocycloalkyl groups having from 1 to 4 ring heteroatoms independently selected from N, N-oxide, O, S, S-oxide, S(O) and S(O)2. Preferably monocyclic heterocycloalkyl groups include, but are not limited to, piperidinyl, oxetanyl, pyrrolyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuryl, tetrahydrothiophenyl, a lactam group (such as pyrrolidinonyl), a lactone group and oxides thereof
- “Heterocycloalkenyl” refers to a non-aromatic monocyclic or polycyclic ring system containing from 3 to 10 ring atoms and preferably from 3 to 7 ring atoms, where one or more atoms in the ring system are elements other than carbon, for example, nitrogen, oxygen or sulfur, alone or a combination thereof; and containing at least one carbon-carbon double bond or carbon-nitrogen double bond. No adjacent oxygen and/or sulfur atoms are present in the ring system. Preferably heterocycloalkenyl groups contain from 5 to 6 ring atoms. The prefix aza, oxa or thia before the root name heterocycloalkenyl means containing at least one nitrogen, oxygen or sulfur atom independently acting as a ring atom. The heterocycloalkenyl may be optionally substituted with one or more substituents as described in the present invention, which are the same or different. The nitrogen or sulfur atom in the heterocycloalkenyl group can be optionally oxidized into the corresponding N-oxide, S-oxide or S,S-dioxide. Preferably heterocycloalkenyl groups include, but are not limited to, 1,2,3,4-tetrahydropyridyl, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridyl, 1,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazolyl, dihydroxazolyl, dihydroxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyl, dihydrofuranyl, fluorodihydrofuranyl and the like. “Heterocycloalkenyl” may also be a substituted ring system where two available hydrogen atoms on the same carbon atom are replaced by a single group ═O (e.g., carbonyl). The term “monocyclic heterocycloalkenyl” refers to a monocyclic form of the heterocycloalkenyl group as described in the present invention, including 4- to 7-membered monocyclic heterocycloalkenyl groups having from 1 to 4 ring heteroatoms independently selected from N,N-dioxide, O, S, S-oxide, S(O), and S(O)2. Preferably monocyclic heterocycloalkenyl groups include, but are not limited to, 1,2,3,4-tetrahydropyridyl, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridyl, 1,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazolyl, dihydroxazolyl, dihydroxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyl, dihydrofuranyl, fluorodihydrofuranyl, dihydrothiophenyl, dihydrothiopyranyl and oxides thereof.
- “Arylalkyl” (or “aralkyl”) refers to an aryl-alkyl- group in which the aryl and alkyl are as defined above. Unless otherwise stated, the alkyl group in the definition “arylalkyl” (or “-alkyl-aryl”) refers to a linear or branched lower alkyl group. Preferably, the arylalkyl includes a lower alkyl group. Preferably arylalkyl groups include, but are not limited to, benzyl, 2-phenethyl and naphthylmethyl. The group is attached to the parent moiety via the alkyl group. The term (and like terms) can be written as “arylalkyl” (or “-alkyl-aryl”), to indicate the point of attachment to the parent moiety. Similarly, “heteroaryl alkyl”, “cycloalkyl alkyl”, “cycloalkenyl alkyl”, “heterocycloalkyl alkyl”, “heterocycloalkenyl alkyl” and the like refer to the heteroaryl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl and the like as described in the present invention, which are attached to the parent moiety via the alkyl group.
- “Alkylaryl” (or “alkaryl”) refers to an alkyl-aryl group where the alkyl and aryl are as described above. Preferably, the alkylaryl group comprises a lower alkyl group. Preferably alkylaryl includes, but is not limited to, tolyl. The group is attached to the parent moiety via the aryl group.
- “Heteroaralkyl” (or “heteroarylalkyl”) refers to a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as described above. Preferably, the heteroaralkyl contains a lower alkyl group. Preferably aralkyl groups include, but are not limited to, pyridylmethyl and quinolin-3-ylmethyl. The group is attached to the parent moiety via the alkyl group.
- “Hydroxyalkyl” refers to a HO-alkyl- group in which the alkyl group is as defined above. Preferably, the hydroxyalkyl contains a lower alkyl group. Preferably hydroxylalkyl groups include, but are not limited to, hydroxymethyl and 2-hydroxyethyl. “Alkoxy” refers to an alkyl-O— group in which the alkyl is as defined above. Preferably alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The group is attached to the parent moiety via oxygen. “Alkoxyalkyl” refers to a group derived from an alkoxy group and an alkyl group as defined in the present invention. The group is attached to the parent moiety via the alkyl group.
- Any of the foregoing functional groups mentioned in the present invention may be unsubstituted or substituted with the substituents described in the present invention. The term “substituted” (or substitution) means that one or more hydrogen atoms on a given atom is/are replaced by a group selected from specified groups, provided that the normal valence of the given atom is not exceeded and that the substitution results in a stable compound. The combination of the substituents and/or variables is permissible only when the combination results in a stable compound. “Stable compound” or “stable structure” means a compound having stability sufficient to be separated from the reaction mixture to a useful purity and prepared into an effective therapeutic agent.
- The term “unsubstituted or substituted” means that a particular group is unsubstituted or substituted with one or more substituents.
- Substitutions on groups such as cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, and aryl fused cycloalkylalkyl include substitutions on any of the ring moieties and/or alkyl moieties of the groups.
- A tautomer refers to a compound produced by the transfer of a proton from one atom to another atom in a molecule. The tautomer also refers to two or more isomeric forms in equilibrium that trend to convert from one isomeric form to another. One of ordinary skill in the art will recognize the possibility of all tautomeric ring atom arrangements. All such isomeric forms of these compounds are expressly embraced in the disclosure of the present invention.
- In particular, the compound of the present invention includes all tautomers thereof, such as keto-enol tautomers. For convenience, in the detailed description and claims of the present invention, some structures of these tautomers and the mixtures thereof (Example 1) are shown below.
- For convenience, only one tautomer of each compound is exemplified in the present invention. It should be noted that the compound of the present invention includes all tautomers.
- A stereoisomer refers to an isomer of a compound having the same molecular formula and having the same joining order, but different spatial arrangement of atoms in the molecule. Stereoisomerism includes cis-trans isomerism, conformational isomerism, enantiomerism and diastereomerism, etc. The cis-trans isomerism is caused by the inability of two carbon atoms connected by a double bond to rotate relatively freely around a sigma bond, and generally refers to the cis-trans isomerism of a double bond of an olefin and also a C═N double bond, a N═N double bond, and a cyclic compound. Enantiomers refer to stereoisomers that are mirror images of each other. Diastereomers refer to stereoisomers in which the molecule has two or more chiral centers and the molecules are in a non-mirror relationship. Unless otherwise indicated, the specification is intended to include individual stereoisomers and mixtures thereof.
- In particular, the compound of the present invention includes all isomers thereof, such as diastereomers and cis/trans (Z/E) isomers.
- For convenience, only one isomer of each compound is exemplified in the present invention. It should be noted that the compound of the present invention includes all stereoisomers.
- The compound of the present invention can form a metal chelate with one or more metal ions, including, but not limited to, copper, iron, magnesium, calcium, zinc, nickel, and platinum. The compound of the present invention includes all metal chelates.
- The term “pharmaceutically acceptable salt” refers to a substance that is suitable for use in humans and/or animals without undue adverse side effects (e.g., toxicity, irritation, and allergies), i.e., having a reasonable benefit/risk ratio. Pharmaceutically acceptable salts include inorganic and organic salts that can be obtained during the final separation and purification of the compound of the present invention, or by reaction of the free acid or base functional group with a suitable base or acid. Acids suitable for salt formation include, but are not limited to, inorganic acids such as hydrochloric acid, phosphoric acid or sulfuric acid, or organic acids such as citric acid, ascorbic acid, tartaric acid, lactic acid, maleic acid, malonic acid, fumaric acid, glycolic acid, succinic acid, propionic acid, acetic acid or methanesulfonic acid. Bases suitable for salt formation include, but are not limited to, inorganic bases such as sodium carbonate, sodium hydroxide, potassium carbonate, potassium hydroxide, lithium hydroxide, calcium acetate, calcium chloride or magnesium chloride, and organic bases such as aminoethanol.
- The term “effective amount” means that the amount of the compound of present invention contained in the administered composition is sufficient to modulate (e.g., inhibit or activate) a mammalian ATG8 homolog.
- The compound of the present invention can be prepared by various similar known methods in the art, and the following reaction schemes are an alternative to the preparation of the compound of the present invention. Those skilled in the art will readily appreciate that these compounds can be prepared using known variations of the conditions and procedures in the following preparative methods. The starting reactants used in the present invention are commercially available unless otherwise stated.
- For example, the compound of the present invention can be synthesized using one of the following general synthesis methods:
- General Synthesis Method I:
- General Synthesis Method II:
- General Synthesis Method III:
- General Synthesis Method IV:
- General Synthesis Method V:
- General Synthesis Method VI:
- The groups or substituents in the above general synthesis method are as defined above. The intermediates can be prepared by methods described in some of the references known to those of ordinary skill in the art. These references include, for example:
- Bioorganic & Medicinal Chemistry Letters, 24(16), 3764-3771, 2014;
- Chemistry—A European Journal, 20(9), 2445-2448, 2014;
- Bioorganic & Medicinal Chemistry, 20(2), 1029-1045, 2012;
- Journal of Organic Chemistry, 82(5), 2630-2640, 2017;
- Tetrahedron Letters, 49 (2008), 4725-4727; Journal of Organic Chemistry, 78(9), 4563-4567, 2013;
- Heterocycles, 28(2), 1015-35, 1989; Journal of Medicinal Chemistry, 57(10), 3924-3938, 2014;
- Journal of Organic Chemistry, 66(24), 8000-8009, 2001; and Tetrahedron Letters, 56(45), 6287-6289, 2015;
- The Journal of Immunology, pp. 380-386, 1999; J. Org. Chem., vol. 53, pp. 1167-1170, 1988;
- Progress in Medicinal Chemistry, vol. 22, pp. 166-242 (1985); J. Med. Chem., pp. 2858-2865 (1997);
- Chem. Pharm. Bull., 46(7), pp. 1165-1168 (1998);
- Bioorganic &
Medicinal Chem. Letters 9, pp. 1625-1630 (1999); - J. Med. Chem., pp. 3044-3045 (1996);
- Journal of Medicinal Chemistry, vol. 39, No. 17, pp. 3238-3240 (1996);
- Bioorganic & Medicinal Chemistry Letters 8, pp. 2669-2674 (1998);
- Bioorganic &
Medicinal Chemistry Letters 7, pp. 1071-1076 (1998); - Immunopharmacology 35, pp. 203-212 (1997).
- The present invention is further elaborated below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.
- Abbreviations: Nuclear magnetic resonance (NMR); triethylamine (TEA); mass spectrometry (MS); dimethylformamide (DMF); N,N-dimethylformamide dimethylacetal (DMF-DMA); diisopropyl ethylamine (DIPEA); N-methylpyrrolidone (NMP); Lenalidomide; benzyl formate (Cbz); sodium sulfate (Na2SO4); tert-butyl formate (Boc); 2-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU)
- Liquid chromatography-mass spectrometry (LCMS); thin layer chromatography (TLC); mg/g/kg; mol/mmol; ml/L; equivalent (eq).
- General Synthesis Conditions:
- Unless otherwise stated, all reactions are carried out under an inert gas atmosphere (such as argon or nitrogen), and the commercially available reagents and anhydrous solvents are used without further treatment.
- The liquid chromatograph-mass spectrometer (LC-MS) is an Agilent 6120B single quadrupole liquid chromatograph-mass spectrometer. Gradient of solvent system: 2 to 98% B over 1.5 min, flow rate 1.2 mL/min; eluent A: water/0.1% TFA, eluent B: ACN/0.1% TFA. Column: Kinetex C18 2.6 μm 2.1×50 mm (Phenomenex), column temperature: 50° C. LC/MS UPLC system (column: Acquity C18 BEH 1.7 μm, 2.1×50 mm at 50° C.; eluent A: water+0.1% formic acid; eluent B: ACN. Gradient: 2 to 98% B over 1.4 min, flow rate 1.0 mL/min. HPLC: method group: 10 to 95%; run time: 10 min.
- Nuclear magnetic resonance (NMR) spectra (such as hydrogen spectrum (1H), carbon spectrum (13C), phosphorus spectrum (31P) and fluorine spectrum (19F)) are recorded on Bruker AMX-400, Gemini-300 or AMX-600 NMR Spectrometer, in a deuterated solvent such as deuterated chloroform, deuterated methanol, deuterated water or deuterated dimethyl sulfoxide, with the deuterated solvent peaks as a reference. The chemical shift δ is in ppm, the coupling constant (J or J) is in Hertz (Hz), and the coupling and split peaks in the NMR spectrum are expressed as: broad singlet (brs), singlet (s), doublet (d), doublet of doublets (dd), triplet (t), quartet (q) and multiplet (m).
-
- Step 1: 5-phenyl-1,3-cyclohexandione (30.0 g, 159.4 mmol) was dissolved in chloroform (100 mL). N, N-dimethylformamide dimethyl acetal (DMFDMA, 20 mL) was added slowly at room temperature and stirred for 1 hr, until TLC showed the reaction was complete. The reaction solution was poured into iced water, the chloroform phase was separated, and the aqueous phase was extracted with dichloromethane. The combined organic phase was washed with water and brine, dried (Na2SO4), and concentrated. The crude product was separated by column chromatography to afford the target intermediate 1-1 (30.4 g, yield 78.4%).
- Step 2: Lenalidomide (910 mg, 3.5 mmol) and the intermediate 1-1 (1.10 g, 4.5 mmol) were dissolved in a mixture of ethanol (20 mL)/dichloromethane (15 mL). The reaction solution was heated and refluxed for 1 hr, until TLC showed the reaction was complete. The reaction solution was filtered while hot, and the solid was washed with ethanol (10 mL×3), dried under suction, beaten in methanol (20 mL), and stirred for 2 hrs. After filtering, the crude product was dissolved in dichloromethane (20 mL), beaten for 1 hr, filtered, and dried to obtain the target compound 1 (1.42 g, yield 89%).
- 1H NMR (400 MHz, DMSO_d6): δ 12.87 (d, J=13.6 Hz, 1H), 10.99 (s, 1H), 8.58 (d, J=13.6 Hz, 1H), 7.89 (dd, J=6.8, 1.2 Hz, 1H), 7.63-7.57 (m, 2H), 7.32-7.29 (m, 4H), 7.23-7.20 (m, 1H), 5.17-5.12 (m, 1H), 4.62-4.44 (m, 2H), 3.43-3.38 (m, 1H), 2.95-2.78 (m, 3H), 2.68-2.55 (m, 3H), 2.45-2.40 (m, 1H), 1.99-1.96 (m, 1H). MS: 458.5 (M+1).
- The synthesis method of the compounds 2-41, 110-121, 124, 126-128, 130-132, and 134-156 was the same as that for the
compound 1. The details of these compounds are shown in Table 1: -
TABLE 1 Com- pound Stmcture 1HNMR, MS (m/z) 2 1H NMR (400 MHz, DMSO-d6) δ 13.42 (s, 1H), 11.18 (s, 1H), 8.74 (d, J = 13.6 Hz, 1H), 8.24 (s, 1H), 7.91 (s, 1H), 7.73 (s, 1H), 7.30 (d, J = 42.2 Hz, 5H), 5.18 (s, 1H), 3.46 (s, 1H), 2.89 (s, 3H), 2.68 (d, J = 19.2 Hz, 4H), 2.10 (s, 1H). MS: 472.1 (M + 1) 3 1H NMR (400 MHz, DMSO_d6) δ: 12.91 (d, J = 13.2 Hz, 1H), 7.91-7.93 (m, 1H), 7.56-7.63 (m, 2H), 7.33 (t, J = 2.4 Hz, 1H), 7.27 (d, J = 8.4 Hz, 1H), 7.03 (t, J = 8.0 Hz, 1H), 6.88 (d, J = 8.0 Hz, 1H), 6.56 (s, 1H), 5.17 (dd, J = 14.0, 5.2 Hz, 1H), 4.64-4.45 (m, 2H), 3.77-3.85 (m, 1H), 2.60-2.94 (m, 7H), 1.97-1.99 (m, 1H). MS: 497.3 (M + 1) 4 1H NMR (400 MHz, DMSO_d6) δ 12.91 (d, J = 16.0 Hz, 1H), 11.01 (s, 1H), 8.61 (d, J = 12.8 Hz, 1H), 7.92 (dd, J1 = 6.8 Hz, J2 = 1.6 Hz, 1H), 7.61- 7.65 (m, 2H), 7.11-7.33 (m, 4H), 5.16 (J = 12.8, 4.8 Hz, 1H), 4.64-4.45 (m, 2H), 3.55-3.62 (m, 1H), 2.72-2.93 (m, 3H), 2.50-2.61 (m, 3H), 2.41-2.45 (m, 1H), 2.27-2.29 (m, 3H), 1.97-2.00 (m, 1H). MS: 472.1 (M + 1) 5 1H NMR (400 MHz, DMSO_d6) δ 13.40 (d, J = 13.2 Hz, 1H), 11.14-11.18 (m, 2H), 8.74 (d, J = 13.2 Hz, 1H), 8.22 (d, J = 8.8 Hz, 1H), 7.89 (t, J = 8.0 Hz, 1H), 7.70 (d, J = 7.2 Hz, 1H), 7.26- 7.34 (m, 2H), 7.01 (t, J = 8.0 Hz, 2H), 6.87 (d, J = 6.8 Hz, 1H), 6.57-6.58 (m, 1H), 5.19-5.14 (m, 3H), 3.80-3.86 (m, 1H), 2.73-3.07 (m, 5H), 2.50-2.63 (m, 2H), 2.05-2.09 (m, 1H). MS: 511.1 (M + 1) 6 MS: 540.3 (M + 1) 7 MS: 526.3 (M + 1) 8 MS: 458.2 (M + 1) 9 MS: 472.3 (M + 1) 10 MS: 458.3 (M + 1) 11 MS: 588.2 (M + 1) 12 MS: 545.3 (M + 1) 13 MS: 623.1 (M + 1) 14 MS: 609.2 (M + 1). 15 MS: 565.3 (M + 1) 16 MS: 643.2 (M + 1) 17 MS: 554.3 (M + 1) 18 MS: 536.3 (M + 1) 19 MS: 476.3 (M + 1) 20 MS: 550.3 (M + 1) 21 MS: 526.3 (M + 1) 22 MS: 542.3 (M + 1) 23 .MS: 526.3 (M + 1) 24 MS: 476.3 (M + 1) 25 MS: 569.4 (M + 1) 26 MS: 583.3 (M + 1) 27 MS: 514.3 (M + 1) 28 MS: 476.3 (M + 1) 29 MS: 508.3 (M + 1) 30 MS: 558.4 (M + 1) 31 MS: 579.4 (M + 1) 32 MS: 488.5 (M + 1) 33 MS: 516.4 (M + 1) 34 MS: 474.3 (M + 1) 35 MS: 548.4 (M + 1) 36 MS: 464.2 (M + 1) 37 MS: 514.3 (M + 1) 38 MS: 497.3 (M + 1) 39 MS: 498.3 (M + 1). 40 MS: 518.3 (M + 1). 41 MS: 515.4 (M + 1). 110 MS: 576.4 (M + 1). 111 MS: 465.3 (M + 1). 112 MS: 460.3 (M + 1). 113 MS: 508.4 (M + 1). 114 MS: 467.4 (M + 1). 115 MS: 460.3 (M + 1). 116 MS: 503.4 (M + 1). 117 MS: 535.3 (M + 1). 118 MS: 488.3 (M + 1). 119 MS: 459.3 (M + 1). 120 MS: 484.3 (M + 1). 121 MS: 458.3 (M + 1). 124 MS: 472.3 (M + 1). 126 MS: 459.4 (M + 1). 127 MS: 472.3 (M + 1). 128 MS: 474.3 (M + 1). 130 MS: 516.3 (M + 1). 131 MS: 464.3 (M + 1). 132 MS: 382.3 (M + 1). 134 MS: 454.4 (M + 1). 135 MS: 535.3 (M + 1). 136 MS: 513.3 (M + 1). 137 MS: 499.2 (M + 1). 138 MS: 481.3 (M + 1). 139 MS: 497.3 (M + 1). 140 MS: 544.3 (M + 1). 141 MS: 594.2 (M + 1). 142 MS: 578.3 (M + 1). 143 MS: 596.3 (M + 1). 144 MS: 560.3 (M + 1). 145 MS: 510.3 (M + 1). 146 MS: 510.3 (M + 1). 147 .MS: 510.3 (M + 1). 148 MS: 552.2 (M + 1). 149 MS: 575.2 (M + 1). 150 MS: 531.3 (M + 1). 151 .MS: 531.3 (M + 1). 152 MS: 531.3 (M + 1). 153 MS: 524.3 (M + 1). 154 MS: 578.2 (M + 1). 155 MS: 543.4 (M + 1). 156 MS: 515.4 (M + 1). -
- Step 1: N-Boc-glycine (405 mg, 2.31 mmol) was dissolved in dry DMF (10 ml). HATU (1.10 g, 2.9 mmol) and DIPEA (516 mg, 4 mmol) were added at room temperature, and stirred for 20 min. Then lenalidomide (500 mg, 1.93 mmol) was added and stirred for another 2 hrs until TLC showed the raw materials were completely reacted. The reaction solution was poured into water, and extracted with EtOAc. The organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 42-1 (511 mg, 64%).
- Step 2: The intermediate 42-1 (500 mg, 1.2 mmol) was dissolved in dichloromethane (DCM, 10 ml). Trifluoroacetic acid (TFA, 10 ml) was added and the reaction was stirred at room temperature for 1 hr, until TLC showed the reaction was complete. The TFA was distilled off under reduced pressure, and the crude product was dissolved in ethanol (30 ml). After dissolution, an appropriate amount of N,N-diisopropylethylamine (DIPEA) was added to adjust the pH to be basic. Then, the intermediate 1-1 (365 mg, 1.5 mmol) was added, and stirred at room temperature for 1 hr, until TLC showed that the reaction was almost complete. The reaction solution was poured into iced water, and a solid was precipitated out and filtered with suction. The filter cake was washed 3 times with ethanol and then 3 times with water, and dried to give the compound 42 (150 mg, 24.3%).
- 1H NMR (400 MHz, DMSO-d6) δ 11.07-10.89 (m, 2H), 10.11 (s, 1H), 8.13 (d, J=14.5 Hz, 1H), 7.82 (dd, J=7.0, 1.8 Hz, 1H), 7.59-7.44 (m, 2H), 7.42-7.13 (m, 5H), 5.15 (dd, J=13.3, 5.1 Hz, 1H), 4.52-4.26 (m, 4H), 3.31 (s, 1H), 3.00-2.50 (m, 6H), 2.41-2.21 (m, 1H), 2.10-1.98 (m, 1H). MS: 515.1 (M+1).
- The synthesis method of the compounds 43-49, 54-57, 59-61, 64, 65, 93, 122-123, and 157-158 was the same as that for the compound 42. The details of these compounds are shown in Table 2:
-
TABLE 2 Com- pound Structure 1HNMR, MS (m/z) 43 1H NMR (400 MHz, DMSO-d6) δ 11.40- 11.24 (m, 1H), 11.01 (s, 1H), 10.98-10.86 (m, 1H), 10.29 (d, J = 11.9 Hz, 1H), 8.25 (d, J = 14.1 Hz, 1H), 8.12 (d, J = 14.6 Hz, 1H), 7.79 (dd, J = 16.2, 7.6 Hz, 1H), 7.61- 7.46 (m, 2H), 7.29 (d, J = 5.2 Hz, 8H), 7.20 (s, 2H), 5.14 (d, J = 11.6 Hz, 1H), 4.66-4.49 (m, 1H), 4.48-4.28 (m, 2H), 3.51 (d, J = 5.8 Hz, 2H), 3.29-2.51 (m, 12H), 2.41-2.31 (m, 1H), 1.95 (t, J = 35.7 Hz, 3H), 1.73-1.52 (m, 2H). MS: 770.8 (M + 1) 44 1H NMR (400 MHz, DMSO-d6) δ 11.30- 10.92 (m, 2H), 10.01 (d, J = 4.0 Hz, 1H), 8.21-8.07 (m, 1H), 7.75-7.65 (m, 1H), 7.51 (dd, J = 12.1, 7.6 Hz, 2H), 7.37- 7.11 (m, 5H), 5.12 (d, J = 11.9 Hz, 1H), 4.31 (d, J = 3.8 Hz, 3H), 3.30-3.16 (m, 1H), 2.89 (d, J = 12.9 Hz, 1H), 2.75 (d, J = 5.8 Hz, 5H), 2.46-2.25 (m, 3H), 2.00 (s, 1H), 1.34 (d, J = 6.7 Hz, 3H). MS: 543.2 (M + 1). 45 1H NMR (400 MHz, DMSO-d6) δ 11.11- 10.98 (m, 2H), 10.05 (s, 1H), 8.15 (d J = 14.4 Hz, 1H), 7.70 (d, J = 7.5 Hz, 1H), 7.55-7.45 (m, 2H), 7.34-7.14 (m, 4H), 7.19 (s, 1H), 5.13 (dd, J = 13.1, 5.2 Hz, 1H), 4.32 (dd, J = 36.8, 17.3 Hz, 2H), 3.75 (d, J = 6.0 Hz, 2H), 3.31-3.21 (m, 2H), 2.97-2.84 (m, 1H), 2.79-2.52 (m, 5H), 2.46-2.32 (m, 32H), 2.03-1.95 (m, 1H). MS: 529.2 (M + 1). 46 1H NMR (400 MHz, DMSO-d6) δ 11.03- 10.87 (m, 2H), 9.81 (s, 1H), 8.15 (d, J = 14.5 Hz, 1H), 7.81 (dd, J = 7.0, 1.5 Hz, 1H), 7.58-7.43 (m, 2H), 7.40-7.15 (m, 5H), 5.14 (dd, J = 13.3, 5.0 Hz, 1H), 4.37 (q, J = 17.6 Hz, 2H), 3.51 (d, J = 6.0 Hz, 2H), 3.38-3.25 (m, 2H), 3.01-2.38 (m, 9H), 2.14-1.94 (m, 1H), 1.62 (d, J = 3.0 Hz, 4H). MS: 557.3 (M + 1). 47 1H NMR (400 MHz, DMSO-d6) δ 11.08- 10.89 (m, 2H), 9.86 (s, 1H), 8.14 (d, J = 14.6 Hz, 1H), 7.85 (dd, J = 7.0, 1.0 Hz, 1H), 7.50 (d, J = 6.9 Hz, 2H), 7.38-7.16 (m, 5H), 5.15 (dd, J = 13.3, 5.1 Hz, 1H), 4.38 (q, J = 17.5 Hz, 2H), 3.55-3.17 (m, 3H), 3.01-2.84 (m, 1H), 2.61 (d, J = 17.5 Hz, 3H), 2.49-2.30 (m, 3H), 2.13- 1.83 (m, 3H), 1.34-1.17 (m, 2H). MS: 543.3 (M + 1). 48 1H NMR (400 MHz, DMSO-d6) δ 11.00 (d, J = 12.8 Hz, 2H), 9.72 (s, 1H), 8.17 (d, J = 14.5 Hz, 1H), 7.73 (dd, J = 7.6, 0.9 Hz, 1H), 7.60-7.44 (m, 2H), 7.30-7.20 (m, 5H), 5.12 (dd, J = 13.1, 5.1 Hz, 1H), 4.38 (q, J = 18.0 Hz, 2H), 4.14 (s, 2H), 3.71 (d, J = 2.1 Hz, 4H), 3.29-3.21 (m, 1H), 2.88-2.29 (m, 6H), 2.06-1.95 (m, 1H). MS: 559.2 (M + 1). 49 1H NMR (400 MHz, DMSO-d6) δ 11.93 (s, 1H), 11.49 (s, 1H), 10-58-10.50 (m, 1H), 8.45 (d, J = 7.2 Hz, 1H), 8.18 (d, J = 6.4 Hz, 1H), 7.59 (t, J = 7.9 Hz, 1H), 7.49 (dd, J = 7.9, 1.2 Hz, 1H), 7.35-7.16 (m, 5H), 5.01 (t, J = 6.0 Hz, 1H), 4.21 (d, J = 5.2 Hz, 2H), 3.39-3.22 (m, 1H), 2.73-2.41 (m, 6H), 2.17-1.98 (m, 2H). MS: 529.4 (M + 1). 54 MS: 627.4 (M + 1). 55 MS: 641.4 (M + 1). 56 MS: 713.5 (M + 1). 57 MS: 727.4 (M + 1). 59 MS: 714.5 (M + 1). 60 MS: 883.6 (M + 1). 61 MS: 612.4 (M + 1). 64 MS: 628.4 (M + 1). 65 MS: 614.4 (M + 1). 93 MS: 653.5 (M + 1). 122 MS: 530.3 (M + 1). 123 MS: 546.3 (M + 1). 157 1H NMR (400 MHz, CDCl3) δ 11.19 (s, 1H), 9.18 (s, 1H), 8.46 (s, 1H), 8.21 (d, J = 14.2 Hz, 1H), 7.72 (dd, J = 10.2, 7.9 Hz, 2H), 7.58 (d, J = 8.0 Hz, 1H), 7.50 (t, J = 7.8 Hz, 1H), 7.32 (t, J = 7.5 Hz, 1H), 7.24 (s, 1H), 7.12 (t, J = 7.6 Hz, 1H), 5.22 (dd, J = 13.2, 5.1 Hz, 1H), 4.44 (s, 2H), 3.83 (t, J = 11.7 Hz, 1H), 3.54 (d, J = 5.9 Hz, 2H), 3.49 (s, 1H), 3.21 (s, 2H), 2.96-2.54 (m, 15H), 2.44-2.32 (m, 1H), 2.25 (s, 1H). MS: 705.1 (M + 1). 158 MS: 763.4 (M + 1). -
- Step 1: The synthesis method was the same as that in
Step 1 of Example 3. - Step 2: The intermediate 50-1 (500 mg, 1.22 mmol) was dissolved in ethanol (20 ml)/water (10 ml). Saturated ammonium chloride (3 mL) and reduced iron powder (560 mg, 10 mmol) were added and refluxed at 80° C. for 1 hr, until TLC showed the reaction was complete. The reaction solution was filtered through diatomaceous earth under sunction while hot. The filter cake was washed with EtOAc. The organic phase was separated, and the aqueous phase was extracted with EtOAc. The combined organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 50-2 (200 mg, 43%).
- Step 3: This step was the same as Step 2 in Example 1. Compound 50, 1H NMR (400 MHz, DMSO-d6) δ 12.73 (d, J=13.5 Hz, 1H), 10.97 (s, 1H), 10.37 (s, 1H), 8.61 (d, J=13.5 Hz, 1H), 8.04 (d, J=8.5 Hz, 2H), 7.70 (t, J=8.3 Hz, 3H), 7.64-7.47 (m, 2H), 7.44-7.12 (m, 5H), 5.26-4.99 (m, 1H), 4.56-4.26 (m, 2H), 3.42 (s, 1H), 2.88 (ddd, J=40.5, 16.2, 11.3 Hz, 3H), 2.74-2.51 (m, 3H), 2.39 (d, J=13.0 Hz, 1H), 2.00 (s, 1H). MS: 577.3 (M+1).
- The synthesis method of the compounds 51-53, 58, 62, 63, and 66 was the same as that for the compound 50. The details of these compounds are shown in Table 3:
-
TABLE 3 Compound Stmcture 1HNMR, MS (m/z) 51 1H NMR (400 MHz, DMSO-d6) δ 13.14 (d, J = 13.0 Hz, 1H), 10.98 (s, 1H), 10.36 (s, 1H), 8.70 (d, J = 13.0 Hz, 1H), 7.89 (dd, J = 37.8, 8.4 Hz, 3H), 7.74-7.51 (m, 3H), 7.41-7.15 (m, 5H), 5.13 (dd, J = 13.3, 5.0 Hz, 1H), 4.50-4.34 (m, 2H), 3.49-3.37 (m, 1H), 3.03-2.76 (m, 3H), 2.76-2.51 (m, 3H), 2.45-2.28 (m, 4H), 2.02-1.93 (m, 1H). MS: 591.3 (M + 1). 52 1H NMR (400 MHz, DMSO-d6) δ 13.49 (d, J = 13.6 Hz, 1H), 10.99 (s, 1H), 10.69 (s, 1H), 8.55 (d, J = 13.8 Hz, 1H), 7.96-7.53 (m, 6H), 7.48-7.15 (m, 6H), 5.23-5.07 (m, 1H), 4.60-4.37 (m, 2H), 3.47-3.33 (m, 1H), 2.79 (s, 3H), 2.65-2.51 (m, 3H), 2.44-2.33 (m, 1H), 2.10-1.93 (m, 1H). MS: 577.2 (M + 1). 53 1H NMR (400 MHz, DMSO-d6) δ 12.87-12.81 (m, 1H), 10.98 (s, 1H), 10.49 (s, 1H), 8.65 (d, J = 13.2 Hz, 1H), 8.11 (s, 1H), 7.84-7.53 (m, 6H), 7.41-7.23 (m, 5H), 5.14 (dd, J = 13.3, 5.0 Hz, 1H), 4.42 (t, J = 10.8 Hz, 2H), 3.48-3.36 (m, 1H), 2.87-2.53 (m, 6H), 2.39 (d, J = 12.9 Hz, 1H), 2.05-1.91 (m, 1H). MS: 577.2 (M + 1). 58 MS: 606.4 (M + 1). 62 MS: 584.3 (M + 1). 63 MS: 598.3 (M + 1). 66 1H NMR (400 MHz, DMSO-d6) δ 12.51 (d, J = 4.0 Hz, 1H), 10.99 (d, J = 5.2 Hz, 1H), 10.47 (d, J = 1.4 Hz, 1H), 9.13 (d, J = 3.6 Hz, 1H), 8.99 (d, J = 3.0 Hz, 1H), 8.37 (d, J = 5.4 Hz, 1H), 7.75 (d, J = 1.8 Hz, 2H), 7.60 (d, J = 4.5 Hz, 2H), 7.45-7.07 (m, 5H), 5.16 (d, J = 7.2 Hz, 1H), 4.44 (d, J = 10.1 Hz, 2H), 3.40 (s, 2H), 3.07-2.78 (m, 4H), 2.67 (d, J = 10.8 Hz, 2H), 1.99 (d, J = 3.4 Hz, 1H). MS: 578.2 (M + 1). -
- Step 1: 5-phenyl-1,3-cyclohexandione (10 g, 53.1 mmol), DIPEA (7.11 g, 55 mmol) and 4-dimethylaminopyridine (2.0 g, 16.4 mmol) were dissolved in 1,2-dichloroethane (140 ml). Acetyl chloride (4.32 g, 55 mmol) was slowly added dropwise at RT, and then reacted at 60° C. for 2 hrs, until TLC showed the reaction was complete. The reaction solution was poured into iced water, the organic layer was separated, and the aqueous phase was extracted with dichloromethane. The organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 73-1 (7.31 g, yield 60%).
- Step 2: The intermediate 73-1 (360 mg, 1.56 mmol) and lenalidomide (200 mg, 0.77 mmol) were dissolved in ethanol/chloroform (10 mL/10 mL), and reacted for 2 hrs under reflux by heating, until TLC showed the reaction was complete. The reaction solution was dried by rotation. The crude product was separated by column chromatography on silica gel to give the compound 73 (90 mg, 25%).
- 1H NMR (400 MHz, DMSO_d6): δ 15.04 (s, 1H), 11.01 (s, 1H), 7.70-7.65 (m, 3H), 7.35-7.24 (m, 5H), 5.18-5.13 m, 1H), 4.40 (q, J=39.2 Hz, 2H), 2.90-2.86 (m, 3H), 2.67-2.51 (m, 3H), 2.48 (s, 3H), 2.46-2.40 (m, 1H), 2.01-1.95 (m, 1H). MS: 472.1 (M+1)
- The synthesis method of the compounds 74-76 was the same as that for the compound 73. The details of these compounds are shown in Table 4.
-
TABLE 4 Compound Stmcture 1HNMR, MS (m/z) 74 1H NMR (400 MHz, DMSO_d6): δ 11.90 (s, 1H), 10.99 (s, 1H), 7.75-7.64 (m, 3H), 7.34-7.32 (m, 4H), 7.24-7.21 (m, 1H), 5.33 (t, J = 6.4 Hz, 1H), 5.14 (dd, J = 12.8, 4.2 Hz, 1H), 4.50-4.34 (m, 4H), 3.36-3.34 (m, 1H), 2.93-2.83 (m, 3H), 2.69-2.54 (m, 3H), 2.45-2.38 (m, 1H). MS: 488.2 (M + 1). 75 1H NMR (400 MHz, DMSO_d6): 14.52 (s, 1H), 11.02 (s, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.17-7.34 (m, 11H), 6.72 (d, J = 8.0 Hz, 1H), 5.12 (dd, J = 13.2, 4.2 Hz, 1H), 4.57-4.37 (m, 2H), 3.50-3.42 (m, 1H), 2.95-2.46 (m, 6H), 2.46-2.38 (m, 1H), 2.01-1.98 (m, 1H). MS: 534.2 (M + 1). 76 1H NMR (400 MHz, DMSO-d6) δ 12.64 (s, 1H), 11.97 (s, 1H), 7.64 (t, J = 7.8 Hz, 1H), 7.36-7.12 (m, 7H), 5.05 (t, J = 5.9 Hz, 1H), 3.44-3.37 (m, 1H), 2.74-2.47 (m, 9H), 2.49 (s, 3H), 2.16-1.97 (m, 2H). MS: 486.3 (M + 1). -
- Step 1: Triphosgene (1.14 g, 3.84 mmol) was dissolved in dichloromethane (20 ml). After cooling to −10° C., 2-azidoethylamine (1.0 g, 11.61 mmol) was slowly added dropwise, and stirred at −10° C. for half an hour. Then, TEA (2.34 g, 23 mmol) was added and reacted for an additional 1 hr. The reaction solution was slowly added dropwise to a solution of lenalidomide (2.0 g, 7.7 mmol) in N,N-dimethylacetamide (20 ml), and then reacted at 65° C. for 1 hr. The reaction solution was poured into iced water, the aqueous phase was extracted with EtOAc, and the organic phase was washed with water and brine, dried and concentrated. The crude product was separated by column chromatography to afford the intermediate 77-1 (2.01 g, 70%).
- Step 2: The intermediate 77-1 (2.0 g, 5.38 mmol) was dissolved in ethanol (50 ml), and then 10% Pd/C (200 mg) was added, and stirred for 1 hr while hydrogen was introduced at RT, until TLC showed the reaction was complete. The Pd/C was filtered off. Then, the intermediate 1-1 (423 mg, 1.74 mmol) was added, and stirred for another 1 hr at room temperature. A solid was precipitated out, which was filtered under suction, washed 3 times with ethanol and dried to give the compound 77 (533 mg, 68%).
- 1H NMR (400 MHz, DMSO_d6): δ 11.02-10.89 (m, 2H), 8.41 (s, 1H), 8.06 (d, J=16.0 Hz, 1H), 7.93 (d, J=8.4 Hz, 1H), 7.42-7.20 (m, 7H), 6.50 (br, 1H), 5.14 (dd, J=13.2. 4.8 Hz, 1H), 4.30 (q, J=13.2 Hz, 2H), 3.56 (br, 2H), 3.37 (br, 1H), 3.25-3.16 (m, 2H), 2.96-2.87 (m, 1H), 2.75-2.57 (m, 4H), 2.46-2.30 (m, 1H). MS: 544.2 (M+1).
- The synthesis method of the compounds 71, 72, and 78-90 was the same as that for the compound 77. The details of these compounds are shown in Table 5.
-
TABLE 5 Com- pound Stmcture 1HNMR, MS (m/z) 71 MS: 663.2 (M + 1). 72 MS: 649.3 (M + 1). 78 1H NMR (400 MHz, DMSO d6): δ 11.00 (br, 2H), 9.68 (s, 1H), 8.13 (d, J = 14.0 Hz, 1H), 7.70-7.20 (m, 8H), 5.12 (br, 1H), 4.40-3.75 (m, 6H), 3.27-3.21 (m, 2H), 2.95-2.55 (m, 3H), 2.38-2.27 (m, 2H), 1.97 (br, 2H). MS: 545.1 (M + 1). 79 1H NMR (400 MHz, DMSO-d6) δ 11.00 (s, 2H), 9.58 (s, 1H), 8.11 (d, J = 14.9 Hz, 1H), 7.74 (s, 1H), 7.54-7.12 (m, 6H), 5.74 (s, 1H), 5.12 (s, 1H), 4.53-4.09 (m, 4H), 3.56 (s, 2H), 2.89 (s, 1H), 2.48 (s, 16H), 2.31 (s, 2H), 2.01 (s, 1H). MS: 657.3 (M + 1). 80 MS: 671.5 (M + 1) 81 MS: 848.5 (M + 1). 82 MS: 608.3 (M + 1). 83 MS: 622.4 (M + 1). 84 MS: 614.3 (M + 1) 85 MS: 741.5 (M + 1). 86 MS: 755.4 (M + 1). 87 MS: 701.5 (M + 1). 88 MS: 833.5 (M + 1). 89 MS: 1118.7 (M + 1). 90 MS: 1032.6 (M + 1). -
- Step 1: 2-aminonicotinic acid (5.00 g, 36.2 mmol) was slowly added to thionyl chloride (50 mL). After stirring at 80° C. for 2 hrs, the thionyl chloride was directly removed under reduced pressure. At RT, The acyl chloride crude product was added in portions to a solution of lenalidomide (2.00 g, 7.72 mmol) and DIPEA (3.8 mL) in N,N-dimethylacetamide (20 mL), and the reaction solution was stirred at room temperature for 2 hrs. The reaction solution was poured into iced water, and extracted with ethyl acetate. The organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 67-1 (620 mg, 21%).
- Step 2: The intermediate 67-1 (200 mg, 0.526 mmol), the intermediate 1-1 (300 mg, 1.23 mmol) and acetic acid (60 mg, 1 mmol) were dissolved in methanol (20 mL)/dichloromethane (20 ml). The reaction solution was heated to 45° C. and reacted overnight. A solid was precipitated out, washed with ethanol and then with dichloromethane, and dried to obtain the compound 67 (32 mg, 10%).
- 1H NMR (400 MHz, DMSO_d6): δ 13.63 (d, J=12.4 Hz, 1H), 10.99 (s, 1H), 10.80 (s, 1H), 9.24 (d, J=12.8 Hz, 1H), 8.64 (d, J=8.4 Hz, 1H), 8.41 (d, J=8.4 Hz, 1H), 7.73-7.60 (m, 3H), 7.48-7.44 (m, 1H), 7.32-7.21 (m, 6H), 5.20-5.14 (m, 1H), 4.58-4.40 (m, 2H), 3.44-3.36 (m, 2H), 2.92-2.80 (m, 3H), 2.67-2.63 (m, 3H), 2.04-1.98 (m, 1H). MS: 578.2 (M+1).
-
- Step 1: 1-(2-azidoethyl)piperazine (0.93 g, 6.0 mmol) was dissolved in tetrahydrofuran (20 mL), succinic anhydride (0.5 g, 5.0 mmol) was added and stirred for 3 hrs at room temperature until the raw materials were detected to disappear by TLC. The reaction solution was concentrated to obtain the intermediate 91-1 (1.46 g, crude) which was directly used in the next step.
- Step 2: The intermediate 91-1 (1.46 g, crude), DIPEA (1.6 mL, 10.0 mmol), and lenalidomide (1.00 g, 3.86 mmol) were dissolved in dry DMF (20 mL), and then HATU (2.8 g, 7.5 mmol) was added and stirred overnight at RT. The reaction solution was poured into iced water, and extracted with EtOAc. The organic phase was washed with water and brine, dried and concentrated. The crude product was separated by column chromatography to afford the intermediate 91-2 (615 mg, 32%).
- Step 3: The synthesis method was the same as that in Step 2 of Example 10.
- Compound 91, 1H NMR (400 MHz, CD3OD): δ 8.27 (s, 1H), 7.71 (d, J=8.0 Hz, 1H), 7.65 (d, J=8.0 Hz, 1H), 7.51 (t, J=8.0 Hz, 1H), 7.32-7.22 (m, 5H), 5.18 (q, J=8.0 Hz, 1H), 4.47 (d, J=3.2 Hz, 1H), 3.63-3.59 (m, 6H), 3.39-3.34 (m, 1H), 2.80-2.49 (m, 17H), 2.21-2.18 (m, 1H). MS: 669.2 (M+1).
-
- Step 1: 4-formyl benzoic acid (1.50 g, 10.0 mmol), DIPEA (3.87 g, 30.0 mmol), and lenalidomide (2.10 g, 8.1 mmol) were dissolved in dry DMF (20 mL), and then HATU (5.70 g, 15.0 mmol) was added and stirred overnight at RT. The reaction solution was poured into iced water, and extracted with ethyl acetate. The organic phase was washed with water and brine, dried and concentrated. The crude product was separated by column chromatography to afford the intermediate 92-1 (613 mg, 20%).
- Step 2: The intermediate 92-1 (400 mg, 1.02 mmol) 1-(2-azidoethyl)piperazine (174 mg, 1.13 mmol), and acetic acid (90 mg, 1.5 mmol) were dissolved in dichloromethane (50 mL)/methanol (10 mL), and stirred at room temperature for half an hour. Sodium cyanoborohydride (126 mg, 2.04 mmol) was added, and continuously stirred overnight at room temperature. The reaction solution was poured into iced water, and extracted with dichloromethane. The organic phase was washed with water and brine, dried and concentrated. The crude product was separated by column chromatography to afford the intermediate 92-2 (140 mg, 26%).
- Step 3: The synthesis method was same as that in Step 2 of Example 12.
- Compound 92, 1H NMR (400 MHz, CD3OD): δ8.24 (s, 1H), 7.96 (d, J=8.0 Hz, 1H), 7.74-7.67 (m, 2H), 7.61-7.50 (m, 3H), 7.31-7.21 (m, 5H), 5.17-5.13 (m, 1H), 4.54 (s, 2H), 3.68 (s, 2H), 3.61-3.58 (m, 2H), 3.36-3.39 (m, 1H), 2.85-2.59 (m, 17H) 2.21-2.19 (m, 1H). MS: 703.3 (M+1).
- The synthesis of the compound 94 was the same as that for the compound 92. The details of the compound are shown in Table 6 below.
-
- Step 1: Thalidomide (2.58 g, 10 mmol) was dissolved in anhydrous DMF (100 mL), and sodium-hydrogen (60%, 440 mg, 11 mmol) was slowly added portionwise in an iced water bath and then stirred for 30 min at room temperature. The raw material 101-1 (3.67 g, 13 mmol) was added, and the reaction solution was stirred at room temperature overnight. The reaction solution was poured into iced water, and extracted with ethyl acetate. The organic phase was washed with water and brine, dried and concentrated. The crude product was separated by column chromatography to afford the intermediate 101-2 (807 mg, 16%).
- Step 2: 101-2 (807 mg, 1.6 mmol) was dissolved in methanol (35 ml), 10% Pd/C (80 mg) was added, and stirred for 24 hrs at room temperature under a hydrogen atmosphere (0.2 MPa), until TLC showed the reaction was complete. Pd/C was removed by filtration, and N-Cbz-aminoacetaldehyde (710 mg, 3.6 mmol) and acetic acid (120 mg, 2.0 mmol) were added to the filtrate. After stirring at room temperature for 10 min, sodium cyanoborohydride (302 mg, 4.8 mmol) was added, and stirred at room temperature for 2 hrs. The reaction solution was poured into iced water, and extracted with EtOAc. The organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 95-3 (271 mg, 31%).
- Step 3: The synthesis method was the same as that in Step 2 of Example 12.
- Compound 101: MS: 612.4 (M+1).
- The synthesis method of compounds 100, 102, and 103 was the same as that for the compound 101. The details of these compounds are shown in Table 7.
-
- Step 1: The raw materials 105-1 (4.414 g, 16.10 mmol), triphenylphosphine (6.33 g, 24.13 mmol) and benzyl hydroxyacetate (2.51 mL, 17.7 mmol) were dissolved in anhydrous tetrahydrofuran (180 mL), and diisopropyl azodicarboxylate (3.49 mL, 17.7 mmol) was slowly added at 0° C. After stirring for 5 min, the reaction solution was slowly warmed to room temperature and stirred overnight. The reaction solution was poured into iced water, and extracted with dichloromethane. The organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 105-2 (4.1 g, 60%).
- Step 2: The intermediate 105-2 (4.1 g, 9.71 mmol) was dissolved in 5:2 ethyl acetate/dichloromethane (200 mL). 10% Pd/C (460 mg) was added, and the reaction solution was stirred for 3 hrs under a hydrogen atmosphere, until TLC showed the reaction was complete. Methanol (200 mL) was added, and heated to reflux to dissolve the product. Pd/C was removed by filtration, and the filtrate was washed with hot methanol. The organic phase was concentrated to give the intermediate 105-3 (3.23 g, 100%).
- Step 3: The intermediate 105-3 (1.0 g, 3.0 mmol), 1-(2-azidoethyl)piperazine (620 mg, 4.0 mmol), and DIPEA (1.03 g, 8.0 mmol) were dissolved in anhydrous DMF (25 mL). HATU (1.9 g, 5.0 mmol) was added at RT, and the reaction solution was stirred overnight. The reaction solution was poured into iced water, and extracted with EtOAc. The organic phase was washed with water and brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 105-4 (720 mg, 51%).
- Step 4: The synthesis method was the same as that in the Step 2 of Example 10.
- Compound 105: MS: 642.4 (M+1).
- The synthesis method of the compounds 104 and 106 was the same as that for the compound 105. The details of these compounds are shown in Table 8:
-
- Step 1: Lenalidomide (780 mg, 3.0 mmol), N-Cbz-aminoacetaldehyde (770 mg, 4 mmol) were dissolved in anhydrous DMF (25 mL), heated to 80° C., stirred for 6 hrs, and then cooled to RT. Sodium borohydride (190 mg, 5 mmol) was added portionwise, and then stirred for 30 min. The reaction solution was poured into iced water, and extracted with ethyl acetate. The organic phase was washed water and then with brine, dried, and concentrated. The crude product was separated by column chromatography to afford the intermediate 108-2 (360 mg, 27%).
- Step 2: The synthesis method was the same as that in Step 2 of Example 10.
- Compound 108, MS: 501.3 (M+1).
- The synthesis method of the compounds 107 and 133 was the same as that for the compound 108. The details of these compounds are shown in Table 9:
-
- Step 1: The raw material 109-1 (830 mg, 3 mmol), the raw material 109-2 (1.0 g, 5 mmol), and DIPEA (775 mg, 6 mmol) were dissolved in anhydrous NMP (20 ml), heated to 90° C. and reacted overnight. The reaction solution was poured into iced water, and extracted with EtOAc. The organic phase was washed with water and then with brine, dried and concentrated. The crude product was separated by column chromatography to afford the intermediate 109-3 (340 mg, 25%)
- Step 2: The synthesis method was the same as that in Step 2 of Example 10.
- Compound 109, MS: 627.5 (M+1).
- The synthesis method of the compound 125 was the same as that for the compound 109. The details of the compound are shown in Table 10.
- By constructing a prokaryotic expression system, the LC3B protein was successfully expressed and purified, and a preliminary screening and verification platform was established using fluorescence polarization experiments to determine the activity of purchased and synthesized small compound libraries. The recombinant protein GST-LC3B (final concentration 180 nM) (SEQ ID NO: 1) and N-terminal FITC-labeled peptide (SEQ ID NO: 2, final concentration 18 nM) were placed in the FP buffer (50 mM HEPES pH 7.5, 0.1 mg/ml BSA and 1 mM DTT), to which a compound serially diluted with the FP buffer was added. Then the mixture was incubated at 25° C. in the dark. The fluorescence polarization value (PerkinElmer Envision, emission wavelength 480 nm; absorption wavelength 535 nm) was monitored, and the IC50 value was calculated using the GraphPad Prism 6.0 program. The test results are shown in Table 11.
- In table 11 the inhibitory activity data of the example compounds for LC3B is summarized (where 1 mM≥IC50>100 μM, the compound is considered to be less active (+) for LC3B; where 15 μM<IC50≤100 μM, the compound is considered to be moderately active for LC3B (+ +); where 3 μM<IC50≤15 μM, the compound is considered to be highly active for LC3B (+++); and where IC50≤3 μM, the compound is considered to be highly active for LC3B (++++)).
-
TABLE 11 IC50 Compound (μM) 1 +++ 2 +++ 3 ++++ 4 +++ 5 ++++ 6 ++++ 7 ++++ 8 +++ 9 +++ 10 +++ 11 ++++ 12 ++++ 13 ++++ 14 ++++ 15 ++++ 16 ++++ 17 ++++ 18 ++++ 19 ++++ 20 ++++ 21 ++++ 22 +++ 23 +++ 24 +++ 25 ++++ 26 ++++ 27 +++ 28 +++ 29 +++ 30 +++ 31 +++ 32 +++ 33 +++ 34 +++ 35 +++ 36 +++ 37 +++ 38 ++++ 39 ++++ 40 +++ 41 ++++ 42 + 43 + 44 + 45 + 46 + 47 + 48 + 49 + 50 ++ 51 ++ 52 ++ 53 ++ 54 +++ 55 +++ 56 +++ 57 +++ 58 ++ 59 + 60 ++ 61 +++ 62 +++ 63 +++ 64 ++ 65 ++ 66 ++ 67 +++ 71 +++ 72 ++ 73 +++ 74 ++ 75 + 76 + 77 ++ 78 ++ 79 ++ 80 ++ 81 ++ 82 +++ 83 +++ 84 +++ 85 ++ 86 ++ 87 ++ 88 ++ 89 ++ 90 ++ 91 ++ 92 ++ 93 ++ 94 ++ 100 ++ 101 ++ 102 ++ 103 ++ 104 ++ 105 ++ 106 ++ 107 ++ 108 +++ 109 ++ 110 ++ 111 ++ 112 ++ 113 +++ 114 + 115 ++ 116 ++ 117 ++ 118 ++ 119 ++ 120 ++ 121 ++ 122 + 123 + 124 ++ 125 ++ 126 +++ 127 +++ 128 + 129 ++ 130 ++ 131 ++ 132 + 133 ++ 134 ++ 135 +++ 136 +++ 137 +++ 138 +++ 139 +++ 140 ++++ 141 ++++ 142 ++++ 143 ++++ 144 ++++ 145 ++++ 146 ++++ 147 ++++ 148 ++++ 149 ++++ 150 ++++ 151 ++++ 152 ++++ 153 ++++ 154 ++++ 155 ++++ 156 ++++ 157 ++++ 158 ++++ - The inhibitory effects of the compounds 1-68, 71-94, and 100-158 on proliferation of lymphoma, multiple myeloma, leukemia, lung cancer, breast cancer, pancreatic cancer and other tumor cells were investigated. For various cell lines, the corresponding complete medium was used, and culture was carried out in an incubator at 37° C. with 5% CO2. The cells were counted, and inoculated into a 96-well plate at 2000-10000 cells/100 μl per well according to the cell volume and growth rate. The suspended cells were treated immediately, and the adherent cells were treated after adherence. The CellTiter-Glo method was used to detect the changes in cell viability 72 hours after the administration, and the cell survival rate at different concentrations was calculated by a formula: Survival rate (%)=(RLU of treatment well−RLU of blank well)/(RLU of control well−RLU of blank well)×100.
- Method for expressing the inhibitory activity of the compounds against the proliferation of tumor cells: Evaluation was made based on the cell survival rate at a compound concentration of 50 μM. 60≤survival rate (%)<90 is considered to have low inhibitory activity against the proliferation of tumor cells (+); 30<survival rate (%)≤60 is considered to have moderate inhibitory activity against the proliferation of tumor cells (++); and survival rate (%)≤30 is considered to have high inhibitory activity against the proliferation of tumor cells (+++). The test results are shown in Table 12. The compounds of the present application have different degrees of inhibition on the aforementioned various tumor cells.
-
TABLE 12 Inhibitory activity of compounds 1-67, 71-94, and 100-158 or salts thereof against proliferation of tumor cells SU- RPMI- MDA- Compound DHL6 8226 K562 A549 MB-453 BxPC-3 1 +++ +++ +++ +++ ++ ++ 2 +++ ++ +++ ++ + + 3 +++ + + + ++ + 4 + +++ ++ + + + 5 + + + +++ +++ + 6 + + + + + + 7 +++ ++ ++ ++ ++ + 8 + ++ ++ ++ + ++ 9 + ++ ++ ++ + ++ 10 + ++ ++ + + ++ 11 + + +++ + + + 12 + + + + + + 13 ++ + + +++ +++ ++ 14 ++ + + +++ +++ + 15 ++ +++ + + + ++ 16 + +++ + + + + 17 + +++ + ++ + + 18 ++ + ++ + + + 19 + ++ ++ + ++ ++ 20 ++ + ++ ++ + + 21 + + ++ ++ + + 22 + + + + ++ ++ 23 +++ +++ ++ +++ ++ ++ 24 +++ + + ++ ++ ++ 25 + + + + + + 26 + + + + + + 27 +++ +++ +++ +++ +++ + 28 +++ +++ +++ +++ +++ ++ 29 ++ +++ +++ +++ +++ ++ 30 +++ +++ +++ +++ +++ + 31 +++ +++ +++ +++ +++ + 32 +++ +++ +++ +++ ++ + 33 +++ +++ +++ +++ +++ + 34 +++ ++ ++ + +++ + 35 +++ +++ +++ +++ ++ ++ 36 +++ + + + ++ + 37 +++ + + + +++ + 38 +++ +++ +++ +++ +++ ++ 39 ++ + +++ + +++ ++ 40 + + +++ +++ + ++ 41 + + +++ +++ + + 42 + ++ ++ ++ + + 43 + +++ +++ +++ + + 44 +++ +++ +++ +++ + + 45 + + + + + + 46 + ++ ++ +++ +++ + 47 +++ + + + +++ ++ 48 +++ +++ +++ +++ +++ + 49 ++ ++ ++ ++ + 50 +++ ++ + + + + 51 + +++ + + + + 52 + +++ +++ ++ ++ + 53 +++ +++ +++ +++ ++ + 54 +++ ++ +++ +++ ++ + 55 +++ ++ + +++ ++ + 56 +++ + + +++ +++ + 57 +++ + + + + + 58 ++ + + + + + 59 +++ +++ +++ +++ + ++ 60 ++ +++ + + ++ 61 ++ + + + +++ + 62 ++ +++ + ++ +++ ++ 63 ++ ++ +++ + + + 64 +++ ++ +++ +++ + 65 +++ +++ +++ +++ +++ + 66 +++ + +++ +++ ++ + 67 +++ +++ +++ +++ ++ + 71 +++ +++ +++ +++ +++ + 72 +++ + +++ + + + 73 +++ + +++ +++ +++ + 74 + + + + + + 75 +++ +++ +++ +++ +++ + 76 +++ +++ +++ +++ ++ 77 + + +++ +++ +++ + 78 + + +++ +++ +++ + 79 + +++ + + ++ ++ 80 + +++ +++ +++ ++ + 81 +++ + +++ +++ ++ + 82 +++ + + +++ ++ + 83 + + + + ++ + 84 +++ +++ +++ + +++ + 85 + +++ ++ ++ + + 86 + + +++ +++ +++ ++ 87 +++ +++ ++ ++ +++ + 88 ++ +++ ++ ++ +++ + 89 ++ ++ ++ ++ +++ + 90 +++ ++ +++ ++ ++ ++ 91 ++ ++ ++ ++ ++ + 92 +++ +++ + + ++ + 93 +++ +++ ++ ++ ++ + 94 +++ +++ +++ +++ +++ + 100 ++ + +++ +++ ++ ++ 101 ++ +++ +++ +++ ++ + 102 ++ +++ +++ +++ +++ + 103 +++ + + +++ +++ + 104 +++ +++ +++ +++ +++ ++ 105 + + + +++ ++ ++ 106 + + + +++ ++ ++ 107 + +++ +++ +++ ++ + 108 + +++ +++ ++ ++ + 109 + +++ ++ ++ + ++ 110 + ++ ++ ++ + ++ 111 +++ +++ +++ + +++ + 112 + ++ ++ + ++ ++ 113 + +++ ++ + +++ + 114 ++ + ++ ++ + + 115 ++ + ++ ++ +++ + 116 + ++ ++ ++ ++ ++ 117 + +++ ++ + + + 118 + + ++ + + + 119 ++ ++ ++ + ++ ++ 120 ++ ++ ++ + ++ + 121 +++ +++ ++ + ++ + 122 +++ + + + +++ + 123 +++ +++ +++ +++ +++ + 124 + + + + +++ ++ 125 +++ +++ + + +++ ++ 126 + +++ + + + ++ 127 +++ + + + + + 128 +++ +++ +++ +++ +++ + 129 +++ ++ + +++ + + 130 +++ ++ ++ +++ +++ + 131 + +++ ++ +++ + 132 +++ +++ ++ + + ++ 133 + + ++ + + ++ 134 + + + + +++ ++ 135 +++ ++ ++ +++ +++ + 136 + +++ ++ +++ + 137 +++ +++ ++ + + ++ 138 +++ ++ ++ +++ +++ + 139 +++ +++ +++ + +++ + 140 +++ +++ +++ +++ ++ ++ 141 +++ ++ ++ +++ +++ + 142 +++ +++ +++ + +++ + 143 +++ ++ ++ +++ +++ + 144 +++ +++ +++ + +++ + 145 +++ ++ ++ +++ +++ + 146 +++ +++ +++ + +++ + 147 +++ +++ +++ +++ ++ ++ 148 +++ ++ ++ +++ +++ + 149 +++ +++ +++ + +++ + 150 +++ ++ ++ +++ +++ + 151 +++ +++ +++ + +++ + 152 +++ +++ +++ +++ ++ ++ 153 +++ ++ ++ +++ +++ + 154 +++ +++ +++ + +++ + 155 +++ ++ ++ +++ +++ + 156 +++ +++ +++ + +++ + 157 +++ +++ +++ +++ ++ ++ 158 +++ ++ ++ +++ +++ + - The in-vivo anti-tumor efficacy of the
compound 1, lenalidomide, dexamethasone and a combination of thecompound 1 or lenalidomide with dexamethasone in human multiple myeloma RPMI8226 cell xenograft tumor model was evaluated. - The test animals were female CB17 SCID mice. Human RPMI8226 cells were cultured in RPMI1640 medium containing 10% heat-inactivated fetal bovine serum and 1% penicillin-streptomycin double antibody in an incubator with 5% CO2 at 37° C. When the cells were in an exponential growth phase, the cells were harvested, counted, and subcutaneously inoculated into the right dorsal portion of each mouse. The mice were grouped and administered when the average tumor volume reached about 150 mm3. Grouping method: the animals were weighed and measured for the tumor volume before administration, and grouped by block design according to the tumor volume. The dosage regimen is shown in Table 13.
- Whether the tumor growth could be inhibited, delayed or cured was investigated. The diameter of the tumor was measured by a vernier caliper. The tumor volume was calculated by a formula: V=0.5×a×b2, in which a and b respectively represent the long diameter and short diameter of the tumor. The anti-tumor effect T/C (%) of the compound was evaluated by a formula: T/C %=TRTV/CRTV×100% (TRTV: RTV of the treatment group; CRTV: RTV of the negative control group). The relative tumor volume RTV was calculated by a formula: RTV=Vt/V0, where V0 is the measured tumor volume at the time of grouping and administration (i.e. day 0), and Vt is the tumor volume at each measurement. T/C (%) reflects the inhibition rate on tumor growth. The therapeutic effect in terms of the tumor weight was evaluated with TGI %, which is calculated by a formula: Inhibition rate on tumor weight (TGI) %=(TWc−TWT)/TWc×100%, in which TWc is the tumor weight in the control group, and TWT is the tumor weight in the treatment group. The weight of the mice bearing tumor in each group was recorded and analyzed, as shown in
FIGS. 1 and 2 and Table 14, and the effect of the compound on the tumor volume of the mice bearing tumor is shown inFIGS. 3 and 4 and Table 15. - The results show that the
compound 1 does not affect the body weight of tumor-bearing mice throughout the administration period (where the weight loss in the group treated with thecompound 1 in combination with dexamethasone was attributed to dexamethasone). Thecompound 1 at a dosage of 17.7 mg/kg (1/3 of the molar dose of lenalidomide) has a tumor inhibition effect comparable to that of lenalidomide at a dosage of 30 mg/kg. When thecompound 1 is administered at a dosage of 53 mg/kg (the same molar dose as lenalidomide), the anti-tumor effect is significantly higher than lenalidomide. Moreover, when used in combination with dexamethasone, thecompound 1 also shows a stronger tumor inhibition effect than lenalidomide. Therefore, thecompound 1 has significant in-vivo anti-tumor efficacy in human multiple myeloma RPMI8226 cell xenograft tumor model, and is more potent than the commercially available drug lenalidomide. -
TABLE 13 Experimental animal grouping and dosage regimen for in-vivo pharmacodynamic test Number Dosage Route of Administration Group of mice (mg/kg) administration frequency 1 Control group 8 — p.o QD × 21 2 Lenalidomide 8 30 p.o QD × 21 3 Lenalidomide 8 30 p.o QD × 21 Dexamethasone 1.0 i.p QD × 21 4 Compound 18 17.7 p.o QD × 21 5 Compound 18 53 p.o QD × 21 6 Compound 18 53 p.o QD × 21 Dexamethasone 1.0 i.p QD × 21 p.o: oral administration i.p: intraperitoneal injection -
TABLE 14 Body weight of tumor-bearing mice in each group ( x ± SEM)Average RCBW* Average body weight (g) (%)/end Number Start of the End of the of the of treatment treatment treatment Group animals Day 1 Day 21Day 21Control group 8 20.84 ± 0.41 22.96 ± 0.64 10.11 p.o. Lenalidomide 8 21.02 ± 0.23 21.90 ± 0.30 4.18 30 mg/kg p.o. Lenalidomide 8 21.23 ± 0.34 20.08 ± 0.25 −5.33 30 mg/kg p.o + Dexamethasone 1 mg/ kg i.p Compound 1 8 21.60 ± 0.36 22.49 ± 0.39 4.13 17.7 mg/ kg p.o Compound 1 8 21.15 ± 0.36 22.25 ± 0.31 5.27 53 mg/ kg p.o Compound 1 8 21.41 ± 0.32 20.46 ± 0.31 −4.46 53 mg/kg p.o + Dexamethasone 1 mg/kg i.p p.o: oral administration i.p: intraperitoneal injection Note: *The relative change in body weight (RCBW) reflects the animal's body weight affected by the drug. The time of the first administration is defined as the first day, and the RCBW (%) is calculated based on the weight on the first day of grouping and administration. Calculation formula: RCBW (%) = ((weight on some day of administration - weight on the first day of administration)/weight on the first day of administration) × 100% -
TABLE 15 Effect of lest compound on tumor volume of RPMI8226 tumor-bearing mice Average volume (mm3) Number Start of the End of the of treatment treatment #T/C Group animals Day 1 Day 21% Control group 8 143.32 ± 15.02 1867.95 ± 278.66 — Lenalidomide 8 140.44 ± 15.82 927.82 ± 164.85 49.67 30 mg/kg Lenalidomide 8 141.35 ± 15.02 233.72 ± 47.47 12.51 30 mg/kg + Dexamethasone 1 mg/ kg Compound 1 8 141.27 ± 14.61 881.71 ± 175.49 47.20 17.7 mg/ kg Compound 1 8 142.38 ± 15.41 674.46 ± 137.82 36.11 53 mg/ kg Compound 1 8 141.54 ± 14.27 179.24 ± 48.35 9.60 53 mg/kg + Dexamethasone 1 mg/kg Note: #T/C % = TRTV/CRTV*100% (TRTV: RTV of the treatment group: CRTV: RTV of the negative control group, RTV = Vt/V1, where V1 is the tumor volume meansured at the time of grouping and administration (i.e. day 1), and Vt is the tumor volume at each measurement.
Claims (10)
Ar-L(-X)p (I)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710365494.7 | 2017-05-22 | ||
CN201710365494.7A CN108929307A (en) | 2017-05-22 | 2017-05-22 | A kind of isoindolone-imide ring -1,3- diketone -2- ene compound, its composition and purposes |
PCT/CN2018/087241 WO2018214796A1 (en) | 2017-05-22 | 2018-05-17 | A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20200071291A1 true US20200071291A1 (en) | 2020-03-05 |
US11021457B2 US11021457B2 (en) | 2021-06-01 |
Family
ID=64395308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/614,493 Active 2038-07-01 US11021457B2 (en) | 2017-05-22 | 2018-05-17 | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof |
Country Status (5)
Country | Link |
---|---|
US (1) | US11021457B2 (en) |
CN (2) | CN108929307A (en) |
AU (1) | AU2018274028B2 (en) |
CA (1) | CA3063804A1 (en) |
WO (1) | WO2018214796A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI3784663T3 (en) * | 2018-04-23 | 2023-10-06 | Celgene Corp | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
CN115403561B (en) * | 2022-08-22 | 2024-03-08 | 西安交通大学 | Intracellular self-assembled protein degradation agent based on thalidomide analogue, and preparation method and application thereof |
CN115385859B (en) * | 2022-08-22 | 2024-03-08 | 西安交通大学 | Protein degradation agent capable of self-assembling in cells and preparation method and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013519675A (en) | 2010-02-11 | 2013-05-30 | セルジーン コーポレイション | Arylmethoxyisoindoline derivative, composition containing the same, and method of use thereof |
CN103396397A (en) | 2013-08-14 | 2013-11-20 | 中国人民解放军军事医学科学院毒物药物研究所 | Lenalidomide derivative and use thereof as medicine |
CN111205268B (en) | 2014-10-30 | 2021-01-26 | 康朴生物医药技术(上海)有限公司 | Isoindoline derivative, intermediate thereof, preparation method, pharmaceutical composition and application |
BR112018008918A8 (en) * | 2015-11-02 | 2019-02-26 | Univ Yale | directed proteolysis chimera compounds and methods for their preparation and use |
-
2017
- 2017-05-22 CN CN201710365494.7A patent/CN108929307A/en not_active Withdrawn
-
2018
- 2018-05-17 US US16/614,493 patent/US11021457B2/en active Active
- 2018-05-17 AU AU2018274028A patent/AU2018274028B2/en active Active
- 2018-05-17 WO PCT/CN2018/087241 patent/WO2018214796A1/en active Application Filing
- 2018-05-17 CN CN201880033821.1A patent/CN110914253B/en active Active
- 2018-05-17 CA CA3063804A patent/CA3063804A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN108929307A (en) | 2018-12-04 |
WO2018214796A1 (en) | 2018-11-29 |
AU2018274028B2 (en) | 2022-04-21 |
CN110914253B (en) | 2022-12-16 |
CN110914253A (en) | 2020-03-24 |
CA3063804A1 (en) | 2019-12-09 |
AU2018274028A1 (en) | 2019-12-12 |
US11021457B2 (en) | 2021-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10590113B2 (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists | |
US11021457B2 (en) | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | |
US11028071B2 (en) | Indazole derivatives as alpha v integrin antagonists | |
JP5932008B2 (en) | Pharmaceutical formulations containing pyrazolopyridine derivatives as NADPH oxidase inhibitors | |
US10851098B2 (en) | Azole amides and amines as alpha v integrin inhibitors | |
US20180161329A1 (en) | Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | |
JP2022521825A (en) | Methods for use as androgen receptor modulators and proteolysis-inducing chimeric ligands | |
US10744128B2 (en) | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof | |
US10682358B2 (en) | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | |
US20230021705A1 (en) | Glp-1r modulating compounds | |
US11325908B2 (en) | CaMKII inhibitors and uses thereof | |
US20190388421A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
US11560370B1 (en) | 5-membered heteroaryl carboxamide compounds for treatment of HBV | |
US20230106583A1 (en) | Heteroaryl compounds | |
US9951061B2 (en) | CaMKII inhibitors and uses thereof | |
JP2018138609A (en) | Naphthyridinedione derivatives | |
US11926613B2 (en) | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | |
WO2023056443A1 (en) | Binders of cereblon and methods of use thereof | |
JP2024508924A (en) | Diazepine derivatives useful in the treatment of Clostridium difficile |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YAO, ZHIYI;LUO, CHENG;XIE, YULI;AND OTHERS;REEL/FRAME:051044/0685 Effective date: 20191101 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |